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1. General features of the liver 
 
The liver is a central organ in whole body metabolism, thermoregulation, and 
physiological homeostasis. The predominant cells in the liver are the hepatocytes. 
These cells comprise up to 70-80% of the total cell population. Other cell types 
include bile duct epithelial cells (cholangiocytes), endothelial cells, Kupffer cells 
(liver-specific macrophages), hepatic stellate cells, portal myofibroblasts and 
hepatic progenitor (or oval) cells (Figure 1).  
Hepatocytes are polarized parenchymal cells. Their basolateral membrane is in 
contact with the blood circulation, while the apical (or canalicular) membrane lines 


















Figure 1. Three-dimensional structure of a liver lobule 
The portal vein and hepatic artery supply the liver with nutrients and oxygenated blood, respectively. Hepatic blood 
flows through sinusoids towards the central vein. Hepatocytes are organized in plates and secrete bile into bile 
canaliculi, which merge in bile ducts. Hepatocytes are separated from sinusoidal endothelial cells by the space of 
Disse, which contains Kupffer cells as well as hepatic stellate cells. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Immunology (Adams et al Aberrant homing of mucosal T cells and extra-intestinal 
manifestations of inflammatory bowel disease), copyright (2006)  
 
 
The bile canaliculi merge into bile-collecting bile ductules. The bile is stored in the 
gall bladder and released into the intestine (duodenum) triggered by food intake.   
Blood enters the liver via the portal vein and the hepatic artery. Most of the blood 
flowing through the liver comes from the intestines (approximately 75%) and is 








2. Bile salt physiology 
 
Bile salt synthesis  
 
A major function of the liver is the production of bile, which aids in the digestion 
of fat-soluble nutrients and the excretion of (fat-soluble) waste products and toxins. 
The functional compounds in bile are bile salts and phospholipids. After secretion 
into the bile, bile salts and phospholipids form mixed-micelles, which are the 
carriers of fat-soluble compounds that facilitate their absorption (for nutrients) in 
the gut or their secretion (of waste products/toxins) via the feces. Bile salts are 
synthesized in the liver, specifically in the hepatocytes, in a multistep enzymatic 
pathway using cholesterol as starting substrate (1). Conversion of cholesterol to 
bile salts involves at least 13 different enzymes and is of key importance to control 
cholesterol homeostasis. Approximately 500 mg of cholesterol is converted on a 
daily base into the primary bile acids cholic acid (CA) and chenodeoxycholic acid 
(CDCA).  
Three different types of modifications are required for the complete conversion of 
cholesterol into a bile salt: 1) hydroxylation of the steroid nucleus, 2) shortening of 
the side chain, and 3) conjugation (amidation) of the side chain to either taurine or 
glycine. The main bile salts formed in human are glycine conjugates, while in 
rodents the taurine conjugates predominate (2). 
Bile salt are synthesized largely via two main routes, the classic (or neutral) and the 
alternative (or acidic) pathway. These two metabolic processes only differ in the 
order of reactions that transform cholesterol to CA or CDCA and intracellular sites 
where the first reaction takes place (3, 4). Each pathway contains only one unique 
enzyme that is responsible for the hydroxylation of the C-7 position. All other 
enzymes are active in both pathways. 
The classic (neutral) route starts with the hydroxylation at the C-7 position in the 
steroid nucleus by 7α-hydroxylase (CYP7A1), an enzyme residing in the 
endoplasmic reticulum (ER). CYP7A is considered to be the rate-limiting step in 
the whole process of bile salt biosynthesis (3, 4). The alternative (acidic) pathway is 
initiated by the hydroxylation of the cholesterol side chain, at carbon C-27, by the 
enzyme sterol 27-hydroxylase (CYP27A1) residing in mitochondria. The resulting 
product, cholesten-3β-27-diol, is subsequently hydroxylated at the C-7 position by 
CYP7B1. 
From this point, the acidic and neutral pathways overlap. The different enzymes 
introducing various changes to the bile salt intermediates are shown in Figure 2. 
The ring modifications are catalyzed by 3β-hydroxy C27-steroid dehydrogenase-
isomerase (3βHSD/HSD3β7) and CYP8B1 in the ER.  
Sterol 12-α-hydroxylase (CYP8B1) (1) leads to the formation of tri-
hydroxycholestanoic acids (THCA) (5) leading to the production of CA. Cyp8B1 is 
therefore a central factor in controlling the ratio of CA over CDCA synthesis and 
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Figure2.: Enzymes and organelles involved in bile salt biosynthesis. 
Bile salts are synthesized 
different intracellular compartments. Changes to the cholesterol backbone along the synthesis route are given in 
bold. Cyp7A1 is considered the rate
reticulum. The first step of the acidic route is catalyzed by mitochondrial CYP27A1. Subsequent enzymatic 
reactions occur in the cytosol, endoplasmic reticulum and peroxisomes. The final step (bile salt conjugation) takes 
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Enterohepatic circulation of bile salts 
 
Food intake triggers the contraction of the gallbladder and releases bile into the 
intestinal lumen. The bile salt/phospholipid mixed-micelles take up fat-soluble 
compounds and carry them  through the intestinal tract so they can be absorbed in 
the gut or efficiently secreted in the feces  (6). At the terminal ileum, the majority 
(~95%) of bile salts is reabsorbed and return to the liver. Arriving at the liver 
through the portal vein, bile salts are taken up by the hepatocytes and re-secreted 
to the bile, thus completing the enterohepatic cycle (6, 7). 
Dedicated bile salt transporters maintain the unidirectional cycling of bile salts 
between the liver and intestine (see Figure 3). 
Bile salts are exported to the bile by the Bile Salt Export Pump (BSEP/ABCD11). 
Bile salt concentrations are 100-1000 fold higher in bile as compared to the 
hepatocyte cytoplasm. Thus, BSEP transports these compounds against a steep 
concentration gradient and is able to do so at the expense of ATP hydrolysis. The 
substrate specificity of BSEP is narrow and restricted to conjugated bile salts (4, 8).  
Bile salt secretion is followed by a passive inflow of water and must be closely 
coordinated with canalicular phospholipid secretion to prevent bile salt-induced 
damage to bile ductular cells (9, 10). Phospholipids are secreted by the 
phospholipid flippase (MDR3/ABCB4) in humans and Mdr2 in rats (10)). The 
major phospholipid in the bile is phosphatidylcholine. Free cholesterol is secreted 
to bile via the ABCG5/G8 heterodimer. Conversion of cholesterol to bile salts and 
cholesterol secretion by ABCG5/G8 are the two major routes of hepatic cholesterol 
elimination (11). 
In the terminal ileum, bile salts are reabsorbed to blood. The first step is uptake 
from the intestinal lumen by the apical sodium-dependent bile acid transporter 
(ASBT/SLC10A2) present in the apical membrane of ileal enterocytes (4, 12, 13). 
Inside enterocytes, bile acids bind to the intestinal bile acid binding protein (I-
BABP) and are transferred to the basolateral membrane for secretion by the 
heterodimeric sodium-independent organic solute transporter Ostα-Ostβ (Ostα/β) 
(4, 14). 
From the ileum, bile salts are transported back to the liver via the portal 
circulation. Import of conjugated bile salts into the hepatocyte is mediated mainly 
by the sodium-dependent taurocholate-co-transporting polypeptide 
(NTCP/SLC10A1). Like ASBT, NTCP is a member of the SLC10 family of sodium 
bile salt co-transporters (4, 15, 16, 17). NTCP is exclusively expressed in the liver (4, 
15) and is localized to the sinusoidal/basolateral membrane of hepatocytes (4, 16, 
18). A significant fraction of the bile salt pool is deconjugated by intestinal bacteria 
(see below). NTCP has a very low affinity for unconjugated bile acids. Recently, 
Oatp1b2 has been shown to be the primary transporter in mice to absorb 













































Figure 3. Bile salts are maintained in the enterohepatic circulation
Bile salts are synthesized in hepatocytes and are exported by the canalicular bile salt export pump (BSEP).
of bile salts is subjected to structural changes (depicted in black in the chemical structures) by the intestinal bacterial 
flora. After passing through the small intestine (brown arrows), bile salts are reabsorbed in the terminal ileum by the 
apical sodium
secreted into the blood circulation (blue arrow) by the heterodimeric organic solute transporter OSTα β
back to the liver. In th
taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs) in the 
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Bile salts may undergo structural changes when exposed to the intestinal flora. A 
significant portion of bile salts is deconjugated (Figure 3), removing the glycine or 
taurine moiety from the side chain (20). In addition, the C7 hydroxyl group may be 
removed from the steroid nucleus converting the primary bile salts CA and CDCA 
to the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), 
respectively (Figure 3).  
Secondary bile acids may accumulate to high levels in the bile acid pool, aggravate 
cholestasis, and contribute to gallstone formation and colon cancer, because of 
their increased hydrophobicity compared to the primary bile salts. Human biliary 
bile is a mixture of CA (35%), CDCA (35%), DCA (25%), LCA (1%), UDCA (2%) 
and a residual fraction containing six different oxo- and 3β-hydroxy- derivatives 
(2%). In contrast, fecal bile consists of DCA (34%), LCA (29%), UDCA (2%), CDCA 
(2%), CA (2%) and the secondary bile acid-derived oxo- and hydroxy- forms 
(isocholic-; 7-oxodeoxycholic-; 7-epicholic-; 12-oxochenodeoxycholic- and 12-
epicholic acid) which amount over 30% of the excreted bile salt pool (20).  
In healthy humans, approximately one-third of the bile salt pool may become de-
conjugated on a daily basis, but biliary bile almost exclusively contains conjugated 
bile salts (4, 21). Thus, the liver very effectively reconjugates bile acids that have 
lost their glycine/taurine side chain in the intestine. In contrast, modifications of 
the hydroxyl groups largely persist during enterohepatic cycling of (secondary) 
bile salts.  
 
Bile salt reactivation with coenzyme A 
 
Unconjugated (C24-)bile salts entering the hepatocyte first need to be activated with 
coenzyme A (CoA) by the fatty acid transport protein 5 (FATP5/ SLC27A5/ 
ACSVL6 / ACSB / BACS / VLCS-H2 in human, VLACSR in mice or BAL in rat) 
(22, 23). FATP5 is specific for reconjugation of C24 bile acids that are present in the 
enterohepatic cycle. CoA activation (thioesterification) is also a crucial step in the 
de novo bile salt synthesis, where the C27-precursors of cholic acid and 
chenodeoxycholic acid THCA and DHCA are CoA-activated before peroxisomal 
side chain shortening and conjugation (amidation) to taurine or glycine. However, 
this activation step is performed by a different enzyme, Very Long-chain acyl-CoA 
Synthetase (VLCS), which is present both in peroxisomes and in the ER (Figure 2) 
(22, 23). FATP5 is present at the basal membrane of hepatocytes (24), a location that 
fits well with the site of entrance of its substrates into hepatocytes (see Figure 2 and 
4). The majority of gall bladder bile acids are unconjugated in Fatp5 (or Bacs)-/- 
mice, stressing the important contribution of reconjugating bile acids that are 





Peroxisomes are involved in the final step of biosynthesis and reconjugation of 
bile salts 
 
In contrast to the 2 separate enzymes for CoA-activation of bile acid intermediates 
in de novo synthesis and in the enterohepatic cycle, there is only one enzyme, bile 
acid coenzyme A:amino acid N-transferase (BAAT), that conjugates glycine or 
taurine to these precursors. The supply of substrates for BAAT from 2 different 
sources that appear either in the peroxisome (in bile salt synthesis) or in the cytosol 
(in the enterohepatic cycle) make the subcellular location of this enzyme highly 
relevant for the putative existence of intracellular bile salt transporters. The 
existence of a peroxisomal pool of BAAT has never been disputed. However, clear 
controversy  exists whether or not a significant amount of BAAT also resides in the 
cytosol that  could be responsible for reconjugation of cycling C24 bile salts. The 
existence of a cytosolic pool of BAAT was concluded from the fact that in 
subcellular fractionation experiments BAAT was always detected in both 
peroxisomal and cytosolic fractions (25-29). However, peroxisomes are fragile 
organelles and are easily ruptured during cell fractionation experiments. As a 
consequence, over 80% of peroxisomal matrix proteins may leak out during this 
procedure and incorrectly designated as “cytosolic” (4, 30, 31). In addition, 
artificially expressed BAAT tagged with the green fluorescent protein (GFP) was 
found predominantly in the cytosol of fibroblasts and HeLa cells (32, 33). In 
contrast, GFP-BAAT was efficiently sorted to peroxisomes of primary rat 
hepatocytes and endogenous rat and human BAAT were detected predominantly, 
if not solely, in peroxisomes of hepatocytes by immunofluorescence microscopy 
and differential membrane permeabilisation by digitonin (34). This implies that 
CoA-activated C24 bile acids need to be transported into hepatocyte peroxisomes 
for their reconjugation (Figure 4) (34). Biochemical evidence for the shuttle of C24 
bile acids into peroxisomes has recently been obtained (see chapter 2; Rembacz et 






























































Figure 4. Bile acids are conjugated inside hepatocyte peroxisomes
Bile acids are synthesized from cholesterol in a cascade of enzymatic reactions that take place in different subcellular 
compartments. The bile acid bios
transported into peroxisomes by a yet unidentified transporter protein. It is known however, that ATP is required for the 
translocation of bile salt intermediates for their peroxi
the production of (chenodeoxy) cholic acid, which is conjugated to glycine or taurine by BAAT. After transport to the 
cytosol via an unknown transporter, bile salts are exported by BSEP to bile.
Re-
OATP(s) or NTCP into hepatocytes. Subsequently, a FATP5/Bal
activated bile acids are imported in
BAAT. It is not known whether PMP70 plays a role in this process and if so, whether it acts as a homodimer or a 
heterodimer with one of its presumed partners (ALDP, ALDPR, P7
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Established activities for bile salt (-intermediates) peroxisomal transport 
 
The identity of proteins that facilitate the transport of bile salt(intermediates) in or 
out the peroxisomes is unknown to date. However, some biochemical 
characteristics of these transport processes have been established and linked to 
candidate proteins.  
Two studies have biochemically assessed the transport of bile salt (-intermediates) 
across peroxisomal membranes (36, 37). In an indirect assay, Une et al. (37) studied 
the conversion of the cholic acid-precursors 3alpha,7alpha,12alpha-trihydroxy-
5beta-cholestanoic acid (THCA) and THCA-CoA to cholic acid when incubated 
with purified rat liver peroxisomes. Cholic acid production was largely dependent 
on ATP and was more efficient starting from THCA-CoA compared to THCA. 
Moreover, CA production form THCA-CoA was inhibited when intact 
peroxisomes were pretreated with proteinase K or by N-ethylmaleimide, sodium 
azide and verapamil, known inhibitors of ATP-binding cassette (ABC)-transporters 
(37). This suggests that the CoA-activated form of THCA is the preferred substrate 
for import into peroxisomes, which largely depends on a protein with ABC-
transporter-type characteristics (see Figure 4).  
After conjugation to taurine or glycine, bile salts are exported from peroxisomes to 
the cytosol. This activity was studied by Visser et al. (36), who reconstituted 
peroxisomal membrane proteins in liposomes and measured uptake of 
radiolabeled GCA and TCA. The transport activity was insensitive to sodium, 
potassium, glycine, ATP or NEM, indicating that this transporter facilitates passive 
unidirectional transport driven by the substrate concentration gradient. A putative 
limitation of the later study is that peroxisomal membrane proteins were isolated 
form Bos taurus kidneys, which are not involved in bile salt synthesis and/or 
enterohepatic cycling (36). A putative liver-specific peroxisomal bile salt 
transporter may therefore be missed in this analysis. 
 
4. Bile salt metabolism in peroxisome disorders.  
 
Peroxisomal biogenesis disorders impair the bile salt biosynthesis 
There are genetic disorders that directly affect the formation or function of 
peroxisomes. Collectively, these disorders are known as peroxisomal disorders, 
which can be subdivided in peroxisome biogenesis disorders (PBD) and single 
enzyme defects. The PBD include Zellweger syndrome (ZS), neonatal 
adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) and are 
characterized by the absence or malformation of peroxisomes. Besides involvement 
in bile salt biosynthesis in the liver, peroxisomes harbor a great variety of 
metabolic activities all over the body, including catabolism of very long chain fatty 
acids, D-amino acids, polyamines, and biosynthesis of plasmalogens. Therefore, 
malfunction of these organelles results in a variety of symptoms that often present 
in early childhood and include skeletal and craniofacial dysmorphism, liver 




result from mutations in PEX genes that code for proteins (peroxins) that are 
required for the proper formation of the organelle, e.g. formation of the organellar 
membrane, targeting of enzymes to peroxisomes, proliferation and inheritance of 
peroxisomes during cell division. 
The absence of normal peroxisomes also severely affects bile salt biosynthesis. In 
fact, the accumulation of bile salt synthesis intermediates DHCA and THCA in 
plasma are diagnostic markers for PBD (41-43). Normal plasma levels of DHCA 
and THCA in healthy subjects are low and are on average  0,77% and 0,12% of total 
pool of bile acids, respectively, while the biosynthetic end products CDCA (53%) 
and CA (14%) predominate the bile salt pool detected in plasma. The ratios of 
THCA/CA and DHCA/CDCA in serum are used as diagnostic measures where 
ratio’s >0.04 and >0.01, respectively, are indicative for Zellweger syndrome (44, 
45).  
In ZS patients, serum CDCA and CA concentration are strongly reduced , but 
show a normal conjugation profile. Remarkably, also part of THCA and DHCA are 
conjugated to taurine (46). As BAAT is likely to reside in the cytosol of hepatocytes 
of Zellweger syndrome patients, this indicates that the enzyme is at least partly 
active in this abnormal cellular location. It is unknown whether BAAT is also 
responsible for the taurine conjugation of bile salt intermediates in ZS subjects. 
Similarly, C27- bile acid biosynthetic intermediates accumulate in bile, liver and 
serum in pex2-/- mice, a rodent model for Zellweger Syndrome (47), and remain 
largely unconjugated, while the small pool of C24-bile acids are mainly conjugated. 
However, when these mice are fed a CA-containing diet, the bile acid pool remains 
largely unconjugated, whereas control animals effectively conjugate dietary CA. 
These data show that peroxisome deficiency leads to a generalized defect in bile 
acid conjugation (47).  
One of the single peroxisomal enzyme defects is BAAT deficiency that has been 
described in two Amish children. These patients presented with pruritus, fat 
malabsorption and vitamin K coagulopathy and high levels of unconjugated bile 
acids in serum and increased urinary excretion of mainly unconjugated and 
glucuronidated/sulfated bile acids (48, 49). The complete absence of conjugated 
bile acids in the serum of these patients reconfirms that BAAT is the sole enzyme 
able to conjugate bile acids to glycine or taurine. 
 
5. Peroxisomes and peroxisomal membrane proteins (PMPs) 
 
Peroxisomes are organelles surrounded by a single membrane that are particularly 
abundant in the mammalian liver. The focus in this thesis is on their role in 
synthesis and enterohepatic cycling of bile salts, but in fact, they may harbor a 
great variety of metabolic and catabolic activities, dependent on the organism, 
tissue, cell type, and environmental conditions. Peroxisomes are conserved 
throughout the eukaryotic kingdom and perform vital functions in organisms 
ranging from yeast, plants, insects, mammals and human. Their involvement in 




and a multitude of different reactions in mammals. Besides their role in bile salts 
synthesis, hepatic peroxisomes are also necessary for β-oxidation of very long 
chain fatty acids (50). 
During the last two decades, much research in this field has been focused on 
identifying and characterizing proteins that are involved in formation of 
peroxisomes, the so-called peroxins. These proteins are involved in peroxisomal 
matrix protein import, membrane biogenesis, peroxisome proliferation, and 
inheritance. The nomenclature established for these proteins states the acronym 
PEX# for the genes and Pex#p for the proteins, where #  indicates a number that 
reflects the order of discovery (51). Many of the peroxins are embedded in –or 
associated with- the peroxisomal membrane. In addition, the peroxisomal 
membrane contains proteins that transport solutes that are substrates or products 
from peroxisomal metabolism. Best studied are the peroxisomal ABC transporters.   
 
Peroxisomal ABC transporters and other peroxisomal substrate transporters 
 
Most eukaryotic ABC transporters are a single protein composed of two 
homologous halves each of them consisting of a hydrophobic transmembrane 
domain and a nucleotide-binding fold (NBD). Alternatively, a functional ABC 
transporter can be build from two separate polypeptides, each containing 1 
transmembrane domain and 1 NBD. All peroxisomal ABC transporters are such 
half-transporters belonging to the subclass D of the ABC protein family (ABCD) 
(52, 53).  
To date 4 peroxisomal ABC half transporters have been identified, in order of 
discovery: the peroxisomal membrane protein of 70 kDa PMP70 (54) (encoded by 
the ABCD3 gene (55)), the adrenoleukodystrophy protein ALDP encoded by 
ABCD1 (56), the ALDP-related protein ALDPR (ABCD2) (57) and the PMP70-
related protein PMP70R/PMP69/P70R (ABCD4) (52, 53, 58, 59). 
 
The best-studied protein of this subfamily is ALDP. Mutations in the ABCD1 gene 
are the cause of X-linked Adrenoleukodystrophy (X-ALD), an inherited disease 
that particularly affects the nervous system and adrenal glands. Biochemically, 
these patients are characterized by the accumulation of very-long chain fatty acids 
(VLCFAs) in blood and other body fluids. It appears that ALDP is required to 
transport these VLCFAs in to peroxisomes to become metabolized to LCFAs, 
which in turn are transported to mitochondria for further chain shortening. 
ALDPR (ABCD2) exhibits overlapping functions to ALDP, as demonstrated by 
normalization of VLCFA levels and increased oxidation of C24:0 and C26:0 in 
ABCD1-/- human and Abcd1-/- mouse cells overexpressing ALDPR (52, 60, 61, 62, 
63). However, Abcd2-/- mice do not show significant abnormalities in VLCFA 
metabolism and, so far, no mutations in human ABCD2 have been found to be 
associated with adrenoleukodystrophy. Thus, the specific physiological relevance 





The 70-kDa peroxisomal membrane protein (PMP70) is a major protein component 
of peroxisomal membrane in the liver. The ABCD3 gene has been characterized 
already over 20 years ago, still a clear physiological function for PMP70 has not 
been  
established yet. Its ATP binding site faces the cytosol (54), which suggests that it 
transports substrates from the cytosol into the peroxisomal matrix. PMP70 has 
been shown to transport CoA esters of LCFAs across the peroxisomal membrane in 
in vitro assays, but a physiological role has not been established in mice or human 
(64). Some unpublished reports have suggested a role for PMP70 in transport of 
bile salt intermediates, but these data await publication in peer-reviewed journals. 
When overexpressed in ABCD1-/- cells, PMP70 is able to correct the defect in 
C24:0 oxidation. Thus, PMP70 and ALDP have partly overlapping substrate 
specificities (52, 60).  
 
It has been suggested that peroxisomal ABC half transporters may functionally 
organize both in homodimers and in heterodimers. Formation of heterodimers 
could potentially broaden the range of substrates that are transported by the 
peroxisomal ABC transporters. Hypothetically, 10 different combinations could be 
formed of the 4 peroxisomal ABC transporters enabling 10 different substrates (or 
families of substrates) to cross the peroxisomal membrane. However, potential 
heterodimerization of these proteins has been solely observed in experiments 
where the proteins were artificially expressed. Endogenous PMP70 and ALDP in 
mouse liver were found to exist predominantly as homodimers (53). In addition, 
the 4 peroxisomal ABC transporters all show a unique tissue distribution and little 
is known about their cell type specific expression in these tissues.  So the presence 
and physiological relevance of peroxisomal ABC transporter-heterodimers remains 
unclear.  
 
Besides the four ABC transporters, also a few other peroxisomal substrate 
transporters have been identified. PMP34 (SLC25A17) was shown to transport ATP 
into the peroxisomal matrix, which is used for the activation of fatty acids (65). 
Little is known about the putative transporters PMP22 (PXMP2) (66), MPV17 
(possibly involved in the reactive oxygen species metabolism (67)) and PXMP4.  
 
6. Peroxisome proliferator-activated receptors (PPARs) affect peroxisome 
biogenesis and bile salt synthesis.  
 
Peroxisome proliferator-activated receptors (PPARs) are three, genetically and 
functionally distinct, ligand-activated transcription factors influencing the 
mammalian development, physiology and homeostasis (68). PPARα ligands fall 
into a large group of “peroxisome proliferators” (clofibrate, bezafibrate, 
ciprofibrate and Wy-14,643) and in rodents, but not in humans, they dramatically 
increase the size and number of hepatic and renal peroxisomes as well as their 




expression of PEX11. Pex11p exists in two isoforms Pex11pα and Pex11pβ and 
promotes peroxisome proliferation (71, 72, 73). Consequently, the number of 
peroxisomes is strongly decreased in Pex11α -/- mice that are unresponsive to 
PPARα ligands (11, 72). 
PPARα is also involved in regulation of de novo synthesis of bile salts and 
transport. The first enzyme in the classical route of bile acid biosynthesis from 
cholesterol, CYP7A1 is repressed by fibrates (11). Further analyses revealed, that 
PPARα down-regulates CYP7A1 by decreasing the levels of Hepatocyte Nuclear 
Factor 4α (11). In contrast, PPARα increases CYP8B1 expression and was shown to 
directly bind to the promoter element of this gene (11, 74).  
It is known that peroxisome proliferators induce ABCD3/PMP70.  
Fibrates have a differential effect on the expression of peroxisomal ABC 
transporters. PPARα does not influence the Abcd1/Aldp and Abcd4/Pmp70r 
expression levels (75). It does, however, strongly induce Abcd2/Aldpr (76) and 
Abcd3/Pmp70 (52) expression. In line with a direct role of Pparα in regulation of 
Abcd3, fenofibrate failed to induce its expression in Pparα -/- mice (77). It was also 
shown, that PPARα agonists downregulate Bsep, Ntcp and Oatp1 (11, 78), 
however, this effect is most likely a result of reduced expression of Hnf4α, which is 
a key transcriptional regulator of these genes (22, 79). In a similar indirect way, also 
Baat expression is reduced by PPARα (28). Since no apparent PPRE could be 
identified in the BAAT/Baat promoter region, it seems most likely that Hnf4α is the 
central factor as Baat expression is strongly decreased in Hnf4α -/- mice (22). 
 
7. Lipid rafts in cellular and peroxisomal membranes. 
 
Lipid rafts in cell membranes 
 
The plasma membrane is a lipid bilayer with embedded (trans-) membrane 
proteins. The main lipid components of cellular membranes are glycerolipids, 
glycerophospholipids, ceramides, glycosphingolipids, sphingomyelins and 
cholesterol (80). 
Biological membranes exist in a fluid or liquid-crystalline phase (so-called lc 
phase). In addition, most cellular and organellar membranes contain certain 
membrane domains, which are especially enriched in sphingolipids and sterols 
(cholesterol) that locally change the membrane physical characteristics. Such 
domains exist in a liquid-ordered (lo) phase (81). Biochemically, they are 
characterized by their resistance to solubilization by detergents (e.g. Triton X-100 
and Lubrol WX) at low temperatures (0-4oC) and are therefore called Detergent 
Resistant Membranes (DRMs) or lipid rafts. After extraction by detergents, lipid 
rafts can be isolated by flotation gradient centrifugation. The majority of DRMs in 
mammalian cells originate from the plasma membrane. However, they are also 
present in intracellular membranes.  
Besides certain lipids, lipid rafts are enriched in specific proteins. Such proteins 




like myristate, palmitate or a glycosylphospatidylinositol (GPI) anchor, or a 
specific hydrophobic architecture. In the pioneering work of Simons and Ikonen 
(Nature 1997), lipid microdomains were proposed to serve as platforms for 
transport of selected membrane proteins or as relay stations in intracellular 
signaling (82). At present, lipid rafts are defined as dynamic, nanoscale sterol-
sphingolipid – enriched assemblies of proteins and lipids. They can further 
organize into larger raft domains by specific lipid-lipid, protein-lipid or protein-
protein interactions.  
The general concept nowadays implements three levels of lipid raft organization in 
cellular membranes (83). Lipid rafts of the first level are nanoscale assemblies (>50 
nm) of cholesterol, sphingolipids and proteins with variable composition. They 
contain GPI-anchored proteins, transmembrane raft proteins and acylated cytosolic 
proteins, which can be modulated by actin filaments. A higher level of 
organization is achieved when nanoscale assemblies cluster into raft platforms that 
are formed in response to membrane trafficking event or external signals that give 
rise to lipid–lipid, lipid–protein and protein–protein oligomerizing interactions. 
These are the structures mainly referred to in the literature involved in membrane 
trafficking and signaling. The highest and the largest (micrometer scale) raft 
structure is a raft phase, observed in vitro in Giant Unilamellar Vesicles (GUVs).  
A subclass of lipid rafts are caveolae and are involved in cell signaling and lipid 
transport (84). They are 50 to 100 nm in size and cholesterol and sphingolipids are 
the predominant lipid components. Caveolae are flask-shaped invaginations of the 
plasma membrane and contain coat proteins (Caveolin-1, -2 and -3) that bind 
directly to cholesterol and support proteins (cavins) (80, 83, 84). Caveolin-1 fulfils 
important functions in the liver as caveolin-1 knock-out mice show impaired 
lipidogenesis and liver regeneration after partial hepatectomy (85). 
 
ABC transporter activity depends on the membrane lipid composition 
 
ABC transporters are localized to lipid rafts, which directly regulate their activity. 
The human P-glycoprotein (Pgp/MDR1/ABCB1) is an example of an ABC 
transporter, which transport activity depends on the lipid environment in the 
plasma membrane. Cellular membranes can be depleted from cholesterol using 
methyl-β-cyclodextrin treatment and/or cholesterol synthesis inhibitors. This 
disrupts the association of Pgp to lipid rafts an strongly inhibited the transport of 
BODIPY-verapamil, a typical substrate of Pgp. Cholesterol repletion re-established 
the transport of BODIPY-verapamil in a dose-dependent manner. This 
demonstrates that Pgp function strongly depends on the cholesterol content of the 
plasma membrane (86). Similar observations were made for breast cancer 
resistance protein (BCRP/ABCG2). Cholesterol depletion decreased, while 
cholesterol repletion increased BCRP activity in MDCKII cells with recombinant 
expression of human BCRP. Moreover, co-immunoprecipitation experiments 





Bile salt transporter activity is modulated by cholesterol 
 
The hepatocyte plasma membranes also contain lipid microdomains and they are 
involved in controlling bile secretion (88). Lipid rafts reside in both the basolateral 
and apical plasma membranes of hepatocytes and contain cholesterol and caveolin. 
There are, however, differences in the specific lipid content. The lipid rafts in the 
apical membrane contain higher amounts of gangliosides, whereas the basolateral 
lipid rafts are more enriched in sphingolipids. The cholesterol content is similar, 
but the apical rafts have a higher cholesterol/phospholipid ratio versus the non-
raft portion of the apical membrane, while the basolateral rafts do not show such 
enrichment. This results in a higher density of basolateral rafts with a lower 
cholesterol:sphingolipid ratio and thus a reduced buoyancy in the flotation 
gradients than rafts isolated from the apical membrane (89).  
 
The typical hepatic bile acid transporters Ntcp and Bsep, as well as several 
members of the Oatp superfamily were found in a proteome analysis of the lipid 
raft-enriched fraction from rat liver (90). More recently, Ntcp was indeed shown to 
be associated to (non-caveolar) lipid rafts in rat liver and its transport activity 
appears to be dependent on the membranous cholesterol content (91). Remarkably, 
the activity of Ntcp increased when cholesterol was depleted in an in vitro 
experiment using HEK293 cells with recombinant expression of Ntcp. Subsequent 
cholesterol repletion reduced the Ntcp transport activity back to control levels (91). 
In addition, BSEP activity has recently been analyzed for its dependence on 
membranous cholesterol content, with opposite results compared to Ntcp. Human, 
rat and mouse BSEP/Bsep were expressed using the baculo virus system and the 
bile salt export activity increased upon cholesterol loading of the insect cell 
membrane vesicles. Cholesterol loading had the most potent effect on rat Bsep, 
where transport activities for TCA, GCA and TCDCA increased 3- to 5-fold. 
Interestingly, cholesterol loading had no significant effect on GCDCA transport 
(92). 
The intestinal bile acid transporter ASBT has also been found to reside in lipid rafts 
in the apical membrane of enterocytes. Methyl-β-cyclodextrin-mediated cholesterol 
depletion abolished the ASBT lipid raft localization and reduced the sodium 
dependent taurocholate transport (93). As described above, cholesterol depletion 
increased the activity of NTCP, the closest homolog of ASBT. The effect of 
cholesterol on the activity of bile acid transporters may in fact be primarily 
dependent on the specific cellular membrane they reside in, as BSEP and ASBT 
both are located in the apical membrane and NTCP in the basolateral membrane.  
 
Thus, all bile acid transporters for which a possible association to lipid rafts has 
been studied so far have been found to reside in such lipid rafts. Moreover, their 
transport activity is modulated by the membranous cholesterol content. The 
peroxisomal membrane also contains -yet to be identified- transporters for bile acid 




associated to some kind of lipid raft. However, prior to the studies in this thesis, 
peroxisomal lipid rafts had not been described yet. Two observations point toward 
the putative existence of peroxisomal lipid rafts: 1. the identification of lipid raft-
like domains in the membrane of peroxisomes of the yeast Yarrowia lipolytica (94) 
and the presence of PMP70 (ABCD3) in the proteome analysis of the lipid raft-
enriched fractions of rat liver (90).  
 
This thesis therefore focused on two interrelated research questions: 
1) do hepatocyte peroxisomes play a role in re-conjugation of C24 bile acids 
and  thereby are an integral part of the enterohepatic cycle of bile acids? 
2) do hepatocyte peroxisomes contain lipid rafts and what is their function? 
 
In both research questions, we were particularly interested in PMP70 as this 



































Aim and outline of this thesis. 
 
The aim of this thesis is to determine the role of hepatocyte peroxisomes in the 
enterohepatic cycling of bile acids and to identify and characterize the putative 
peroxisomal bile acid transporters involved.  
 
In chapter 1, we provide the necessary background of the essential functions of the 
liver and in particular bile salt synthesis and transport. We introduce peroxisomes 
and their established function in bile acid synthesis. Moreover, we provide details 
of known peroxisomal substrate transporters and the relevance of specific lipid 
microdomains in the activity of bile acid transporters. 
 
In chapter 2, we aim to develop a novel experimental procedure to study 
intracellular sorting and glycine/taurine conjugation of cholic acid in rat 
hepatocytes in order to establish a putative role of peroxisomes in this process. We 
make use of stable isotope-labeled CA (D4CA) to be able to differentiate between 
endogenously produced CA and externally added CA by mass spectrometry, the 
latter representing the bile acids that return from the intestine to the liver.  
 
In Chapter 3, we use the novel “CA-conjugation and intracellular transport assay” 
to study the putative role of PMP70 (ABCD3) in transporting bile acids into 
peroxisomes for glycine/taurine conjugation. Expression of PMP70 in primary 
hepatocytes is induced by the PPARα agonist fenofibric acid or inhibited by RNA 
interference and the effect on glycine/taurine conjugation and transcellular 
transport of CA is analyzed.  
 
In chapter 4, we analyze the putative presence of lipid rafts in the peroxisomal 
membrane of HepG2 cells and rat hepatocytes, with particular focus on PMP70. 
Lipid rafts are isolated from HepG2 cells and rat hepatocytes after solubilization 
with Triton X-100 or Lubrol WX. In addition, they are analyzed for the presence of 
various peroxins and peroxisomal ABC transporters. Cholesterol depletion and 
repletion experiments are performed with HepG2 cells and the effect on 
subcellular location of peroxisomal membrane proteins and peroxisome biogenesis 
is analyzed.  
 
In chapter 5, we further characterize peroxisomal lipid rafts and particularly focus 
on the putative presence of caveolin-1 therein. Livers from caveolin-1 knockout 
mice are analyzed for possible defects in peroxisome biogenesis. 
 
In chapter 6, we provide an integrated discussion of the role of peroxisomes and 
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Unconjugated bile salts shuttle through hepatocyte peroxisomes 







Introduction: Bile acid-CoA:amino acid N-acyltransferase (Baat) conjugates bile 
salts to glycine or taurine, which is the final step in bile salt biosynthesis. In 
addition, Baat is required for reconjugation of bile salts in the enterohepatic 
circulation. Recently, we showed that Baat is a peroxisomal protein, implying 
shuttling of bile salts through peroxisomes for reconjugation. However, the 
subcellular location of Baat remains a topic of debate. The aim of this study was to 
obtain direct proof for reconjugation of bile salts in peroxisomes. 
Methods: Primary rat hepatocytes were incubated with deuterium-labeled cholic 
acid (D4CA). Over time, media and cells were collected and the levels of D4CA, D4-
tauro-CA (D4TCA) and D4-glyco-CA (D4GCA) were quantified by liquid 
chromatography-tandem mass spectrometry (LC/MS/MS). Subcellular 
accumulation of D4-labeled bile salts was analyzed by digitonin permeabilization 
assays and subcellular fractionation experiments. 
Results: Within 24 hours, cultured rat hepatocytes efficiently (> 90%) converted 
and secreted 100 µM D4CA to D4TCA and D4GCA. The relative amounts of D4TCA 
and D4GCA produced were dependent on the presence of glycine or taurine in the 
medium. Treatment of D4CA-exposed hepatocytes with 30-150 µg/ml digitonin led 
to the complete release of D4CA, D4GCA and Gapdh (cytosolic marker). Full 
release of D4TCA, catalase and Baat was only observed at 500 µg/ml digitonin, 
indicating the presence of D4TCA in membrane-enclosed organelles. D4TCA was 
detected in fractions of purified peroxisomes, which did not contain D4CA and 
D4GCA.  
Conclusion: We established a novel assay to study conjugation and intra- and 
trans-cellular transport of bile salts. Using this assay, we show that cholic acid 













Bile salts are synthesized in the liver and are the driving force of bile flow. Bile is 
crucial for intestinal absorption of fats and fat-soluble vitamins, as well as the 
elimination of excess cholesterol and waste products from the body. In the terminal 
ileum, 90-95% of the bile salts are reabsorbed and transported back to the liver. 
Import and export of bile salts in hepatocytes and enterocytes is mediated by well-
characterized transmembrane substrate transporters (1).  
Fecal loss of bile salts is compensated by de novo bile salt synthesis in the liver. 
Hepatic bile salt synthesis involves at least 13 different enzymes that are located in 
different subcellular compartments, including the endoplasmic reticulum (ER), 
mitochondria, peroxisomes and the cytosol. Bile salts are made from cholesterol 
and this requires three key modifications of the cholesterol backbone: (1) 
hydroxylation of the steroid nucleus, (2) shortening of the side chain and (3) 
conjugation/amidation of glycine or taurine to the side chain. The last two 
modifications take place in peroxisomes (2). Bile acid-coenzyme A:amino acid N-
acyltransferase (BAAT) catalyzes the third and final modification of bile salts 
before they enter the enterohepatic cycle (3). 
The activity of BAAT remains crucial also during enterohepatic cycling of bile salts. 
A significant portion of bile salts is deconjugated by intestinal bacteria. 
Approximately one-third of the bile salt pool may undergo deconjugation on a 
daily basis in healthy humans (4). Still, unconjugated bile salts are also reabsorbed 
in the enterohepatic circulation and transported back to the liver. However, the 
fraction of unconjugated bile salts in the total bile salt pool is very low, indicating 
an efficient reconjugation process. The efficiency of bile salt reconjugation is 
further stressed by the fact that over 97% of the therapeutic bile salt 
ursodeoxycholate (UDCA) is conjugated to taurine or glycine after a single pass 
through isolated perfused rat livers (5). 
Unconjugated bile salts are first activated with coenzyme A (CoA) by the fatty acid 
transport protein 5 (FATP5; SLC27A5), which is located at the basolateral 
membrane of hepatocytes (6, 7). Next, the CoA-activated C24-bile salts are the 
substrate for BAAT. It has been postulated that a cytosolic pool of BAAT is 
responsible for reconjugating the recycling pool of unconjugated bile salts (8-10). 
However, we recently applied digitonin permeabilization assays and 
immunofluorescence microscopy on endogenous and GFP-tagged human 
BAAT/rat Baat and found that it is predominantly, if not solely, present in 
peroxisomes of hepatocytes (11). An exclusive peroxisomal location of BAAT 
implies that CoA-activated unconjugated bile acids need to be transported into 
peroxisomes, followed by glycine/taurine conjugation and export out of these 
organelles, a yet unexplored bile salt transport process. 
In this study, we sought further proof for the transit of unconjugated bile salts 
through peroxisomes. For that purpose, we established a novel assay that allows 
the detection of (un)conjugated bile salts in peroxisomes. Rat hepatocytes were 
exposed to deuterated cholic acid (D4CA). Over time, the concentrations of taurine- 
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and glycine-conjugated D4CA in cells and medium were determined. At peak 
intracellular accumulation of D4TCA and D4GCA, digitonin permeabilization 
assays and cell fractionation experiments were performed. Our data show for the 
first time that unconjugated bile salts shuttle through peroxisomes to become 





Specified pathogen-free male Wistar rats (220–250 g; Charles River Laboratories 
Inc., Wilmington, MA, USA) were housed under standard laboratory conditions 
with free access to standard laboratory chow and water. Experiments were 
performed following the guidelines of the local Committee for Care and Use of 
laboratory animals.  
 
Primary cells and culture conditions 
Rat hepatocytes were isolated and cultured in William’s medium E in a humidified 
incubator at 37 °C and 5% CO2, as described previously (12). In selected 
experiments (see below), hepatocytes were cultured in minimal essential medium 
(MEM, Invitrogen, Breda, The Netherlands). Hepatocyte viability and purity were 
over 90%.  
 
Uptake and conversion of deuterated cholic acid by primary rat hepatocytes 
Primary rat hepatocytes were plated at a density of 1.0 x 105 cells/cm2. After a 24 
hour attachment period, cells were incubated with 25, 100 or 300 µM [2,2,4,4-
D]Cholic acid (D4CA; isotopic purity 98%, ISOTEC, Miamisburg, OH, USA) for 0 to 
24 h. For taurine or glycine conjugation preference assays, hepatocytes were 
cultured in MEM, supplemented with 666 µM glycine (Sigma-Aldrich, St. Louis, 
MO, USA) and/or 666 µM taurine (Sigma-Aldrich) in the presence of 100 µM 
D4CA. At indicated time points, media and cells were collected followed by 
subcellular fractionation or immediate storage at -20º C. 
 
 
Subcellular fractionation and isolation of peroxisomes 
The subcellular fractionation and isolation of peroxisomes from rat liver was 
performed essentially as described previously (13) using PEG1500-containing 
homogenization buffer (isolation medium-3). Peroxisomes were purified from the 
500 x g supernatant (post-nuclear supernatant-PNS) using Nycodenz density 
gradient centrifugation according to the method described by Verheyden et al. (14). 
12 mL PNS was loaded on top of a discontinuous Nycodenz gradient (2mL 56%, 3 
mL 45% , 15 mL 30% and 5 mL 18%) and spun in a vertical rotor (Sorvall, SV288, 
Thermo Fisher Scientific, Waltham, MA, USA) at 20,000 rpm for 2 hours at 4 °C in a 
slow acceleration/deceleration mode. Equal volumes of all supernatants, pellets 
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and gradient fractions were analyzed by western blotting or were further purified 
for mass spectrometry. 
 
Digitonin Assay  
Digitonin assays were performed essentially as described before (11), with the 
basic difference that digitonin treatments were performed on rat hepatocytes 
attached to collagen-coated culture discs in stead of treated in suspension. Equal 
volumes of supernatant and pellet fractions were analyzed by western blotting or 
further processed for mass spectrometry. 
 
Quantification of cell death. 
Apoptotic cell death was visualized by acridine orange nuclear staining (15) and 
quantified by determining caspase-3 activity (16). The arbitrary fluorescence unit 
(AFU) was corrected for the amount of total protein in the cell lysate. Necrotic cell 
death was quantified by determining lactate dehydrogenase (LDH) leakage (17) 
and Sytox green® (Invitrogen) according to the suppliers’ protocol. 
 
SDS-PAGE and western blotting.  
Protein samples were separated by SDS-PAGE and analyzed by western blotting 
according to established procedures (11). Protein concentrations were determined 
using the Bio-Rad Protein Assay system (Bio-Rad, Hercules, CA, USA) using 
bovine serum albumin as standard. Primary antibody dilutions used in this study 
are shown in Supplementary Table S1. Proteins signals were detected and 
quantified in a ChemiDoc XRS system (Bio-Rad). Protein band intensities were 
quantified using Quantity One software (Bio-Rad). 
 
Purification of bile salts for mass spectrometry 
Media samples (0.1-1.5 mL) from D4CA-exposed hepatocytes were collected at 
indicated time points and diluted 1,000-fold in an internal standard (IS) solution 
(containing 100 ng/mL each of CA, TCA and GCA in H2O). Hepatocytes were 
washed twice in 1x ice-cold Hank's buffered salt solution (HBSS; Invitrogen), 
scraped in 250 µL 75% (v/v) methanol and 1,000-fold diluted in IS solution. 
Digitonin assay samples (1 mL, both representing supernatant and pellet fraction) 
were diluted 200-fold in IS solution. Nycodenz gradient fractions were 1,000-fold 
diluted in IS solution. Total bile salts were purified using reversed phase C18 
columns (Sep-Pak C18 cartridge; Waters, Milford, MA, USA) as described before 
(18).  
 
LC/MS/MS analysis of bile salts 
A detailed description of the LC/MS/MS analysis of bile salts is given in the 
supplementary Material and Methods. In short, LC/MS/MS analysis was 
performed using a triple quadrupole mass spectrometer API 3000 (Applied 
Biosystems, Foster City, CA, USA) using ESI ionization in the negative mode. CA 
and D4CA were detected using single ion monitoring at m/z 407 and m/z 411, 
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respectively. Detection of GCA, D4GCA, TCA and D4TCA was performed using 
the selected reaction-monitoring mode. Two LC-200 HPLC pumps (Perkin-Elmer, 
Waltham, MA, USA) coupled to a series 200 autosampler (Perkin-Elmer) were 
used. Chromatography was performed with a Luna C18(2) (Phenomenex, 
Torrance, CA, USA) analytical column (50x2.0 mm; particle size 3 µm). 
 
Calculation and interpretation of LC/MS/MS data 
The peak area for the D4-labelled bile salt was determined and related to the 
corresponding unlabeled bile salt added as IS. This ratio was corrected for the 
natural isotope abundance of the IS. For the calculation of intracellular bile salt 
concentrations, the cellular volume of one million hepatocytes was set at 20 µL, 
being the higher limit of estimations reported by others (19-24).  
 
Statistical analysis 
All numerical results are reported as the mean of at least 3 independent 




In vitro cultured rat hepatocytes efficiently convert exogenously added cholate 
to taurocholate and glycocholate 
We first determined the rate and specificity by which primary rat hepatocytes 
convert exogenously added cholic acid (CA) to taurocholic acid (TCA) and/or 
glycocholic acid (GCA). 24 h-attached hepatocytes were exposed to various 
concentrations deuterated CA (25, 100 and 300 µM D4CA; Fig. 1. left, middle and 
right panels, respectively). Media (Fig. 1A) and cells (Fig. 1B) were collected after 3 
and 24 h of incubation. D4TCA and D4GCA and the input-bile salt (D4CA) were 
readily detectable in the medium after 3 h of incubation (Fig. 1A). D4CA 
concentrations were below input levels (7, 60 and 225 µM for the input of 25, 100 
and 300 µM, respectively). The presence of D4TCA (6, 10 and 10 µM, respectively) 
and D4GCA (6, 15 and 15 µM, respectively) in the medium after 3 h exposure time 
indicates that D4CA is taken up, CoA-activated, taurine/glycine conjugated by and 
exported from the hepatocytes. After 24 h, D4CA was absent in medium of cells 
exposed to 25 µM (Fig 1A,B. left panels). Instead, D4TCA (12 µM) and D4GCA (10 
µM) were detected in these samples. Only small amounts (5 µM) of D4CA were 
detected in the medium of hepatocytes exposed to 100 uM D4CA for 24 h, which 
was effectively converted to D4TCA (23 µM) and D4GCA (68 µM) (Fig. 1A. middle 
panel). After 24 h-exposure of hepatocytes to 300 µM D4CA, 70 µM D4CA, 40 µM 
D4TCA and 160 µM D4GCA were detected in the medium (Fig. 1A. right panel). 
  
Intracellular accumulation of taurocholate and glycocholate in cholate-exposed 
rat hepatocytes 
Simultaneously with the media samples, hepatocytes were harvested in order to 
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Figure 1. Unconjugated bile acids are efficiently converted by rat hepatocytes to their taurine and glycine 
conjugates 
indicated time points, media (A) and cells (B) were collected and the concentrations of D
determined by mass spectrometry. Representative data from 3 independent experiments are shown.
 
Figure 2. Transient accumulation of conjugated bile salts after exposure to D
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Figure 3. Incubation of rat hepatocytes with 100 µ
rat hepatocytes were incubated with either 100 µ
measurements in total cell lysates (A) or LDH activity measurements in the medium (B). Treatment 
digitonin was used as positive control for LDH leakage. Results are presented as fold induction compared to 
untreated control hepatocytes, which are set to 1. In addition, hepatocytes exposed for 24 h to 50 uM GCDCA or 
100 uM D
top panels: bright field image, bottom panels: fluorescence image).
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Selective membrane permeabilization of rat 
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Figure 4. Rat hepatocytes prefer taurine over glycine as a substrate for bile salt conjugation.
hepatocytes were incubated for 24 h wi
µM taurine and/or glycine. Media (A) and cells (B) were collected, followed by bile salt purification and analysis as 
in Fig. 1.
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using Nycodenz density gradient centrifugation. Equal volumes of all gradient fractions were analyzed by western 
blotting
bile salt purification and analysis (B). C shows an enlargement of the bottom 8 fractions of the gradient.
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In this study, we established a novel assay that allows the study of transcellular 
and intracellular transport and conjugation of bile salts by rat hepatocytes in vitro. 
Primary rat hepatocytes effectively convert exogenously added deuterated cholic 
acid (D4CA) to its taurine and/or glycine conjugates (D4TCA and D4GCA, 
respectively). Using digitonin permeabilization assays and peroxisome isolations, 
we demonstrate that D4TCA transiently resides in peroxisomes. This provides 
direct evidence that unconjugated bile salts shuttle through peroxisomes to become 
(re-)conjugated.  
Reconjugation of deconjugated bile salts is an important process. Over 30% of the 
total bile salt pool may become deconjugated by intestinal bacteria on a daily basis 
(4). Our previous study showed that the enzyme catalyzing bile salt conjugation, 
BAAT, is localized predominantly, if not solely, in peroxisomes (11). This suggests 
that bile salts need to shuttle through peroxisomes for reconjugation. However, the 
possible existence of a cytosolic pool of BAAT remains a matter of debate (8-11). 
Therefore, we developed this novel assay to study trans- and intracellular 
transport and conjugation of D4CA. The use of D4CA allowed us to specifically 
follow its (re-)conjugation route, independent from endogenous-produced CA. 
In the intact liver, bile salt reconjugation is highly efficient as 97% of infused 
UDCA is conjugated to taurine or glycine after one single pass through rat livers 
(5). The in vitro cultured hepatocytes also perform this function with significant 
efficiency with less than 10% of the D4CA unaccounted for after 24 h. This part of 
deuterium-labeled bile salts may still reside in the hepatocytes, be present as (CoA-
)intermediate or is metabolized to other products. The ratio between the amounts 
of GCA and TCA formed can be strongly manipulated by the levels of glycine and 
taurine in the growth medium. A high preference for TCA formation is observed 
when both amino acids are present in excess. This is in line with the predominant 
presence of taurine-conjugated bile salts in rats (26). However, in the presence of 
only glycine, GCA is efficiently formed. These data show that the availability of 
glycine and/or taurine strongly determines the final conjugation profile. Glycine-
conjugated bile salts are generally more cytotoxic compared to their taurine-
equivalents (25). Taurine supplementation in cholestatic diseases may therefore 
limit liver damage. This is especially relevant in humans that have a predominance 
of glycine-conjugated bile salts. 
Cultured rat hepatocytes accumulated high concentrations of D4TCA and D4GCA 
after  exposure to 100 µM D4CA. The cellular volume of a hepatocyte is estimated 
to be between 4 and 20 pL (19-24). Assuming 20 pL as the volume of a rat 
hepatocyte, we estimated that the peak intracellular concentration of D4TCA and 
D4GCA were approximately 200 µM and 400 µM, respectively, while D4CA levels 
were in the range of the concentrations in the medium. The intracellular 
accumulation of conjugated bile salts is transient, peaks at 3 h exposure and then 
declines. This suggests that export of D4TCA and D4GCA is limiting and cannot 
keep up with the production of conjugated bile salts. In our model with 
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7beta position, respectively; see (27)) by fluorescence microscopy. Only 3alpha-
NBD-cholate was taurine conjugated and exported to the medium by cultured rat 
hepatocytes. However, the efficiency of conjugation is much lower (>90%) 
compared to D4CA. Interestingly, a clear accumulation of 3alpha-NBD-CA in 
subcellular structures was detected at early time points (see Supplementary Fig. 
S2). Unfortunately, due to technical limitations, we have been unable so far to 
identify these subcellular structures (see Supplementary data for details). Still the 
detection of a clear punctuate staining pattern for 3alpha NBD-cholate in 
hepatocytes supports our data that bile salts (transiently) accumulate in membrane 
enclosed organelles. 
Remarkably, we did not detect D4GCA in the peroxisomal fractions. Still, BAAT is 
believed to be responsible for both taurine and glycine-conjugation of bile salts (3).  
This may indicate  that the peroxisomal bile salt exporter in rat hepatocytes has a 
higher affinity for GCA compared to TCA. Clearly, D4TCA and D4GCA also 
accumulate in the cytosol of hepatocytes, implying that the export of conjugated 
bile salts from hepatocytes by the bile salt export pump (BSEP) is also a rate-
limiting step in our assay. This is most likely the result of a suboptimal location 
and/or activity of BSEP in cultured hepatocytes.  
The identity of the peroxisomal bile salt transporters (importer and exporter) is 
unknown to date. A possible importer of CoA-activated C24 bile salts is the 70-kDa 
Peroxisomal Membrane Protein (PMP70/ABCD3). PMP70 is an ATP-binding 
cassette transporter that is highly expressed in the liver (28). It has been proposed 
to transport long chain fatty acids into peroxisomes (29, 30). Recent research 
suggests that it may also transport bile acid intermediates, though thorough 
experimental evidence has not been presented yet (31). Importantly, the protein-
mediated transport of conjugated bile salts across the peroxisomal membrane has 
recently been demonstrated in vitro (32). The characteristics of the transport 
activity, e.g. ATP independent, make it unlikely that PMP70, or another 
peroxisomal ABC-transporter, is involved in this step.  
Zellweger Syndrome patients have no (functional) peroxisomes and accumulate 
intermediates of bile salt biosynthesis in their serum, variable amounts of which 
are conjugated (33, 34). This suggests that  BAAT is (partially) active in the cytosol 
of these patients and is able to conjugate the accumulated bile salt intermediates. 
Recent studies using peroxisome-deficient Pex2-/- mice indeed show that the 
efficiency of conjugation of both C24 bile acids and C27 intermediates is reduced, 
but not absent, under normal conditions in these mutants. Moreover, bile acid 
conjugation is further impaired when these animals are fed a cholate-containing 
diet (35). Thus, reconjugation of bile salts may not strictly depend on the shuttle of 
bile salts through peroxisomes. Rather, it strongly increases the efficiency of the 
process.  
In summary, we provide evidence that unconjugated bile salts shuttle through 
peroxisomes for taurine or glycine conjugation. Defects in the shuttle of bile salts 
through these organelles may lead to yet unrecognized cholestatic disorders. 
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SUPPLEMENTARY TABLE S1 
 
Table S1. Antibody dilutions for western blotting 
Antibody Dilution Company 
Rabbit α-PMP70 1:1,000 Sigma-Aldrich, St. Louis, MO, USA 
Rabbit α-Baat 1:2,000 Generous gift of Prof. C. Falany, Birmingham, AL, USA (8) 
Rabbit α-catalase 1:2,000 Calbiochem, La Jolla, CA, USA 
Mouse α-cytochrome C 1:2,000 BD Biosciences, Franklin Lakes, NJ, USA 
Mouse α-Gapdh 1:10,000 Calbiochem, La Jolla, CA, USA 
 
 
SUPPLEMENTARY MATERIAL AND METHODS 
 
LC/MS/MS analysis of bile salts 
LC/MS/MS analysis was performed using a triple quadrupole mass spectrometer 
API 3000 (Applied Biosystems, Foster City, CA, USA) operating with an ESI 
ionization source in the negative mode. A capillary voltage of -4500V and a source 
temperature of 400°C were used. The declustering potentials were -96 V, -101 V 
and -100 V for (D4)TCA, (D4)CA and (D4)GCA, respectively. Due to the lack of any 
specific and stable fragment ions, detection of CA and D4CA was performed using 
single ion monitoring at m/z 407 and m/z 411, respectively. Detection of GCA, 
D4GCA, TCA and D4TCA was performed using the selected reaction-monitoring 
mode. The transitions of the deprotonated molecules to their corresponding 
product ions were recorded at m/z 464.2  73.9 (GCA), m/z 468.2  73.9 
(D4GCA), m/z 514.1  79.9 (TCA) and m/z 518.1  79.9 (D4TCA). The collision 
energy used was -114 eV for TCA and D4TCA and -72 eV for GCA and D4GCA. For 
the chromatographic separation, two LC-200 HPLC pumps (Perkin-Elmer, 
Waltham, MA, USA) coupled to a series 200 autosampler (Perkin-Elmer) were 
used, all of them controlled by the mass spectrometer data system. 
Chromatography was performed with a Luna C18(2) (Phenomenex, Torrance, CA, 
USA) analytical column (50x2.0 mm; particle size 3 µm) in combination with a frit 
filter (Upchurch Scientific Inc, Oak Harbor, WA, USA). Ultra pure water and 
acetonitrile were used as mobile phases A and B, respectively. The initial mobile 
phase was ultra pure water:acetonitrile 60:40 v/v %, which was kept constant for 
2.5 minutes. Subsequently, the solvent was changed to 30:70 v/v % in 1 minute 
and was kept constant for 2 minutes. In the next step, the solvent was changed to 
10:90 v/v % in 0.5 minute, and kept constant for 2 minutes. Finally, the solvent was 
changed to the initial composition and was kept constant for 4.5 minutes. Column 




















































Figure S1. Incubation of rat hepatocytes with 100 µ
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Peroxisomes are organelles highly enriched in the liver, which play a central role in 
bile salt homeostasis. The final steps of bile salt biosynthesis occur inside 
peroxisomes, including side chain shortening and conjugation to taurine or 
glycine, after which they enter the enterohepatic cycle. In this cycle, significant 
amounts of bile salts are deconjugated in the intestine and after recycling to the 
liver need to pass through peroxisomes again for reconjugation. In contrast to our 
knowledge about bile salt transporters in plasmamembranes, very little is known 
about transport of bile salt (intermediate)s across peroxisomal membranes. Here, 
we analyzed the putative involvement of the peroxisomal ABC-transporter Pmp70 
(Abcd3) in this process. 
Primary rat hepatocytes were exposed to the PPARα ligand fenofibric acid (FFA) to 
induce expression of Pmp70. Small interfering RNA was used to prevent FFA-
induced expression of Pmp70. FFA- and/or siRNA-treated hepatocytes were 
exposed for 3 h to deuterium-labeled cholic acid (D4CA) and conversion to and 
accumulation of D4-tauro cholic acid (D4TCA)  in hepatocyes and medium were 
quantified by LC/MS/MS mass spectrometry. 
FFA treatment of rat hepatocytes strongly induced Pmp70 expression (5-10 fold) 
and  increased the accumulation of D4TCA in the medium (+15%), while reducing 
the intracellular levels of D4CA (-44%) and D4TCA (-15%). SiRNA treatment 
effectively prevented the FFA-induced expression of Pmp70 in rat hepatocytes and 
concomitantly increased the intracellular levels of D4CA and D4TCA and decreased 
D4TCA levels in the medium. FFA did not change the expression of other factors in 
the conjugation and transport of CA (Fatp5, Baat, Ntcp and Bsep). 
These data suggest a role for Pmp70 in the transport of unconjugated bile salts into 











Bile salts are synthesized from cholesterol in the liver and are secreted to bile. Bile 
allows absorption of fat and fat-soluble vitamins in the intestine. Moreover, bile 
salt biosynthesis is the main route of cholesterol elimination from the body. In the 
terminal ileum, 90-95% of bile salts is reabsorbed and transported back to the liver 
in a process that is called the enterohepatic circulation. Bile salt import and export 
in hepatocytes and enterocytes are mediated by well-known and characterized 
transporters, including NTCP, OATP1B1 and BSEP in the liver and ASBT and 
OSTαβ in the intestine (1).  
De novo synthesis in the liver compensates the fecal loss of bile salts. The synthesis 
involves at least 13 different enzymes localized to different intracellular 
compartments, including the cytosol, endoplasmic reticulum (ER), mitochondria 
and peroxisomes. Bile salts are synthesized from cholesterol that undergoes 3 main 
modifications, e.g. hydroxylation of the steroid nucleus, side chain shortening (-
oxidation) and side chain conjugation (amidation) to taurine or glycine. The last 
two steps take place in peroxisomes (2). Bile acid-coenzyme A:amino acid N-
acyltransferase (BAAT) is responsible for the third (and final) modification step of 
bile salts (3).  
Taurine/glycine conjugating of bile salts remains crucial also during the 
enterohepatic cycle, since a significant portion of biliary bile salts is deconjugated 
by intestinal bacteria. Up to one third of bile salts return to the liver in a de-
conjugated form (4). The liver has a high capacity to re-conjugates bile salts as 
exemplified by the 97% efficient conjugation of infused UDCA with glycine or 
taurine after a single pass through the isolated and perfused rat liver (5).  
Unconjugated bile salts entering the hepatocyte are activated with Coenzyme A 
(CoA) by the fatty acid transport protein 5 (FATP5/ SLC27A5/ ACSVL6 / ACSB / 
BACS / VLCS-H2 in human or Bal in rat), which is located at the basolateral 
membrane of hepatocytes (6, 7, 8, 9). Next, C24-bile salt-CoA esters are conjugated 
to taurine or glycine by BAAT (10). It has been proposed that a cytosolic pool of 
BAAT is responsible for the reconjugation of bile salts returning from the intestine 
(11, 12). However, using cell fractionation and microscopical techniques we found 
that BAAT is predominantly, if not solely, present in peroxisomes of human and 
rat hepatocytes (13). In support of this, we recently showed that cholic acid shuttles 
through peroxisomes for taurine conjugation (Rembacz et al, 2010 (14)). These 
observation suggest the existence of yet unidentified transport systems (import 
and export) for bile salt (intermediate)s in the peroxisomal membrane.  
Indeed, experiments with purified peroxisomes reveal the presence of proteins that 
support transport of taurocholic acid (TCA) (15) and C27 bile acid biosynthesis 
intermediates 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid (THCA) 
and 3 alpha,7 alpha-dihydroxy-5 beta-cholestanoic acid (DHCA) (16) across 
peroxisomal membranes. Transport of THCA and DHCA appears to be ATP 
dependent and is inhibited by compounds that block the activity of ATP-binding 
cassette (ABC-)transporters, e.g. verapamil, sodium azide and N-ethymaleimide 
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(16). C24 CoA-activated bile salts may use the same transporter to enter 
peroxisomes. The identity of peroxisomal bile salt importer(s) and exporter(s) is 
unknown to date. 
A likely candidate for the importer of CoA-activated C24 and C27 bile salts is the 
peroxisomal membrane protein of 70-kDa (Pmp70/Abcd3), an ATP-binding 
cassette (half-) transporter highly expressed in the liver (17). Pmp70 is suggested to 
transport long chain fatty acids into peroxisomes, but direct evidence for this 
activity is not yet available (18, 19).  
Pmp70 is a major component of peroxisomal membrane in hepatocytes. Its ATP-
binding site faces the cytosol (20), suggesting transport of substrates into 
peroxisomes. Pmp70 primarily exists as homodimer (21), but the formation of 
heterodimers between Pmp70 and other peroxisomal ABC half-transporters, such 
as ALDP, has also been suggested (22, 23). Pmp70 expression is regulated by 
peroxisome proliferator-activated receptor-alpha (PPARα), a nuclear receptor 
activated by hypolipidemic agents like clofibrate, bezafibrate, ciprofibrate, 
fenofibrate  or Wy-14,643 (19, 24, 25). In rodents, but not in humans, they 
dramatically increase the size and number of hepatic and renal peroxisomes as 
well as their metabolic activities (24, 26, 27). 
In this work, we investigated the role of Pmp70 in bile salt shuttling through 
peroxisomes. We manipulated Pmp70 expression in cultured rat hepatocytes using 
fenofibric acid and RNA-interference. Subsequently, rat hepatocytes with variable 
Pmp70 levels were exposed to D4CA and conversion to and accumulation of 
D4TCA in cells and medium were analyzed by LC/MS/MS mass spectrometry 
(14). Our data demonstrate for the first time the involvement of Pmp70 in bile salt 
metabolism in hepatocytes. 
 
MATERIALS AND METHODS 
 
Animals 
Specified pathogen-free male Wistar rats (220–250 g) were purchased from Charles 
River Laboratories Inc. (Wilmington, MA, USA). Rats were housed under standard 
laboratory conditions with free access to standard laboratory chow and water. 
Experiments were performed following the guidelines of the local Committee for 
Care and Use of Laboratory Animals.  
 
Hepatocyte isolation and culture conditions 
Hepatocytes were isolated and cultured in William’s E as described previously 
(28). Cells were cultured in a humidified incubator at 37 °C and 5% CO2. 
Hepatocyte viability and purity were always more than 90%.  
 
siRNA-mediated knock down of Pmp70 
Small interfering RNA duplexes specific for Abcd3/Pmp70 knock down were 
designed (sense 5'-GAGACAGGGUACUUCAUAdTdT-3'; antisense 5’-UAU 
GUUGUACCCUGUCUCdTdT-3’) and purchased from Eurogentec (Maastricht, 
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The Netherlands). Human MRP1 complexes (sense 5'-
GGAGUGGAACCCCUCUCU-3'; antisense 5’-AGAGAGGGGUUCCACUCCdTdT-
3’) were used as siRNA control. For transfection experiments, siRNA duplexes 
were complexed with Lipofectamin 2000 according to manufacturer’s instructions 
(Invitrogen, Breda, The Netherlands). Hepatocytes were transfected with 
siRNA/Lipofectamin complexes in a suspension and let attach in 6-well collagen-
coated plates in a concentration of 8×105 cells/well.  
 
Fenofibric acid (FFA) treatment 
Four hours after attachment, primary rat hepatocytes were treated with 5-250 µM 
fenofibric acid (Sigma, Zwijndrecht, The Netherlands) for variable time periods as 
specified in the result section. SiRNA treated hepatocytes were exposed to FFA 8 
hours after transfection. 
 
SDS-PAGE and Western blotting.  
Protein samples were separated by SDS-PAGE and analyzed by Western blotting 
according to established procedures (13). Protein concentrations were determined 
using the Bio-Rad Protein Assay system (Bio-Rad Hercules, CA, USA) using 
bovine serum albumin as standard. Primary antibody dilutions are summarized in 
Table 1. Proteins signals were detected and quantified using a ChemiDoc XRS 
system (Bio-Rad, Hercules, CA, USA). Protein band intensities were quantified 
using Quantity One software (Bio-Rad). 
 









Uptake and conversion of deuterated cholic acid (D4CA) by primary rat hepatocytes 
Primary rat hepatocytes were plated at a density of 1.0 x 105 cells/cm2. After a 24 
hour attachment period, cells were incubated with 100 µM [2,2,4,4-D]Cholic acid 
(D4CA; isotopic purity 98%, ISOTEC, Miamisburg, OH, USA) for 3 hours. Cells and 
media were harvested and levels of D4CA and D4TCA were quantified by 
LC/MS/MS according to a recently established procedure (14). 
 
RNA isolation and Q-PCR 
Total RNA was isolated from hepatocytes with Tri Reagent (Sigma, St Louis, MO), 
according to manufacturer’s instructions. Messenger RNA levels of selected genes 
were quantified using the ABI PRISM 7700 (Applied  Biosystems, California, USA). 
Antibody Dilution Company 
Rabbit α-PMP70 1:1,000 Sigma-Aldrich, St. Louis, MO, USA 
Rabbit α-Baat 1:2,000 Generous gift of dr C. Falany, Birmingham, AL, USA (10) 
Rabbit α-catalase 1:2,000 Calbiochem, La Jolla, CA, USA 
Mouse α-cytochrome C 1:2,000 BD Biosciences, Franklin Lakes, NJ, USA 
Mouse α-Gapdh 1:10,000 Calbiochem, La Jolla, CA, USA 
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Q-PCR conditions were as described (29). Details about primers and probes are 
shown in Table 2. 
The expression of each gene of interest was normalized with respect to the 
endogenous control, 18S using the ∆∆Ct method. The data are given as fold-
induction versus 18S as the mean of three independent measurements +/- SD.  
 
Table 2. Primers and probes used for qPCR gene expression level measurements 
 
Subcellular fractionation and peroxisomal isolation 
The subcellular fractionation and isolation of peroxisomes from rat liver was 
performed essentially as described (30) using PEG1500-containing homogenization 
buffer (isolation medium-3). Peroxisomes were purified from the 500g supernatant 
(postnuclear supernatant [PNS]) using Nycodenz density gradient centrifugation 
according to the method described by Verheyden et al., (31). Twelve mL PNS was 
loaded on top of a discontinuous Nycodenz gradient (2 mL 56%, 3 mL 45%, 15 mL 
30%, and 5 mL 18%) and centrifuged in a vertical rotor (Sorvall, SV288, Thermo 
Fisher Scientific, Waltham, MA) at 20,000 rpm for 2 hours at 4oC in a slow 
acceleration/deceleration mode. Equal volumes of all supernatants, pellets and 
gradient fractions were analyzed by Western blotting or were further purified for 
mass spectrometry as described previously (14). 
 
Differential membrane permeabilisation assays using digitonin  
Digitonin assays were performed as previously described (14). Equal volumes of 
supernatant and pellet fractions were analyzed by Western blotting or further 
processed for mass spectrometry essentially as described (14). 
 
(Immunofluorescence) Microscopy 
Cells were cultured on coverslips coated with collagen and after specified time of 
stimulation with FFA fixed with 4% paraformaldehyde. The rabbit pAb against 
Pmp70 was used in a 1:500 dilution followed by a secondary mAb carrying the 
FITC fluorophore. Images were taken with a confocal scanning laser microscope 
(TCS 4D; Leica, Heidelberg, Germany) equipped with argon/krypton laser and 
coupled to a Leitz DM IRB (Leica, Heidelberg, Germany) inverted microscope. 
Gene Forward primer Reverse primer FAM -probe-TAMRA 
18S CGGCTACCACATCCAAGGA CCAATTACAGGGCCTCGAAA CGCGCAAATTACCCATCCCGA 





Baat TGTAGAGTTTCTCCTGAGACATCCTAA GTCCAATCTCTGCTCCAATGC TGCCAACCCCTGGGCCCAG 
HMG-CoAs TGGTGGATGGGAAGCTGTCTA CTGCGGTAAGCTGCATAGCAT CCAAGGCCCGCAGGTAGCACTG 
Pex11α GCCCGCCACTACTACTATTTCCT TCTGTCGCGTGCAACTTGTC 
CATATGCAGCAAGACCTCATAC
AGATCCCG 
Aldp CATCTGGCCTGCTCATGGTA TTCATGGCTTCTGAGTCTGACTCT 
CCCCATCATCACAGCCACTGGC
T 
Acox1 GCCACGGAACTCATCTTCGA CCAGGCCACCACTTAATGGA CCACTGCCACATATGACCCCAAGACCC 
Fatp5/Bal GTGCTGATTGTGGATCCAGAC GAATGTTCTCAGCTAGCAGCTTG 
CCAGGAGAACCTGGAAGAAGTC
CTTCC 
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Purification of bile salts for mass spectrometry 
Media and cell samples for deuterated bile salt LC/MS/MS analysis were purified 
with C-18 columns in the presence of unlabeled internal standards essentially as 
described (14).  
 
LC/MS/MS analysis of bile salts 
D4CA and D4TCA were quantified by LC/MS/MS as previously described (14). In 
short, LC/MS/MS analysis was performed using a triple quadrupole mass 
spectrometer API 3000 (Applied Biosystems, Foster City, CA) using ESI ionization 
in the negative mode. CA and D4CA were detected using single ion monitoring at 
m/z 407 and m/z 411, respectively. Detection of TCA, and D4TCA was performed 
using the selected reaction-monitoring mode. Two LC-200 HPLC pumps (Perkin-
Elmer, Waltham, MA) coupled to a series 200 autosampler (Perkin-Elmer) were 
used. Chromatography was performed with a Luna C18(2) (Phenomenex, 
Torrance, CA) analytical column (50 × 2.0 mm; particle size 3 µm). 
 
Statistics 
The peak area’s for the D4-labeled bile salts were determined and related to the 
corresponding unlabeled bile salts added as internal standards (IS). This ratio was 
corrected for the natural 13C isotope abundance of the IS.  
The data are reported as percentage change to control hepatocytes and presented 
as mean of three independent experiments ± SEM. Student’s t-test and Kruskal-
Wallis H-test (one-way ANOVA test by ranks) were used to evaluate significance 





Small interfering RNA efficiently reduces Abcd3 transcript levels in cultured 
primary rat hepatocytes, but not Pmp70 protein. 
To analyse the putative involvement of Pmp70 in bile salt transport through 
peroxisomal membranes, we aimed to repress its expression in cultured rat 
hepatocytes through transient transfection with Abcd3-selective siRNA duplexes, 
following the procedure we successfully used for caveolin-1 (Woudenberg et al., 
2010 (32)). Abcd3 mRNA levels were significantly reduced by siRNA treatment 
already after 16 h (70% reduction) and further declined up to 32 h (90% reduction; 
Fig. 1A). Strongly reduced Abcd3 levels were maintained up to 72 h after 
transfection. Unfortunately, Pmp70 protein levels did not mirror the strong 






























Pmp70 protein levels dropped slowly, but persistently in untreated rat hepatocytes 
to approximately 50% after 72 hours in culture. At all time points tested, siRNA 
treatment lead 
compared to control cells. These data suggest that cultured rat hepatocytes 
produce only limited amounts of Pmp70 




As an alternative approach, we aimed to selectively induce the expression of 
Pmp70 and analyze its effect on bile salt metabolism. Fenofibric acid (FFA) is a 
potent agonist of Ppar
including Pmp70, as well as several other proteins involved in lipid metabolism. 
Primary rat hepatocytes were exposed for 24 and 48 h to 50 
levels of 
Expression of well
peroxisomal Acox1 and Pex11a as well as 
FFA. 
stable for the next 24 h. The increase in 
increase in Pmp70 protein levels (Fig. 2G). In contrast, expression of the Pmp70 
homolog Aldp (
a time 
conjugation enzyme Baat were unaltered after 24 h incubation with FFA (Fig. 2F). 
Abcd3
 
frame of 48 hours (Figure 2 E). In addition, mRNA levels of the bile salt
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Figure 1: Small interfering RNA efficiently 
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(B) Western blot analysis demonstrates 
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depict treated hepatocytes and white bars 
represent controls. 
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After 48 h a 2-fold increase in Baat mRNA levels were detected, but this is 












































Figure 2: Genes responding to Pparα stimulation with fenofibric acid (FFA) 
 
Pparα target genes: mitochondrial 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (A), peroxisomal acyl-
Coenzyme A oxidase 1 (B), and Pex11α (C) are upregulated directly upon Pparα stimulation with FFA, 
already after 24 hours. 
Bile acid CoA: amino acid N-acyltransferase (Baat ) does not respond to Pparα stimulation within the first 24 
hours (D).   
The peroxisomal ABC half-transporters Aldp and Pmp70 are differentially regulated by Pparα. Abcd1/Aldp (E) 
expression is not altered upon FFA treatment of isolated rat hepatocytes. Abcd3/Pmp70 (F) is a Pparα target 
gene and is directly upregulated in response Pparα stimulation already after 24 hours. Western blot analysis 
revealed a strong Pmp70 protein induction in total cell lysates of hepatocytes treated with 50µM FFA after 24 







Since Abcd3/Pmp70 in rat hepatocytes appeared to respond directly to 
Ppar
maximal Abcd3 induction. FFA dose
Pmp70 protein levels with a maximum induction at 50 µM FFA after 24 h exposure 
(Fig. 3). FFA exposure did not significantly change the Baat protein 
in line with the unchanged Baat mRNA levels after 24 h (Fig. 2F). All following 





















FFA treatment does not lead to an aberrant subcellular location of increased 
levels of peroxisomal proteins in cultured rat hepatocytes.
It has been reported that Ppar
Baat and catalase protein levels in the cytosol (12). We therefore determined 
whether FFA
modulate the conjugation and subcellular tr
hepatocytes. Cultured rat hepatocytes were treated for 24 hours with 50 µM of FFA 
and were analyzed by immunofluorescence microscopy for the subcellular location 
of Pmp70 (Fig 4A and B). Pmp70 was readily detected in distinct 
the cytoplasm of control rat hepatocytes. In 24 h FFA
dotted staining pattern was detected, but with a strongly increased fluorescence 
staining intensity, as shown by CLSM with a fixed laser intensity (compare 
and B). Fractionation of a post nuclear supernatant from untreated and FFA
treated rat hepatocytes by Nycodenz density gradient centrifugation revealed no 





dependent upregulation of Abcd3 by FFA in cultured hepatocytes.
agonist (FFA) stimulation, we 
-treated rat hepatocytes (Fig. 4 C and D). Baat was predominantly detected 
-treatment of rat hepatocytes had similar effects, which may directly 
α activation in mice results in a relative increase in 
-dependently increased Abcd3 mRNA and 
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the peroxisomal matrix proteins Baat and catalase.
 
A and B) Immunostaining  for Pmp70 reveals a strong increase of punctuated Pmp70 signal in rat hepatocyt
treated with 50µM FFA for 24 hours (B) when compared to untreated hepatocytes (A).
C and D) Western blot analysis of Nycodenz gradient fraction after separation of post
from control (C) and FFA
loaded. Gapdh (cytosolic marker) remains in the top fractions after centrifugation. PMP70 and Baat migrate to high 
density fractions peaking at 
organelles containing Baat and Pmp70 in fractions 9
Nycodenz density gradient centrifugation. These may represent immatu
and Baat show a similar fractionation patterns in control and FFA
E and F) Western blot analysis of supernatant (S) and pellet (P) fractions after extraction of control (E) and FFA
treated (F) h
extracted at low concentrations digitonin (30 µg/mL), whereas catalase and Baat are only effectively extracted at 
high digitonin concentrations (500 µg/mL). The
hepatocytes.
 FFA treatment induces PMP70 expression without affecting its intracellular distribution or that of 
epatocytes with increasing concentrations of digitonin. Gapdh (cytosolic marker)  is completely 
 
-treated (D) rat hepatocytes. Fractions 16
fractions 2-5 where typically mature peroxisomes are detected. The nature of the 
 extraction profile is the same for control and FFA
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in high density fractions (fractions 2
conditions. Besides the typical high
enriched in Pmp70 and Baat (fractions 9




not alter the subcellular location of peroxisomal matrix proteins, we performed 
digitonin permea
(Fig. 4 E and F) (Pellicoro 
control rat hepatocytes to 30 
cytosolic marker Gapdh 
the cellular fraction representative of a peroxisomal location. Only at 500 µg 
digitonin, catalase and Baat are fully extracted from the cells (Fig. 4E). An identical 
digitonin
treated rat hepatocytes (Fig. 4F). 
 
FFA does not affect expression of plasma membrane bile salt transporters.
Bile salt fluxes through hepatocytes are largely controlled by the bile salt 
transporters Ntcp (
treatment caused any changes in the levels of these two proteins and found that 
they remained unaffected by FFA concentrations ranging from 25 to 250 
5). 
Collectively, these data show that FFA 
strong increase in peroxisomal Pmp70, without affecting key bile salts transporters 












Increased CA to TCA conversion by FFA
Next, we analyzed whether FFA treatment modulates 
conjugation of bile salts by exposing rat hepatocytes to deuterium
acid (D
conjugated cholic acid (D
to a significant decrease in cellular D
44%). Similarly, cellular D
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-treated rat hepatocytes.
Figure 5: FFA treatment does not
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treated hepatocytes. Data are presented as relative 
concentrations compared to control cells.  Intracellular 
levels of both D
FFA
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In this study, we examined the putative role of Pmp70 in glycine/taurine 
conjugation and/or transhepatocyte transport of externally added cholic acid (CA) 
by primary rat hepatocytes. Induction of Pmp70 by the PPARα ligand fenofibric 
acid (FFA) lead to increased conversion of CA to TCA, while simultaneous 
inhibition of Pmp70 expression through RNA interference suppressed the 
conversion of TCA leading to reduced concentrations of TCA in de medium. In 
addition, intracellular levels of CA and TCA decreased in FFA-treated rat 
hepatocytes, which were increased again when co-treated with Pmp70-specific 
RNA interference. These data suggest the involvement of Pmp70 in transcellular 
bile salt transport and/or conjugation to taurine. 
Peroxisomes house the enzymes for the final steps in bile salt synthesis. This 
includes bile acid-coenzyme A:amino acid N-acyltransferase  (Baat) that conjugates 
taurine or glycine to de novo synthesized chenodeoxycholic acid (CDCA) and cholic 
acid (CA). Baat is also essential for reconjugation of bile salts that are deconjugated 
by intestinal bacteria and return to the liver. Thus, for the efficient taurine/glycine 
conjugation, bile salt (-intermediates) are transported in and out peroxisomes. 
Protein-mediated transport of the C27 bile acid biosynthesis intermediates 3 alpha,7 
alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid (THCA) and 3 alpha,7 alpha-
dihydroxy-5 beta-cholestanoic acid (DHCA) across peroxisomal membranes, as 
well as the primary bile salts GCA and TCA, has been previously demonstrated 
(15, 16). Transport of THCA and DHCA, especially their CoA-activated forms, was 
shown to be stimulated by ATP, while transport of GCA and TCA was not. 
Moreover, transport of THCA-CoA was inhibited by N-ethymaleimide, sodium 
azide and verapamil, known inhibitors of ABC-transporters. Irrespective of the 
biochemical characteristics of the putative peroxisomal bile salt transporters, the 
identity of the peroxisomal bile salt transporters remains elusive so far.  
Pmp70 is a likely candidate to act as importer for bile salt (-intermediates) into 
peroxisomes. It is highly expressed in hepatocyte peroxisomes and its topology 
suggests it to transport substrates into peroxisomes. It is an ABC transporter 
requiring ATP to efficiently transport substrates, even against steep concentration 
gradients. Indeed, unpublished studies have been reported that suggest a role for 
Pmp70 in the transport of bile acid intermediates, however, no experimental data 
are publicly available yet to firmly support this claim (33, 34). More solid evidence 
is available to show that Pmp70 translocates CoA-activated long chain fatty acids 
into peroxisomes (18, 19), but this does not exclude a possible involvement of 
Pmp70 in transport of bile salt intermediates, as many ABC transporters have a 
broad substrate specificity. 
Here, we analyzed the putative role of Pmp70 in the process of bile acid re-
conjugation of C24 bile salts that reside in the pool of enterohepatic cycling bile 



















































Figure 9. Putative role of Pmp70 in peroxisomal import of CoA
 
A model where Pmp70 plays a general role in (putative) import of both bile acid intermediates and de
salts returning from enterohepatic circulation for their conjugation inside peroxisomes. 
Fenofibric acid (FFA
PPRE located in the Pmp70 promoter, which results in Pmp70 upregulation. Ppar
upregulation (Aldp and other possible heterodimerizing partners are shown in gre
heterodimerizing partners of Pmp70 (ALDPR and P70R). Pmp70 (putative) heterodimerization is proposed since 
different substrates (originating from 
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facilitate their import as a homodimer. It has been established that peroxisomal import of bile acid
(green and red arrows) is ATP
independent (pink oval).
 
 to be imported into peroxisomes for their further processing. It is possible however, that Pmp70 might 
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Pmp70 expression was manipulated by treatment of primary rat hepatocytes with 
fenofibric acid (FFA) with or without co-treatment with Pmp70-specific siRNA. 
Unfortunately, Pmp70 protein expression could not be significantly reduced in 
control hepatocytes using siRNA. Even though mRNA levels of Abcd3 were 
strongly reduced 16 h after transfection, Pmp70 protein levels remain comparable 
to control-transfected rat hepatocytes. This suggests that Pmp70 is a relatively 
stable protein in primary rat hepatocytes. Using the same experimental setup, we 
have been able to effectively reduce protein levels of caveolin-1 in primary rat 
hepatocytes (32). Successful siRNA-mediated Pmp70 silencing has been reported 
for C6 rat glial cells (35). These cells are highly proliferative in culture, while 
primary rat hepatocytes are not, which may be the main reason why Pmp70 
protein reduction was not detected in the later cells. 
Consequently, we needed to design an alternative approach to manipulate Pmp70 
levels in rat hepatocytes. We aimed to increase the Pmp70 expression level by 
treating rat hepatocytes with FFA and analyze the effect on taurine conjugation 
and transcellular transport of D4CA. As FFA activates PPARα and will change 
expression of multiple genes (24, 26, 36, 37), we determined Pmp70-specific effects 
on CA conjugation  and transport by preventing induction of Pmp70 through FFA 
by co-treatment with siRNA. 
FFA rapidly induced Abcd3 mRNA levels in culture rat hepatocytes, which was 
mirrored by a rapid (within 24 h) and strong (5-10 fold) induction of Pmp70 
protein. FFA-treated rat hepatocytes exposed for 3 h to 100 µM D4CA showed a 
clear reduction in intracellular accumulation of D4CA and D4TCA in conjunction 
with a small, but significant increase in D4TCA in the medium. Importantly, 
expression of other genes/proteins in the D4CA conjugation and transport cascade, 
e.g. Ntcp(Slc10a1), Bal/Fatp5, Baat and Bsep (Abcb11), was not significantly 
changed by the 24 h treatment with FFA.  
Although reduced levels of Baat have been reported in livers of mice fed with 
PPARα agonists (12), we did not observe this in short-term FFA-exposed primary 
rat hepatocytes. Reduced Baat expression in vivo may thus be caused by secondary 
factors (e.g. long-term dietary effect) unrelated to transcriptional regulation by 
PPARα.  
To establish a direct effect of Pmp70 in the D4CA conjugation and transport 
process, we combined the FFA exposure with Abcd3-targeted siRNA treatment. 
Indeed, the FFA-induced expression of Pmp70 was strongly suppressed by the co-
treatment with siRNA. These cells showed increased intracellular levels of D4CA 
and D4TCA again with reduced accumulation of D4TCA in the medium. Taken 
together, these data suggest a direct role for Pmp70 in taurine conjugation and/or 
transcellular transport of CA in hepatocytes and thus plays a role in maintaining 
high levels of conjugated bile salts in the pool that cycle between the liver and 
intestine. 
A limitation of our study is the relative small effect that is observed on CA 
conjugation and transport in relation to the strong changes in Pmp70 expression. 
Rat hepatocytes contain high amounts of Pmp70, which may be involved in 
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transport of a variety of different substrates, including bile salt (intermediate)s. The 
Pmp70 levels in control cells may therefore be largely sufficient to accommodate 
the flux of CA-metabolites in our in vitro assay. Still, FFA-induction of Pmp70 and 
RNAi-mediated inhibition of Pmp70 showed consistent effects on CA conjugation 
and transcellular transport, implying a role for this protein in this process. 
Obviously, a full knock down of Pmp70 expression, either in vitro or in vivo, may 
definitely establish the role of Pmp70 in transport of bile salt (intermediates) into 
the peroxisome. In this respect, it is encouraging that unpublished data suggest 
that bile salt intermediates accumulate in the Abcd3 knock out mouse. On the other 
hand, bile salt conjugation may not be completely blocked in the absence of Pmp70 
as peroxisomes treated with proteinase K still show uptake of THCA and THCA-
CoA (16). Thus, also passive diffusion may partly compensate for the absence of 
transporter-mediated import of bile salt (intermediates) into peroxisomes. Pmp70 
deficiency may therefore not result in a strong phenotype as observed for patients 
with genetic defects in bile salt biosynthesis, transport or in patients with 
peroxisome biogenesis disorders (1, 2, 34, 38-42). On the other hand, it appears 
likely that Pmp70 is also involved in transport of other substrates, like long chain 
fatty acids, as it is broadly expressed in many tissues, e.g. not restricted to digestive 
organs that metabolize and transport bile salts. 
It seems likely that one transporter is responsible for both the import of C27 (de novo 
synthesis) and C24 (enterohepatic cycling) of bile salt (intermediates) into 
peroxisomes. However, two separate transporters with high substrate specificity 
cannot be excluded at this moment. Alternatively, Pmp70 may form heterodimers 
with other peroxisomal ABC transporters, like ALDP (Abcd1) or ALDPR (Abcd2) 
and thereby form transporters with specific affinities for selected substrates. This 
could be a potent regulatory mechanism for peroxisomal bile salt transport 
activities. Peroxisomal transport would then be an extremely flexible and efficient 
process:  when necessary, new transporter formulations could be formed in an 
immediate response to changing substrate demands (see Figure 9). ALDP-
deficiency in adrenoleukodystrophy, however, is not associated with changes in 
the bile salt profile, thus it is not an obligate partner for Pmp70 in transport of bile 
salt (intermediates) (43). 
In conclusion, our data provide first experimental evidence that Pmp70 is involved 
in the import of bile salt intermediates into hepatocyte peroxisomes. Future 
experiments with whole body- or liver-specific knock-down of Pmp70 in mice need 
to reveal its effect on bile salt homeostasis in vivo to establish if defects in 
peroxisomal bile salt transport machinery may contribute to cholestatic disorders. 
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Introduction: Peroxisomes are particularly abundant in the liver and are involved 
in bile salt synthesis and fatty acid metabolism. Peroxisomal membrane proteins 
(PMPs) are required for peroxisome biogenesis, e.g. the interacting partners Pex13p 
and Pex14p, and its metabolic function, e.g. the ATP-binding cassette (ABC) 
transporters ALDP and PMP70. Impaired function of PMPs is the underlying cause 
of Zellweger syndrome and X-linked adrenoleukodystropy (X-ALD). Here, we 
studied for the first time the putative association of PMPs to cholesterol-enriched 
lipid rafts and their function in peroxisome biogenesis. 
Material and methods: Lipid rafts were isolated from Triton X-100- or Lubrol WX-
lyzed HepG2 cells and analyzed for the presence of various PMPs by western 
blotting. Lovastatin and methyl-β-cyclodextrin were used to deplete cholesterol 
and disrupt lipid rafts in HepG2 cells, followed by immunofluorescence 
microscopy to determine the subcellular location of catalase and PMPs. 
Cycloheximide was used to inhibit protein synthesis. GFP-tagged fragments of 
PMP70 and ALDP were analyzed for their lipid raft association. 
Results: PMP70 and Pex14p are associated with Triton X-100-resistant rafts, ALDP 
with Lubrol WX-resistant rafts and Pex13p is not lipid raft associated in HepG2 
cells. The minimal peroxisomal targeting signals in ALDP and PMP70 are not 
sufficient for lipid raft association. Cholesterol depletion leads to dissociation of 
PMPs from lipid rafts and impaired sorting of newly synthesized catalase and 
ALDP, but not Pex14p and PMP70. Repletion of cholesterol to these cells efficiently 
reestablished the peroxisomal sorting of catalase, but not for ALDP.  
Conclusions: Human PMPs are differentially associated with lipid rafts 
independent of protein homology and/or their functional interaction. Cholesterol 
















Peroxisomes are single membrane-bound organelles that are especially abundant 
in the human liver. They are involved in a wide range of metabolic processes, 
including β-oxidation of fatty acids, bile acid biosynthesis, plasmalogen 
biosynthesis and the removal of reactive oxygen species that are generated as a 
consequence of the high peroxisomal metabolic activity (1, 2). Malfunctioning of 
peroxisomes is associated with life-threatening diseases like Zellweger Syndrome 
(ZS) and X-linked adrenoleukodystrophy (X-ALD). ZS is caused by mutations in 
PEX genes and is characterized by impaired bile salt synthesis leading to the 
accumulation bile salt intermediates (3). PEX genes encode proteins called 
peroxins, which are required for the normal biogenesis of peroxisomes. 16 different 
human peroxins have been identified to date. Most of these proteins are associated 
with the peroxisomal membrane and function in import of peroxisomal matrix 
proteins, like catalase and bile acid-CoA:amino acid N-acyltransferase. Pex13p and 
Pex14p (Fig. 1A) are crucial components for the import of peroxisomal matrix 
proteins. They physically interact with each other suggesting that they act together 
in the process of peroxisomal matrix protein import (4, 5).  
X-ALD is caused by mutations in the ABCD1 gene encoding the 
adrenoleukodystrophy protein ALDP. X-ALD is characterized by elevated levels of 
very long chain fatty acids (VLCFAs) in body fluids and reduced VLCFA β-
oxidation in peroxisomes (6). ALDP is an ATP-binding cassette (ABC-) transporter 
that, together with the highly homologous ALDRP/ABCD2, PMP70/ABCD3 and 
PMP70R/ABCD4 (PMP69), form the ABCD subfamily (2). ALDP expression is 
detected in most tissues with moderate levels in the liver. PMP70 is highly 
expressed in the liver (6). ALDP and PMP70 are thought to be involved in the ATP-
dependent transport of VLCFAs and LCFAs across the peroxisomal membrane, 
respectively. The peroxisomal ABC transporters are so-called half transporters. 
They contain 6 clustered membrane spanning domains and 1 ATP-binding domain 
(Fig. 1A). Dimerization leads to the formation of functional substrate pumps 
resembling the prototypical ABC-transporter, P-glycoprotein/Multidrug resistance 
1 protein (P-gp/MDR1). Our knowledge about the functions of peroxins and 
peroxisomal substrate transporters is steadily increasing, but remarkably little is 
known about the embedding of these peroxisomal membrane proteins (PMPs) in 
the peroxisomal membrane and their association with specific lipids. 
Research on protein-lipid interactions has been especially focused on their 
coexistence in detergent–resistant lipid microdomains, routinely called lipid rafts 
(7, 7, 8, 8). Plasma membrane lipid rafts are enriched in cholesterol and 
(glyco)sphingolipids as well as specific membrane proteins. Biochemically, lipid 
rafts are characterized by their insolubility in non-ionic detergents (typically Triton 
X-100) at low temperatures and their subsequent buoyancy in sucrose flotation 
gradients. They function in protein trafficking, signal transduction, organization of 







association may directly regulate the activity of substrate transporters, including 
that of ABC transporters (12-14).  
In this study, we analyzed the association of the PMPs Pex13p, Pex14p, ALDP and 
PMP70 with peroxisomal lipid rafts. Our data reveal the existence of different 
types of lipid rafts in the peroxisomal membrane and that impaired lipid raft 
assembly leads to peroxisome biogenesis defects.  
  
EXPERIMENTAL PROCEDURES  
 
Pre-established cell lines and plasmids (15-17), as well as standard culture 
conditions and procedures for transient transfection, RNA isolation, quantitative 
Polymerase Chain Reaction (18), SDS-PAGE, western blotting (19) and 
immunofluorescence microscopy (19) are described in Supplementary 
Experimental Procedures. 
 
Isolation of detergent-resistant lipid microdomains (lipid rafts) 
Lipid rafts were isolated from 1×107 HepG2 cells as described by Slimane et al. (20) 
with minor modifications. Cells were washed two times in ice-cold HBSS 
(Invitrogen BV, Breda, The Netherlands) and lysed in 2.5 mL ice-cold TNE buffer 
(20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA) or 1% Lubrol WX (Lubrol 17A17 Serva, Heidelberg, 
Germany) in the presence of CompleteTM protease inhibitors (Roche, Basel, 
Switzerland) and 25U/µL Benzonase® (EMD Biosciences, Inc. La Jolla, CA, USA). 
The cell lysate was passed ten times through a 22g needle and incubated on ice for 
30 min. The lysate was mixed 1:1 with 80% (w/v) sucrose in TNE buffer and 4 ml 
was transferred to the bottom of a 12 mL centrifuge tube and overlaid with 4 mL 
35% (w/v) and 4 mL 5% (w/v) sucrose in TNE buffer. The remainder of the lysate 
in 40% (w/v) sucrose was used as total protein extract (T). The gradients were 
centrifuged for 20 h at 36,000 rpm at 4°C in a Beckman SW 41 rotor. Fractions of 1 
mL were harvested from the top of the gradient. The pellet was resuspended in 1 
mL 35% (w/v) sucrose in TNE buffer and saved as pellet fraction (P). 
 
Cholesterol depletion and repletion of HepG2 cells and use of cycloheximide 
In order to deplete cholesterol from cellular membranes in vitro, the Lubrol WX-
extraction protocol described above was performed in the presence of 10 mM 
methyl-β-cyclodextrin (m-β-CD; Sigma-Aldrich, St. Louis, MO, USA), followed by 
flotation gradient centrifugation. 
Growing HepG2 cells were depleted from cholesterol (in vivo depletion), by 
incubating them for 24 h at 37oC in DMEM (without FBS) in the presence of 10 µM 
lovastatin (Sigma-Aldrich, St. Louis, MO, USA) and/or 2 mM m-β-CD. In selected 
experiments, HepG2 cells were co-treated with 0.02 mg/mL cycloheximide to 
inhibit protein synthesis. In order to restore cellular cholesterol levels, 24 h 
lovastatin/m-β-CD-treated cells were subsequently incubated with preformed    





m- β-CD/cholesterol complexes (400 µg/mL cholesterol) in serum free DMEM, 
essentially as described before (20, 21).  
 
Cholesterol isolation and concentration measurements  
Cholesterol was isolated from total cell extracts using the Bligh-Dyer method (22). 
Cholesterol concentrations were determined spectrophotometrically by a 





Pex13p, Pex14p, PMP70 and ALDP are differentially associated with lipid rafts. 
To determine whether PMPs are associated with detergent-resistant lipid 
microdomains/lipid rafts, we performed the standard lipid raft-extraction protocol 
on liver-derived human HepG2 cells using Triton X-100 or Lubrol WX, followed by 
flotation gradient centrifugation. Figure 1D shows that cytosolic proteins (GAPDH, 
actin) and the peroxisomal matrix protein catalase were solely detected in the 
bottom fractions (8-12) of the gradient after Triton X-100 extraction, whereas 
significant amounts of lipid raft markers (c-Src, flotillin) were detected in fraction 4 
and 5. PMP70 and Pex14p showed a similar gradient distribution as c-Src, 
suggesting that these proteins are, at least partly, associated with lipid rafts 
(quantification shown in supplementary Fig. S1A). In contrast, ALDP and Pex13p 
were only detected in the bottom (solubilized protein) fractions of the gradient. To 
detect less stringent association to lipid rafts, HepG2 cells were also extracted by 
Lubrol WX (Fig. 1C and E). The distribution of marker proteins (GAPDH, actin, 
catalase, flotillin and c-Src) shows that cellular membranes are efficiently disrupted 
by Lubrol WX and that lipid rafts float to fractions 4 to 6. Total protein 
concentrations were slightly higher in fractions 4-6 after Lubrol WX-extraction (Fig. 
1C) compared to Triton X-100 (Fig. 1B), confirming the lower stringency of the 
detergent. As expected, PMP70 and Pex14p were predominantly present in 
fractions 4 to 6 after Lubrol WX extraction (Fig. 1E). In addition, peak fractions of 
ALDP were also observed in these fractions, while Pex13p was solely detected in 
the bottom gradient fractions (Figs. 1E and S1B).  
These data show that PMPs have differential extractability by Triton X-100 and 




























































models for the membrane topology of the human PEX13p, PEX14p, ALDP and PMP70. Numbers indicate amino 
acid positions. ALDP and PMP70 are highly homologous proteins with comparable membrane topology. The 
amino acid positions fo
(B,D) or 1% Lubrol WX (C,D) followed by flotation gradient centrifugation. One (1) ml fractions (in total 12) were 
collected from the top and analyzed for protein concent
volumes from the gradient fractions were analyzed using specific antibodies against the lipid raft markers c
and flotillin, the non
peroxisomal membrane proteins Pex13p, Pex14p, ALDP and PMP70 (D,E). Equal volumes of the unfractionated 
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PMPs dissociate from Lubrol WX
HepG2 membranes in vitro.
Proteins dissociate from lipid rafts when the membrane cholesterol content is 
reduced (24). To analy
HepG2 cells were extracted with Lubrol WX in the presence of 10 mM methyl
cyclodextrin (m
shows that this results in a shift of peak fractions of c
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PMPs dissociate from Lubrol WX
HepG2 membranes in vivo.
Next, we aimed to analyze the effect of peroxi
HepG2 cells. Standard protocols that deplete the plasma membrane from 
cholesterol did not disrupt the raft association of PMPs in HepG2 cells (Fig. S2). 
Therefore, we optimized the conditions to obtain sufficient deple
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cells were lysed in the presence of 1% 
Lubrol WX in the absence (A) and 
presence (B) of 
cyclodextrin followed by 
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cellular cholesterol, including that at intracellular sites. Co
cells with lovastatin (10 µM, cholesterol synthesis inhibitor) and m
lead to a reduction of over 90% of cellular cholesterol levels (Fig. 3A), whic
required to disrupt lipid rafts (25). The larger portion of these cells remained viable 
as indicated by unchanged transcript and protein expression levels of peroxisomal 
marker proteins (Fig. 3B and C), no induction of apoptotic markers (caspase
act
active endocytosis pathway (Fig. S3F
Lubrol WX
Src, PMP70, ALDP and Pex14p were largely absent from the raft
fractions 4 and 5 (Fig. 3E, compared to control cells in Fig. 3D). Pex14p and c
appeared in fractions 8 to 12, indicating that they were s
WX extraction. In contrast, peak levels of PMP70 and ALDP were detected in 
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ivity; Fig. S3A), minor amounts of necrosis (LDH leakage; Fig. S3B) and an 




mRNA’s (B) and proteins (C) were determined in HepG2 cells treated with a combination of 10 µM lovastatin and 
2 mM m
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Effect of cellular cholesterol deple
To determine whether cellular cholesterol depletion affects peroxisome biogenesis, 
we analyzed the subcellular location of PMP70, ALDP, Pex14p and the 
peroxisomal matrix enzyme catalase in lovastatin/m






































A peroxisomal location for all these proteins is detected in untreated HepG2 cells 
(panels A
Figure 4. 
Human HepG2 cells were cultured for 24 h in the absence (A
methyl
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In this study, we show that human peroxisomal membrane proteins are 
differentially associated with lipid rafts and that sequences other than the 
peroxisomal membrane targeting signal (mPTS) are required for lipid raft-
association. Cholesterol depletion leads to missorting of catalase and ALDP, but 
not of Pex14p and PMP70. Peroxisomal sorting of catalase is effectively restored 
upon cholesterol repletion. Thus, cholesterol is required for the assembly of 
peroxisomal lipid rafts and for efficient peroxisome biogenesis.  
Lipid rafts have been detected in plasma membranes and various organellar 
membranes, but this is the first report that they also exist in mammalian 
peroxisomal membranes. A clear hierarchy appears to exist in the lipid raft-
association of PMPs. The ABC-transporter PMP70 and the peroxin Pex14p show 
the strongest lipid raft-association of the PMPs studied here. In contrast, the 
PMP70-homologue, ALDP, is effectively extracted by Triton X-100, but resists 
Lubrol WX solubilisation. The significance of the behavior of membrane proteins 
after Lubrol WX extraction, or any other mild detergent, is a matter of debate (26-
28). However, the fact that the integral PMP Pex13p is completely extracted by 
both detergents strongly suggests that ALDP is embedded in a lipid environment 
different from PMP70, Pex14p and Pex13p. 
Pex13p and Pex14p physically interact with each other and with Pex5p, the cycling 
receptor crucial for targeting of peroxisomal matrix proteins (29-32). Studies with 
the yeast orthologs showed that the relative amounts of Pex13p and Pex14p must 
be tightly balanced for normal peroxisome biogenesis (33). In rat liver, however, 
Pex13p and Pex14p were detected in separate protein complexes in the 
peroxisomal membrane (34). Our observation that Pex14p and Pex13p show 
different lipid raft-association characteristics is in line with the existence of 
separate Pex13p- and Pex14p-containing protein complexes and suggests that their 
transient interaction is crucial for peroxisome biogenesis.  
The cholesterol content in the peroxisomal membrane is low (35). Still, it appears to 
serve a crucial role in peroxisomal lipid raft assembly and sorting of peroxisomal 
matrix and membrane proteins. In cholesterol-depleted HepG2 cells, Pex14p and 
PMP70 become Triton X-100-extractable, but sorting to the peroxisomes is not 
disturbed for these proteins. In contrast, targeting of catalase and ALDP is 
impaired under these conditions. This implies that cholesterol depletion leads to 
selective effects on the sorting of peroxisomal proteins, which is most likely a 
direct effect of the disruption of peroxisomal lipid rafts. If there would be a basal 
requirement for cholesterol for peroxisome biogenesis, than a generalized effect on 
sorting of peroxisomal proteins would be expected when cholesterol levels were 
insufficient.  The peroxisomal sorting of catalase is efficiently re-established when 
cholesterol is supplied to the cholesterol-depleted HepG2 cells. This is most likely 
the result of the reestablishment of the lipid raft association of PMPs involved in 







folded and oligomeric proteins (36). Thus, both newly-synthesized catalase and 
cytosol-accumulated catalase are targeted to peroxisomes when the import 
machinery is restored. Importantly, cholesterol-depletion does not induce leakage 
of resident proteins from peroxisomes as shown by cycloheximide co-treatment. 
Interestingly, cholesterol-repletion did not efficiently restore the peroxisomal 
location of ALDP. This indicates that missorted ALDP is incompetent to return to 
peroxisomes of cholesterol-repleted HepG2 cells and that effective targeting of 
newly-synthesized ALDP is only slowly established in these cells. 
To date, the only other report about lipid microdomains in peroxisomal 
membranes is on ergosterol/ceramide-rich (ECR) domains in peroxisomes of the 
yeast Yarrowia lipolytica (37). These ECR domains play a role in a complex 
transition of pre-peroxisomal structures to mature peroxisomes, but it is unclear 
whether similar mechanisms are involved in human peroxisome biogenesis. 
Therefore, it remains to be determined whether a functional relationship exists 
between the human peroxisomal rafts and the Y. lipolytica ECR domains.  
The distinct detergent-extractability of ALDP and PMP70 indicate that the lipid 
environment of these two highly homologous ABC-transporters in the peroxisomal 
membrane is different. Whether they exist in spatially separated lipid rafts or that 
different extractability is a result of a heterogeneous lipid distribution within one 
raft remains to be determined, as for rafts occurring in other cellular membranes 
(28). Several other ABC transporters, (MDR1/Pgp/ABCB1, MRP1/ABCC1, 
BCRP/ABCG2) have been shown to reside in lipid rafts and their substrate 
transporting activity is regulated by their lipid environment (13, 14, 38-41). It is 
therefore likely that also the activity of PMP70 and ALDP is controlled by their 
association to specific lipids. The protein-lipid interaction is not (solely) 
determined by the mPTSs of ALDP and PMP70, since correctly sorted GFP-tagged 
fragments of ALDP and PMP70 appear not to be lipid raft associated. It is 
interesting to note that significant amounts of ALDP and PMP70 appear to remain 
associated with lipids after Lubrol WX-extraction of cholesterol-depleted HepG2 
cells, as indicated by their accumulation at the 40%-35% sucrose interphase after 
flotation gradient centrifugation. Pex14p and c-Src, in contrast, are fully solubilized 
under these conditions. This may indicate that ALDP and PMP70 are associated 
with other lipids that reside in the peroxisomal membrane. The slight, but highly 
reproducible difference in peak fractions of raft-associated c-Src versus PMPs after 
flotation gradient centrifugation of Lubrol WX-extracted HepG2 cells may be a 
result of this peroxisome-specific lipid environment.  
It is relevant to note that many X-ALD patients are treated with cholesterol 
lowering drugs like lovastatin and simvastatin (42, 43) aimed to reduce VLCFA 
levels. In X-ALD patients with residual ALDP protein-activity, cholesterol 
reduction could theoretically effect the subcellular location of ALDP thereby 
further reducing its function and aggravating X-ALD disease symptoms. In our 
HepG2 cells, treatment with lovastatin alone reduced the cellular cholesterol levels 
to maximally 50% compared to control cells. This reduction did not affect the raft 





association of ALDP, nor PMP70 or Pex14p (supplementary Fig. S5). It is therefore 
unlikely that lovastatin treatment alone will be harmful due to effects on 
peroxisome biogenesis.  
In summary, our data show that PMPs are differentially associated with detergent-
resistant lipid rafts. Cholesterol depletion leads to disruption of the lipid raft 
association and peroxisome biogenesis defects. The role of peroxisomal lipid rafts 
in diseases where peroxisomes are malfunctioning, e.g. Zellweger Syndrome and 
X-ALD, needs further analysis. 
 
ACKNOWLEDGEMENTS 
Dr. J.W. Kok (Department of Cell Biology, UMCG, Groningen, The Netherlands) is 




1.  Wanders RJ, Waterham HR. Biochemistry of 
mammalian peroxisomes revisited. Annu Rev 
Biochem 2006;75:295-332. 
2.  Theodoulou FL, Holdsworth M, Baker A. Peroxisomal 
ABC transporters. FEBS Lett 2006;580(4):1139-1155. 
3.  Sundaram SS, Bove KE, Lovell MA, Sokol RJ. 
Mechanisms of disease: Inborn errors of bile acid 
synthesis. Nat Clin Pract Gastroenterol Hepatol 
2008;5(8):456-468. 
4.  Williams C, Distel B. Pex13p: docking or cargo 
handling protein? Biochim Biophys Acta 
2006;1763(12):1585-1591. 
5.  Azevedo JE, Schliebs W. Pex14p, more than just a 
docking protein. Biochim Biophys Acta 
2006;1763(12):1574-1584. 
6.  Berger J, Albet S, Bentejac M, Netik A, Holzinger A, 
Roscher AA, et al. The four murine peroxisomal ABC-
transporter genes differ in constitutive, inducible and 
developmental expression. Eur J Biochem 
1999;265(2):719-727. 
7.  Simons K, Ikonen E. Functional rafts in cell 
membranes. Nature 1997;387(6633):569-572. 
8.  Brown DA. Lipid rafts, detergent-resistant 
membranes, and raft targeting signals. Physiology 
2006;21:430-439. 
9.  Brown DA, London E. Functions of lipid rafts in 
biological membranes. Annual Review of Cell and 
Developmental Biology 1998;14:111-136. 
10. Simons K, Toomre D. Lipid rafts and signal 
transduction. Nature Reviews Molecular Cell Biology 
2000;1(1):31-39. 
11. Rajendran L, Simons K. Lipid rafts and membrane 
dynamics. J Cell Sci 2005;118(Pt 6):1099-1102. 
12. Troost J, Lindenmaier H, Haefeli WE, Weiss J. 
Modulation of cellular cholesterol alters P-glycoprotein 
activity in multidrug-resistant cells. Molecular 
Pharmacology 2004;66(5):1332-1339. 
13. Dos Santos SM, Weber CC, Franke C, Muller WE, 
Eckert GP. Cholesterol: Coupling between membrane 
microenvironment and ABC transporter activity. 
Biochem Biophys Res Commun 2007;354(1):216-221. 
14. Storch CH, Ehehalt R, Haefeli WE, Weiss J. 
Localization of the human breast cancer resistance 
protein (BCRP/ABCG2) in lipid rafts/caveolae and 
modulation of its activity by cholesterol in vitro. J 
Pharmacol Exp Ther 2007;323(1):257-264. 
15. Kashiwayama Y, Asahina K, Shibata H, Morita M, 
Muntau AC, Roscher AA, et al. Role of Pex19p in the 
targeting of PMP70 to peroxisome. Biochim Biophys 
Acta 2005;1746(2):116-128. 
16. Kashiwayama Y, Asahina K, Morita M, Imanaka T. 
Hydrophobic regions adjacent to transmembrane 
domains 1 and 5 are important for the targeting of the 
70-kDa peroxisomal membrane protein. J Biol Chem 
2007;282(46):33831-33844. 
17. Landgraf P, Mayerhofer PU, Polanetz R, Roscher 
AA, Holzinger A. Targeting of the human 
adrenoleukodystrophy protein to the peroxisomal 
membrane by an internal region containing a highly 
conserved motif. Eur J Cell Biol 2003;82(8):401-410. 
18. Blokzijl H, Vander Borght S, Bok LIH, Libbrecht L, 
Geuken M, Van den Heuvel FAJ, et al. Decreased P-
glycoprotein (P-gp/MDR1) expression in inflamed 
human intestinal epithelium is independent of PXR 
protein levels. Inflammatory Bowel Diseases 
2007;13(6):710-720. 
19. Pellicoro A, van den Heuvel FA, Geuken M, 
Moshage H, Jansen PL, Faber KN. Human and rat 
bile acid-CoA:amino acid N-acyltransferase are liver-
specific peroxisomal enzymes: implications for 
intracellular bile salt transport. Hepatology 
2007;45(2):340-348. 
20. Slimane TA, Trugnan G, van Ijzendoorn SCD, 
Hoekstra D. Raft-mediated trafficking of apical 
resident proteins occurs in both direct and transcytotic 
pathways in polarized hepatic cells: Role of distinct 
lipid microdomains. Molecular Biology of the Cell 
2003;14(2):611-624. 
21. Klein U, Gimpl G, Fahrenholz F. Alteration of the 
myometrial plasma membrane cholesterol content 
with beta-cyclodextrin modulates the binding affinity of 
the oxytocin receptor. Biochemistry 
1995;34(42):13784-13793. 
22. Bligh EG, Dyer WJ. A Rapid Method of Total Lipid 
Extraction and Purification. Canadian Journal of 
Biochemistry and Physiology 1959;37(8):911-917. 
23. Gamble W, Vaughan M, Kruth HS, Avigan J. 
Procedure for Determination of Free and Total 







Suitable for Studies with Cultured-Cells. Journal of 
Lipid Research 1978;19(8):1068-1070. 
24. Laliberte JP, McGinnes LW, Peeples ME, Morrison 
TG. Integrity of membrane lipid rafts is necessary for 
the ordered assembly and release of infectious 
newcastle disease virus particles. Journal of Virology 
2006;80(21):10652-10662. 
25. Foster LJ, De Hoog CL, Mann M. Unbiased 
quantitative proteomics of lipid rafts reveals high 
specificity for signaling factors. Proc Natl Acad Sci U 
S A 2003;100(10):5813-5818. 
26. Shogomori H, Brown DA. Use of detergents to study 
membrane rafts: the good, the bad, and the ugly. Biol 
Chem 2003;384(9):1259-1263. 
27. Chamberlain LH. Detergents as tools for the 
purification and classification of lipid rafts. FEBS Lett 
2004;559(1-3):1-5. 
28. Pike LJ. Lipid rafts: heterogeneity on the high seas. 
Biochem J 2004;378(Pt 2):281-292. 
29. Albertini M, Rehling P, Erdmann R, Girzalsky W, Kiel 
JA, Veenhuis M, et al. Pex14p, a peroxisomal 
membrane protein binding both receptors of the two 
PTS-dependent import pathways. Cell 1997;89(1):83-
92. 
30. Fransen M, Terlecky SR, Subramani S. Identification 
of a human PTS1 receptor docking protein directly 
required for peroxisomal protein import. Proceedings 
of the National Academy of Sciences of the United 
States of America 1998;95(14):8087-8092. 
31. Schliebs W, Saidowsky J, Agianian B, Dodt G, 
Herberg FW, Kunau WH. Recombinant human 
peroxisomal targeting signal receptor PEX5. Structural 
basis for interaction of PEX5 with PEX14. J Biol Chem 
1999;274(9):5666-5673. 
32. Otera H, Harano T, Honsho M, Ghaedi K, Mukai S, 
Tanaka A, et al. The mammalian peroxin Pex5pL, the 
longer isoform of the mobile peroxisome targeting 
signal (PTS) type 1 transporter, translocates the 
Pex7p.PTS2 protein complex into peroxisomes via its 
initial docking site, Pex14p. J Biol Chem 
2000;275(28):21703-21714. 
33. Bottger G, Barnett P, Klein AT, Kragt A, Tabak HF, 
Distel B. Saccharomyces cerevisiae PTS1 receptor 
Pex5p interacts with the SH3 domain of the 
peroxisomal membrane protein Pex13p in an 
unconventional, non-PXXP-related manner. Mol Biol 
Cell 2000;11(11):3963-3976. 
34. Reguenga C, Oliveira ME, Gouveia AM, Sa-Miranda 
C, Azevedo JE. Characterization of the mammalian 
peroxisomal import machinery: Pex2p, Pex5p, 
Pex12p, and Pex14p are subunits of the same protein 
assembly. J Biol Chem 2001;276(32):29935-29942. 
35. Lyons HT, Kharroubi A, Wolins N, Tenner S, 
Chanderbhan RF, Fiskum G, et al. Elevated 
cholesterol and decreased sterol carrier protein-2 in 
peroxisomes from AS-30D hepatoma compared to 
normal rat liver. Arch Biochem Biophys 
1991;285(2):238-245. 
36. Platta HW, Erdmann R. Peroxisomal dynamics. 
Trends Cell Biol 2007;17(10):474-484. 
37. Boukh-Viner T, Guo T, Alexandrian A, Cerracchio A, 
Gregg C, Haile S, et al. Dynamic ergosterol- and 
ceramide-rich domains in the peroxisomal membrane 
serve as an organizing platform for peroxisome fusion. 
J Cell Biol 2005;168(5):761-773. 
38. Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, 
Cogne S, et al. Control of P-glycoprotein activity by 
membrane cholesterol amounts and their relation to 
multidrug resistance in human CEM leukemia cells. 
Biochemistry 2005;44(11):4499-4509. 
39. Marbeuf-Gueye C, Stierle V, Sudwan P, Salerno M, 
Garnier-Suillerot A. Perturbation of membrane 
microdomains in GLC4 multidrug-resistant lung 
cancer cells--modification of ABCC1 (MRP1) 
localization and functionality. FEBS J 
2007;274(6):1470-1480. 
40. Pal A, Mehn D, Molnar E, Gedey S, Meszaros P, 
Nagy T, et al. Cholesterol potentiates ABCG2 activity 
in a heterologous expression system: improved in 
vitro model to study function of human ABCG2. J 
Pharmacol Exp Ther 2007;321(3):1085-1094. 
41. Telbisz A, Muller M, Ozvegy-Laczka C, Homolya L, 
Szente L, Varadi A, et al. Membrane cholesterol 
selectively modulates the activity of the human 
ABCG2 multidrug transporter. Biochim Biophys Acta 
2007;1768(11):2698-2713. 
42. Di Biase A., Salvati S, Vari R, Avellino C, Sforza F, 
Cappa M, et al. Susceptibility to oxidation of plasma 
low-density lipoprotein in X-linked 
adrenoleukodystrophy: effects of simvastatin 
treatment. Mol Genet Metab 2000;71(4):651-655. 
43. Pai GS, Khan M, Barbosa E, Key LL, Craver JR, 
Cure JK, et al. Lovastatin therapy for X-linked 
adrenoleukodystrophy: clinical and biochemical 




















SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
 
Cell lines, culture conditions and transient transfection 
The human hepatoma cell line HepG2 was cultured in Dulbecco’s modified Eagle 
medium (DMEM), supplemented with GlutaMax-1, 4,500 mg/L D-glucose, sodium 
pyruvate, pyridoxine and with 10% (v/v) heat-inactivated (56°C, 30 min) fetal 
bovine serum (FBS), 100 U/mL penicillin G, 100 mg/mL streptomycin and 250 
ng/mL fungizone (Invitrogen BV, Breda, the Netherlands). The cell cultures were 
passaged twice a week. HepG2 cells were transfected using Lipofectamin 2000 
(Invitrogen BV, Breda, The Netherlands) at a ratio of 3 µL Lipofectamin 2000 per 
µg plasmid DNA as recommended by the manufacturer. 
 
Plasmids 
Plasmids expressing PMP70(AA.1-659)-GFP, PMP70(AA.1-375)-GFP, PMP70(AA.1-
144)-GFP, ALDP(AA.1-745)-YFP, ALDP(AA.1-281)-GFP, ALDP(AA.1-164)-GFP, 
ALDP(AA.67-164)-GFP have been described before (15-17). 
 
RNA isolation and Quantitative Polymerase Chain Reaction (Q-PCR) 
The isolation of total RNA, its conversion to cDNA and its analysis by Q-PCR was 
carried out as described before (18). Primers and probes used in this study are 
listed in supplementary Table S1. The expression of each gene of interest was 
normalized to 18S (∆∆Ct method). 
 
SDS-PAGE and western blotting 
Equal volumes of the gradient fractions and the fractions P and T were separated 
by SDS-PAGE and analyzed by western blotting according to established 
procedures (19). Protein concentrations were determined using the Bio-Rad Protein 
Assay system (Bio-Rad Hercules, CA, USA) using bovine serum albumin as 
standard. All primary antibodies used are listed in supplementary Table S2. Horse 
radish peroxidase-conjugated secondary antibodies (HRP-conjugated swine-anti 
rabbit, rabbit anti-goat and rabbit anti-mouse, Dako A/S, Glostrup, Denmark) and 
the phototope®-HRP Western Blot Detection System (Cell Signaling technology 
Inc, Danvers, MA) were used for detection according to the manufacturers’ 
protocols. The blots were exposed in a ChemiDoc XRS system (Bio-Rad). Protein 
band intensities were quantified by the Quantity One software (Bio-Rad, Hercules, 
CA, USA).  
 
Immunofluorescence microscopy 
Control, cholesterol-depleted and cholesterol-repleted HepG2 cells (6x105 cells) 
were fixed with 4% paraformaldehyde, labeled and analyzed as described 






















































Figure S1. Quantification of western blot signals of flotation gradients after Triton X
extraction of HepG2 cells. 
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Figure S3. Analysis of necrosis, apoptosis and endocytosis in cholesterol
Human HepG2 cells were cultured for 24 h in the absence (control) or presence of 10 µM lovastatin and 2 mM 
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Background: Caveolae are a subtype of cholesterol-enriched lipid 
microdomains/rafts that are routinely detected as vesicles pinching off from the 
plasmamembrane. Caveolin-1 is an essential component of caveolae. Hepatic 
caveolin-1 plays an important role in liver regeneration and lipid metabolism. 
Expression of caveolin-1 in hepatocytes is relatively low and it has been suggested 
to reside also at other subcellular locations than the plasmamembrane. Recently, 
we found that the peroxisomal membrane contains lipid microdomains. Like 
caveolin-1, hepatic peroxisomes are involved in lipid metabolism. Here, we 
analyzed the subcellular location of caveolin-1 in rat hepatocytes. 
Methods: The subcellular location of rat hepatocyte caveolin-1 was analyzed by cell 
fractionation procedures, immuno-fluorescence and immuno-electron microscopy. 
GFP-tagged caveolin-1 was expressed in rat hepatocytes. Lipid rafts were 
characterized after Triton X-100 or Lubrol WX extraction of purified peroxisomes. 
Fenofibric acid-dependent regulation of caveolin-1 was analyzed. Peroxisome 
biogenesis was studied in rat hepatocytes after RNA interference-mediated 
silencing of caveolin-1 and caveolin-1 knock out mice. 
Results: Cell fractionation and microscopical analyses reveal that caveolin-1 
colocalizes with peroxisomal marker proteins (catalase, PMP70, ALDP, Pex14p, 
BAAT) in rat hepatocytes. Artificially expressed GFP-caveolin-1 accumulated in 
catalase-positive organelles. Peroxisomal caveolin-1 is associated with detergent-
resistant microdomains. Caveolin-1 expression is strongly repressed by the 
PPARα-agonist fenofibric acid. Targeting of peroxisomal matrix proteins, 
peroxisome number and shape were not altered in rat hepatocytes with 70-80% 
reduced caveolin-1 levels and in livers of caveolin-1 knock out mice. 
Conclusions: Caveolin-1 is enriched in peroxisomes of hepatocytes. Caveolin-1 is 
not required for peroxisome biogenesis, but this unique subcellular location may 













Caveolae are subtypes of lipid microdomains/rafts that are morphologically 
recognizable as flask-like invaginations of the plasma membrane. They are 
particularly involved in signal transduction and endocytosis (1). The characteristic 
protein component of caveolae are the caveolins that interact strongly with 
cholesterol (2). Three different caveolins (caveolin-1, caveolin-2 and caveolin-3) 
have been described. Caveolin-1 is crucial for the formation of caveolae in non-
muscle cells (1) and is highly expressed in lung, heart and adipose tissue (3). In 
accordance with this expression profile, severe pulmonary defects, abnormal 
cardiac function and lipid disorders have been reported in caveolin-1 knockout 
mice (4-6).  
Caveolin-1 is only moderately expressed in the liver (7, 8), where it has been 
detected in hepatocytes, Kupffer cells, stellate cells and endothelial cells (8-12). 
Still, hepatic caveolin-1 is involved in important metabolic pathways like 
(intracellular) cholesterol trafficking (13) and lipid homeostasis (14). The important 
function of hepatic caveolin-1 is evident from the impaired liver regeneration and 
low survival of caveolin-1-/- mice after partial hepatectomy (15). In hepatocytes, 
caveolin-1 has been detected in the plasmamembrane. However, significant 
amounts of caveolin-1 have also been detected intracellularly, where it has been 
reported to localize to lipid droplets, endoplasmic reticulum, Golgi and/or 
mitochondria (3, 8, 14). We became interested in a putative peroxisomal 
localisation of caveolin-1 after we detected that the peroxisomal membrane 
contains lipid microdomains/rafts (Woudenberg, J. et al., Chapter 4).  
Peroxisomes are required for important hepatocyte functions like bile acid 
biosynthesis and β-oxidation of very long chain fatty acids (VLCFAs) (16, 17). 
Typical marker proteins for peroxisomes are the peroxins that are required for 
peroxisome biogenesis, the peroxisomal antioxidant enzyme catalase and the 
peroxisomal ATP-binding cassette (ABC) transporters, the Adrenoleukodystrophy 
Protein (ALDP, ABCD1) and 70 kDa Peroxisomal Membrane Protein (PMP70) (18, 
19). Recently, we found that ALDP, PMP70 and the peroxins Pex13p and Pex14p 
are differentially associated with lipid rafts in human peroxisomes (Woudenberg, J. 
et al., Chapter 4). Cellular depletion of cholesterol leads to defective sorting of the 
peroxisomal enzyme catalase, indicating that lipid rafts are required for 
peroxisome biogenesis.  
As caveolae are a subtype of lipid rafts, we here analyzed the subcellular location 
of caveolin-1 in rat hepatocytes using biochemical and microscopical techniques. 
Caveolin-1 was predominantly detected in peroxisomes. Expression of caveolin-1 
is strongly reduced after exposure to fenofibric acid, a strong ligand for the 
peroxisome proliferator activated receptor alpha (PPARα). Peroxisome biogenesis 
defects were not observed after RNA-mediated silencing of caveolin-1 in rat 
hepatocytes and in livers of caveolin-1 knock out mice. We discuss these findings 











Specified pathogen-free male Wistar rats (220–250 g) were purchased from Charles 
River Laboratories Inc. (Wilmington, MA, USA). They were housed under 
standard laboratory conditions with free access to standard laboratory chow and 
water. Experiments were performed following the guidelines of the local 
Committee for Care and Use of laboratory animals.  
Caveolin-1 knock out and wild type mice (4, 15) were kept under a controlled 
humidity and lighting schedule with a 12 hours dark period. All animals received 
human care in compliance with institutional guidelines regulated by the European 
Community. Food and water were available ad libitum. Male mice were sacrificed 
at the age of 12 weeks after which livers were removed and processed for western 
blotting or immunofluorescence microscopy. 
 
Primary cells and culture conditions 
Hepatocytes were isolated and cultured in William’s E medium as described 
previously (20). Cells were cultured in a humidified incubator at 37 °C and 5% 
CO2. Hepatocyte viability and purity were always more than 90% as assessed by 
trypan blue exclusion. 
 
Plasmids and transient transfection 
Full-length mouse caveolin-1 cDNA was obtained from C2C12 myoblast cells by 
PCR and cloned into pGEM-T-easy (Promega, Leiden, Netherlands). Constructs 
were sequenced and a clone without errors was selected. BglII and SalI restriction 
sites were added to the caveolin-1 cDNA by PCR using adapter-primers  
(For-BglII: 5’-GGACTCAGATCT-ATGTCTGGGGGCAAATACGTGGAC-3’, Rev-
SalI: 5’-TACAAGAGTCGA-CTGCGAGAGCAACTTGGAATTG-3’). The resulting 
PCR product was inserted as a BglII-SalI DNA fragment in the corresponding sites 
of pEGFP-C1 (Clontech, Palo Alto, CA, USA), resulting in an expression vector 
with caveolin-1 fused to the C-terminus of enhanced green fluorescent protein 
(EGFP).  
Primary rat hepatocytes were transiently transfected with EGFP-caveolin-1 using 
electroporation, as described previously (21). After 48 h, the expression of the 
hybrid protein was analyzed by western blotting and the subcellular location of 
EGFP-caveolin-1 was analyzed using fluorescence microscopy. 
 
 
Caveolin-1 RNA interference 
Primary rat hepatocytes were plated at a density of 1.25 x 105 cells/cm2 in 
William’s E Medium with Glutamax supplemented with 1% heat-inactivated fetal 
calf serum (Invitrogen) and dexamethasone (Sigma-Aldrich, St. Louis, MO) in the 






presence of double-stranded siRNA duplexes (Table 1) aimed to silence caveolin-1 
(siRNA-Cav, Invitrogen). Control cells were transfected with oligonucleotides 
directed against luciferase (siRNA-Luc, Invitrogen). Lipofectamine (Invitrogen) 
was used as transfection reagent according to the manufacturer’s instructions. 
After 24 h, cells were either fixed for immunofluorescence microscopy or lysed for 
Q-PCR or western blot analysis. 
 
Table 1. Primers used for caveolin-1 RNA interference 
 
RNA Sense Antisense Company/Reference 
luciferase 5'-cuu acg cug agu acu ucg auu-3' 5'-ucg aag uac uca gcg uaa guu-3' Invitrogen 
caveolin-1 5’-aau cuc aau cag gaa gcu cuu -3’ 5-gag cuu ccu gau uga gau uuu-3’ Invitrogen, (38) 
 
Fenofibric acid treatments 
Primary rat hepatocytes were plated as described previously (20). Four (4) hours 
after plating, cells were incubated with 50 µM fenofibric acid (Sigma-Aldrich) or 
0.1% DMSO (solvent for fenofibric acid) for 24 h. Cells were lysed for Q-PCR or 
western blot analysis. 
 
RNA isolation and Quantitative Polymerase Chain Reaction (Q-PCR) 
The isolation of total RNA, its conversion to cDNA and its analysis by Q-PCR was 
carried out as described previously (22). Primers and probes used in this study are 
listed in Table 2. The expression of each gene of interest was normalized with 
respect to the endogenous control, 18S (∆∆Ct method). 
 
Table 2. Primers and probes 
Gene Sense Antisense Probe 
18S 5'-cgg cta cca cat cca agg 
a -3' 5'-cca att aca ggg cct cga aa-3' 
5'FAM-cgc gca aat tac cca ctc ccg a-
TAMRA3' 
caveolin-1 5’-aac cgc gac ccc aag c-3’ 
5-ccg caa tca cat ctt caa agt c-
3’ 
5’FAM-tct caa cga cga cgt ggt caa gat-
TAMRA3’ 
Pex11p 5´-gcc cgc cac tac tac tat ttc ct-3´ 5´-tct gtc gcg tgc aac ttg tc-3´ 
5´FAM-cat atg cag caa gac ctc ata cag 
atc ccg -TAMRA3´ 
PMP70 5’-ctg gtg ctg gag aaa tca tca at-3’ 
5’-cca gat cga act tca aaa cta 
agg t-3’ 
5’FAM-tga tca tgt tcc ttt agc aac acc 
aaa tgg-TAMRA3’ 
AOX 5´-gcc acg gaa ctc atc ttc ga-3´ 5´-cca ggc cac cac tta atg ga-3´ 
5´FAM-cca ctg cca cat atg acc cca aga 
ccc-TAMRA3´ 
Baat 5´-tgt aga gtt tct cct gag 
aca tcc taa-3´ 5´-gtc caa tct ctg ctc caa tgc-3´ 
5´FAM-tgc caa ccc ctg ggc cca g-
TAMRA3´ 
catalase 5’-gga tta tgg cct cc gaga tct-3’ 
5-acc ttg gtc agg tca aat gga t-
3’ 
5’FAM-atg cca tcg cca gtg gca att acc-
TAMRA3’ 
 
Subcellular fractionation and isolation of peroxisomes 
The subcellular fractionation and isolation of peroxisomes from rat liver was 
performed as described previously by Antonenkov et al. using isolation medium-3 
(23). Peroxisomes were further purified from the 17,000 x g pellet by Nycodenz 
density gradient centrifugation according to established methods (24). For 
westernblot analysis, pellet fractions were resuspended in the same volume as the 








Isolation of detergent-resistant microdomains from peroxisomes 
Purified peroxisomal fractions from the Nycodenz gradients were pooled and 
centrifuged in an SS34 rotor at 17,000 x g. The pellets (1-1.5 mg protein) were 
subjected to extraction by 1% Triton X-100 (Sigma-Aldrich) or 1% Lubrol WX 
(Sigma-Aldrich) for the isolation of Triton X-100- or Lubrol WX-resistant rafts, 
respectively, according to established methods (25). Equal volume fractions of the 
gradient were analyzed by western blotting. 
 
SDS-PAGE and western blotting 
Protein samples were separated by SDS-PAGE and analyzed by western blotting as 
described before (21). Protein concentrations were determined using the Bio-Rad 
Protein Assay system (Bio-Rad Hercules, CA, USA) using bovine serum albumin 
as standard. Primary antibodies used are listed in Table 3. Horse radish 
peroxidase-conjugated secondary antibodies (HRP-conjugated swine anti-rabbit, 
rabbit anti-goat and rabbit anti-mouse, Dako A/S, Glostrup, Denmark) and the 
phototope®-HRP western blot Detection System (Cell Signalling Technology Inc, 
Danvers, MA, USA) were used for detection according to the manufacturers’ 
protocols. The blots were exposed in a ChemiDoc XRS system (Bio-Rad).  
 
Immunofluorescence microscopy 
Immunofluorescence microscopy was performed on 4-µm thick sections from 
paraffin-embedded mouse liver as well as on paraformaldehyde (4%)-fixed 
primary rat hepatocytes.  
 
Table 3. Antibody dilutions for protein analysis 
Antibody WB IF EM Company/Reference 
Mouse α-ALDP 1:1000 1:100  Clone 1D6, Euromedex, Mundolsheim France 
Rabbit α-Baat 1:2000   Generous gift of Prof. C. Falany, USA (39) 
Rabbit α-BSEP 1:2000   (40) 
Rabbit α-calnexin 1:2000   SPA 860D, Stressgen, MI, USA 
Rabbit α-catalase 1:2000 1:200  Calbiochem, La Jolla, CA, USA 
Mouse α-catalase 1:2000 1:200 1:200 Sigma-Aldrich, St. Louis, MO, USA 
Rabbit α-caveolin-1 1:1000 1:100 1:100 N20, Santa Cruz Inc, CA, USA 
Mouse α-cytochrome C 1:2000   BD Biosciences, Franklin Lakes, NJ, USA 
Mouse α-Gapdh 1:10.000   Calbiochem, La Jolla, CA, USA 
Mouse α-EGFP 1:1000   Roche Diagnostic, Almere, NL 
Goat α-Pex13p 1:1000   Abcam, Cambridge, UK 
Rabbit α-Pex14p 1:2000   Generous gift of Dr. M. Fransen, BE (41) 
Rabbit α-PMP70 1:1000   Sigma-Aldrich, St. Louis, MO, USA 
Rabbit α-c-Src 1:500   sc18, Santa Cruz Inc., CA, USA 
 
Sections were deparaffinized in xylene followed by rehydration and antigen 
retrieval was performed using EDTA buffer. Liver sections and hepatocytes were 
labelled and analyzed as described previously (21). Primary antibody dilutions are 
listed in Table 3. Images were captured with a TCS SP2/AOBS confocal laser 







All numerical results are reported as the mean of at least 3 indep
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Primary rat hepatocytes were analyzed by immunofluorescence microscopy to determine the subcellular location 
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To obtain further proof for a peroxisomal location of hepatic caveolin
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antibodies against EGFP, a protein band with the expected molecular weight of 49 
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To confirm the presence of caveolin
fractionation studies on rat liver. After differential centrifugation of osmotically
stabilized total liver homogenates, caveolin
the 17,000 x g pellet fraction also containing the markers for peroxisomes, 
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17,000 x g pellet fraction were separated using Nycodenz density gradient 
centrifugation. Western blot analyses showed that the peroxisomal markers 
PMP70, Pex14p, catalase and Baat were enriched in fractions 3
unique high density
was also highly enriched in these fractions and clearly separated away from 
mitochondria (cytochrome C, fractions 12
fractions 12
fractions 12
peroxisomes during cell fractionation studies of rat liver. Only minor amounts may 


























In order to determine whether peroxisomal caveolin
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Importantly, significant amounts of Pex14p, PMP70 and cav
X-
reported before in human HepG2 cells (Woudenberg, J. et al, Chapter 4). PMP70 
and Pex14p largely resisted Lubrol WX extraction when performed on purified
peroxisomes (Fig 4B) and total hepatocyte lysates (Fig. S3B), with a predominant 
flotation to fractions 4 and 5. As expected, also the majority of peroxisomal 
caveolin
catalase and Baat
fraction in this gradient (Fig. 4B). These results demonstrate that peroxisomal 
caveolin























peroxisomal location of Baat in primary rat hepatocytes.
To study whether caveolin
enzymes, we inhibited its expression by RNA interference. Transient transfection 
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cells (Fig. 5B, C). Immunofluorescence microscopy analysis showed that the 
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Catalase sorting, peroxisome number and shape in hepatocytes of caveolin
knock out mice.
To obtain conclusive evidence for a putative role of caveolin
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Finally, we determined whether expression of caveolin
genes encoding peroxisomal proteins. Primary rat hepatocytes were treated for 24 
h with the ligand for PPA
Pex11, PMP70 and acyl coenzyme A oxidase (AOX) were strongly induced by this 
compound (Fig. 7A). In contrast, expression of Baat was not responsive to 
fenofibric acid treatment. Remarkably, fenofibric a
the mRNA levels of caveolin
These data show that expression of caveolin
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In this study, we show that caveolin-1 in rat hepatocytes is present in peroxisomes. 
Peroxisomal caveolin-1 is highly resistant to Triton X-100 extraction, more so than 
PMP70 and Pex14p that were previously shown to reside in peroxisomal lipid rafts 
(Woudenberg, J. et al., Chapter 4). Hepatic caveolin-1 is negatively regulated by the 
PPARα agonist fenofibric acid, which induces peroxisome proliferation. In line 
with this, peroxisome biogenesis is still intact in the absence of caveolin-1. 
Expression of caveolin-1 in the liver is relatively low (7, 8), where it is particularly 
enriched in endothelial cells and stellate cells (9-11). Still, significant amounts of 
caveolin-1 are detected in hepatocytes (8, 12, 26). Previous studies have 
predominantly focused on the role of caveolin-1 in internalization of caveolae from 
the plasma membrane. However, it has also been noted that caveolin-1 may reside 
at other subcellular locations, including the endoplasmic reticulum, Golgi 
apparatus, endosomes, lipid droplets (27) and mitochondria (3, 8, 14). Our 
observation that significant amounts of caveolin-1 appear to reside in the 
peroxisomal membrane of hepatocytes therefore came as a surprise. A possible 
peroxisomal location of caveolin-1 in hepatocytes may, however, been overlooked 
in previous studies. Caveolin-1 has been shown to co-fractionate with catalase after 
Nycodenz gradient separation of mouse liver organelles (28), clearly separated 
from plasma membranes and the Golgi apparatus. Other studies excluded the 
analysis of peroxisomal marker proteins (29) and caveolin-1 may have been miss-
assigned to plasma membranes or the endoplasmic reticulum, as peroxisomes also 
may co-fractionate with these subcellular fractions (30). In addition, 
immunofluorescence microscopy studies revealed that caveolin-1 co-localized with 
PMP70 in peroxisomal structures in the rat hepatoma cell line mcA-RH7777 (31). 
Our study shows that significant amounts of caveolin-1 co-localize with the 
peroxisomal markers catalase, Baat, ALDP, PMP70 and Pex14p in rat hepatocytes 
using both cell fractionation and microscopical techniques. Also, EGFP-tagged 
caveolin-1 expressed in rat hepatocytes was found to accumulate in cellular 
structures that contain the peroxisomal marker catalase. Similar to endogenous 
caveolin-1, EGFP-caveolin-1 also sorted to other subcellular organelles and the 
plasma membrane, which was especially evident in cells expressing high levels of 
the hybrid protein (Fig. S2). This may suggest that peroxisomes are the primary 
subcellular destination of caveolin-1 when the cellular levels of this protein are 
low. Alternatively, a cell type-specific sorting pathway may exist in hepatocytes 
that drives the accumulation of caveolin-1 in peroxisomes. A similar hepatocyte-
specific sorting pathway has been detected for the enzyme BAAT (21).  
In the plasma membrane, caveolin-1 is an integral membrane protein with its 
hydrophilic N- and C-terminus exposed to the cytosol (32). We found that also in 
hepatocyte peroxisomes, caveolin-1 is an integral peroxisomal membrane protein 
with its hydrophilic N- (and most probably also C-) terminus facing the cytosol 







caveolae, which are morphologically characterized by their flask-shaped 
appearance. Such structures have not yet been described at the peroxisomal 
surface. The level of caveolin-1 in the peroxisomal membrane may be too low to 
form caveolae and its function may be unrelated to vesicle traffic to or from this 
organelle. On the other hand, local concentrations of caveolin-1-specific staining 
were often observed in immunofluorescence and occasionally in immunoelectron 
microscopy (Fig. S5), which may suggest local caveolae formation.  
Recently, we found that ALDP, PMP70 and Pex14p are associated with 
peroxisomal lipid rafts and that these microdomains are essential for peroxisome 
biogenesis in human HepG2 cells (Woudenberg, J. et al., Chapter 4). PMP70 and 
Pex14p were detected in Triton X-100-resistant lipid rafts, while ALDP was 
detected in Lubrol WX-resistant lipid rafts. Pex13p, also an integral component of 
the peroxisomal membrane and interacting partner of Pex14p, appeared not to be 
associated with either of these biochemically-defined lipid rafts. PMP70 and 
Pex14p are also detected in Triton X-100-resistant lipid rafts in rat liver extracts, as 
was caveolin-1 (Fig. S3). All the PMPs were, however, fully solubilized when 
purified hepatocyte peroxisomes were extracted with Triton X-100 (Fig. 4A). This is 
most likely due to the very low lipid:protein ratio in purified fractions of 
peroxisomes compared to total cell extracts. Consequently, peroxisomal 
membrane(lipid)s are exposed to high detergent concentrations when purified 
peroxisomes are used in these extraction procedures. It is well-known that lipid 
raft-associated proteins eventually will be extracted when the detergent:lipid ratio 
is increased, also in total cell lysates (33). Nevertheless, peroxisomal caveolin-1 
resisted Triton X-100 extractions even when performed on purified rat hepatocyte 
peroxisomes. These data suggest that three biochemically distinguishable lipid 
rafts exist in the peroxisomal membrane that contain either 1) caveolin-1, 2) PMP70 
and/or Pex14p or 3) ALDP (Fig. S6). Pex13p does not seem to associate with either 
of these peroxisomal microdomains. 
The function of peroxisomal caveolin-1-containing lipid rafts is currently 
unknown. The absence of caveolin-1 did not affect the peroxisomal location of 
catalase in mouse liver. This suggests that caveolin-1 is not required for 
peroxisome biogenesis, while other types of peroxisomal lipid rafts are 
(Woudenberg, J. et al., Chapter 4). Moreover, caveolin-1 expression was strongly 
reduced by treating rat hepatocytes with the PPARα agonist fenofibric acid, which 
induces peroxisome proliferation. This observation actually suggests a negative 
link between caveolin-1 and peroxisome proliferation. Although such a repressive 
effect of caveolin-1 on peroxisome proliferation is highly speculative, it is in line 
with the low levels of caveolin-1 and high numbers of peroxisomes in hepatocytes 
(7, 34). Previously, mouse liver caveolin-1 has been shown to be positively 
regulated by PPARγ (35). In contrast to PPARα, which is an important regulator of 
(peroxisomal) fatty acid oxidation, PPARγ stimulates the storage of fatty acids and 
lipids (35). Caveolae and caveolin-1 are involved in intracellular cholesterol and 
lipid metabolism. Hepatocyte peroxisomes are involved in the conversion of 






cholesterol to bile acids and in β-oxidation of VLCFAs. Peroxisomal caveolin-1 
may therefore be involved in transporting substrates for these metabolic activities 
to or from the peroxisomes. Related to this, caveolin-1 has been suggested to play a 
role in lipid droplet formation. Hepatocytes accumulate triacylglycerol and 
cholesteryl esters in these lipid droplets during liver regeneration (15, 36). The 
levels of hepatic cholesterol and triglycerides increase ten-fold (36) during the first 
24 h after partial hepatectomy, which coincides with an increased number of 
peroxisomes (37). The lipid droplets are usually detected in the vicinity of 
peroxisomes (15). The number of hepatic lipid droplets is strongly decreased in 
caveolin1-/- mice and liver regeneration is strongly compromised after partial 
hepatectomy, resulting in increased mortality. 
In conclusion, caveolin-1 resides in the peroxisomal membrane of hepatocytes. It 
does not seem to play a crucial role in peroxisome biogenesis. Future research 
needs to establish whether peroxisomal caveolin-1 is required for efficient liver 
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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
 
Extraction of peroxisomal membrane proteins 
The extraction of peroxisomal membrane proteins (PMPs) was performed 
according to established methods (1) with some adaptations. Three (3) fractions of 
~250 µg purified peroxisomes were pelleted at 100,000 x g in a Beckman TLA-100.3 
rotor (Beckman, Fullerton, CA, USA). The pellets were resuspended in 1 mL of 
either 100 mM Tris-HCl, pH 8.0, or 1 M NaCl in 100 mM Tris-HCl, pH 8.5, or 0.1 M 
Na2CO3, pH 11.0 and incubated on ice for 15 minutes. Insoluble materials were 
pelleted by centrifugation for 15 minutes at 200,000 × g at 4 °C in a Beckman TLA-
100.3 rotor (Beckman). Pellet fractions were resuspended in the appropriate buffer 
as described above. Equal volume fractions were analyzed by western blotting. 
 
Proteinase K protection assay 
Aliquots of purified peroxisomes (approximately 100 µg) were subjected to proteolysis by 
proteinase K as described previously (2). These aliquots were incubated with either 
0 or 0.2 mg/ml proteinase K (Invitrogen) in the presence or absence of 0.1% Triton 
X-100 (Sigma-Aldrich) for 30 minutes at 4ºC. The proteinase K digestion was terminated by 
the precipitation of each sample with 12.5% trichloroacetic acid (TCA, Sigma-
Aldrich), followed by TCA protein precipitation (3). Equal volumes of all protein 
samples were analyzed by western blotting. 
 
Immunogold labeling and electron microscopy  
Ten million freshly isolated hepatocytes were pelleted and fixed with 2% 
glutaraldehyde (Sigma-Aldrich) at 4ºC for 30 minutes and further processed according to 
the method described by van der Wel et al. (4). Briefly, cryo-sections were prepared 
according to Tokuyashu (5) followed by immunogold labeling (6). Primary antibodies 
(Table 3) were visualized using gold conjugated secondary antibodies (5 nm gold-
conjugated goat-anti mouse and 15 nm gold-conjugated goat-anti rabbit, BB 
International, Cardiff UK). Images were captured on a FEI CM100 Bio (FEI Co., 
Hillsboro, OR). Digital pictures were taken at 80kV accelerating voltage. 
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Figure S1. Expression of caveolin
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expressed in rat hepatocytes.
Primary rat hepatocytes were transiently transfected 
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Freshly isolated rat liver peroxisomes were lysed in buffers containing 1 M sodium chloride or 100 mM sodium 
bicarbonate (pH 11) and compared to hypertonic lysis of peroxisomes (100 mM Tris HCl). Ins
pelleted by centrifugation. Equal volume fractions of pellets and supernatants were analyzed by western blotting 
using antibodies against PMP70, Pex14p, catalase, Baat and caveolin
were su
Equal volumes of all protein samples were analyzed by western blotting using antibodies against PMP70, Pex14p, 
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In rat hepatocytes, some caveolin
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-1 antibody. 
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Chapter 6  
108 
 
General discussion and future perspectives 
 
In this thesis, we have studied various aspects of peroxisome biogenesis and 
functions in bile salt homeostasis. We have demonstrated for the first time that bile 
acids in the enterohepatic cycle shuttle through peroxisomes to become (re-) 
conjugated to taurine or glycine. The 70-kDa peroxisomal membrane protein 
(PMP70/Pmp70) is the most dominant proteinaceous component of the membrane 
of liver peroxisomes and manipulation of PMP70 expression in rat hepatocytes 
directly affects bile acid conjugation and transport by rat hepatocytes. PMP70 
appears to be associated with peroxisomal lipid rafts, which are small detergent-
resistant microdomains in cellular membranes, but had not been found in 
mammalian peroxisomes before. In fact, peroxisomal membrane proteins show 
distinct lipid-raft association characteristics, suggesting the presence of at least 3 
different types of lipid rafts in mammalian peroxisomes. Remarkably, hepatocyte 
peroxisomes appeared to contain most of the cellular amount of caveolin-1, a 
protein that is involved in lipid transport and in most other cell types is 
characteristically detected in endocytotic pits at the plasmamembrane. We show 
that peroxisomal lipid rafts are required for peroxisome biogenesis. Their putative 
role in bile salts and/or lipid transport remains to be determined.  
 
Detailed information is available about transporters that are involved in bile salt 
shuttling between liver and the intestine. Little is known, however, how bile salts 
are transported inside hepatocytes and enterocytes. This is especially relevant for 
bile salts that lost their taurine or glycine moiety in the intestine, since they need to 
be re-conjugated in the liver. Earlier studies showed that the enzyme responsible 
for bile salt reconjugation, bile acid CoA:amino acid:N-acyltransferase (BAAT), 
resides predominantly (if not solely) in peroxisomes (1), however, direct evidence 
for bile salt transport in and/or out of peroxisomes has not been demonstrated by 
others.  
In chapter 2, we show that deuterium-labeled cholic acid (D4CA) shuttles through 
peroxisomes to become conjugated to taurine in cultured rat hepatocytes. We 
propose a model where unconjugated bile acids that return to the liver are  taken 
up by Oatps (or Ntcp) and subsequently activated to CoA-esters by Fatp5/Bal, 
which resides at the basolateral membrane. CoA-activated bile acids enter 
peroxisomes where they are conjugated to taurine or glycine. We developed an 
assay that shows a time-dependent conversion of D4CA and intracellular 
accumulation of newly-formed conjugates (D4TCA and D4GCA). We observe that 
the strongest accumulation occurs at the three-hour time point of incubation with 
D4CA and speculate that this effect is most likely caused by retention of conjugates 





The fact that bile acids need to enter peroxisomes for conjugations is in line with 
our previous work that revealed that BAAT is predominantly, if not solely, present 
in peroxisomes. The intracellular localization of BAAT has been a topic of various 
studies, with variable outcomes. Some authors reported that this enzyme resides in 
the cytosol (O'Byrne J. et al., 2003 (2)), while others detected it both in peroxisomes 
and in the cytosol (He D. et al., 2003 (3) and Solaas K. et al., 2000 (4)). In some 
experiments, 75% of  BAAT activity was found in cytosolic fractions  (Styles NA. et 
al., 2007 (5)). Other authors have suggested that there are two forms of this 
enzyme, one residing in peroxisomes and the other in the cytoplasm (Solaas K. et 
al., 2004 (6)). Mutations in the gene encoding BAAT lead to a bile salt pool that is 
completely uncojugated (7, 8). This indicates that there is only one enzyme able to 
perform glycine/taurine conjugation of bile salts, at least in human. The 
combination of immunofluorescence microscopy and digitonin permeabilization 
assays on rat and human hepatocytes revealed a typical peroxisomal location for 
BAAT (Pellicoro A. et al., 2007 (1)). With the detection of conjugated D4TCA in 
peroxisomes isolated from hepatocytes that were exposed to D4CA, the studies in 
this thesis now also provide direct evidence that unconjugated bile acids shuttle 
through peroxisomes. 
 
For the proper interpretation of the subcellular accumulation of D4-conjugates, it 
was crucial to exclude the possibility that they may also accumulate in a 
canalicular network formed between polarized rat hepatocytes in culture. Such 
canalicular networks are, however, formed at later time points (48-72 hours after 
attachment) in rat hepatocyte cultures. In our study, the hepatocytes were used 
within 24 hours after attachment. Moreover, the hepatocytes were washed with 
Ca2+-free HBSS, which disrupts tight junctions and thereby the interaction between 
hepatocytes that is required to maintain canalicular vacuoles and/or network. 
Finally, the canalicular is rich in cholesterol and is permeabilized at low (30 ug/ml) 
concentrations digitonin. In contrast, D4TCA was only completely released at high 
(500 ug/ml) concentrations digitonin, indicating that it is present in organelles 
with membranes with low cholesterol content. The peroxisomal membrane is 
relatively low in cholesterol content. 
 
Peroxisomes are fragile organelles that easily get damaged and lose (part of) their 
content during cell fractionation experiments (9, 10)  This is probably the main 
reason why in many experiments significant amounts of Baat were detected in 
fractions that represent the cytosol. We used an optimized protocol for isolation of 
peroxisomes to minimize the leakage of matrix proteins, such as Baat and catalase 
(Antonenkov et al., 2004 (9)). Polyethylene glycol 1500 is added to buffers to 
stabilize organellar membranes during the isolation procedure This lead to a 
strong reduction of peroxisomal damage during the hepatocyte homogenization 
step and allowed the separation of the various organelles and cytosol from a 
postnuclear supernatant (PNS) fraction using a discontinuous Nycodenz® gradient 
(11). Previously, this was only done by loading an organelle-enriched high-speed 
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centrifugation pellet fraction. Direct loading of a PNS fraction onto the Nycodenz® 
gradient minimized the osmotic damage to peroxisomes and provided additional 
evidence for a predominant peroxisomal localization of BAAT. 
The separation of a PNS by Nycodenz® density gradient centrifugation 
additionally allowed the detection of solutes/metabolites in peroxisome-enriched 
fractions from the gradient, which has not been documented before. After exposing 
hepatocytes for 3 h to D4CA we were able to detect the conjugation product D4TCA 
in the peroxisomal peak fraction. The D4TCA peak intensity was relatively low, but 
its distribution in the high-density fraction of the Nycodenz gradient followed 
exactly that of peroxisomal marker proteins. The low amounts of D4TCA in these 
fractions may be a result of a very efficient export process of conjugated bile acids 
from the peroxisome or release of these bile acids during the isolation procedure. 
Indeed, most of D4TCA was detected on the top of the Nycodenz gradient where 
cytosolic compounds are present. Cytosolic D4TCA could also be a result of 
potential reuptake of previously produced and secreted D4TCA (12). Because it is 
already conjugated, it will not travel through peroxisomes again, but add to the 
cytosolic concentration of this bile salt. When studying the overall dynamics of 
D4CA conjugation to either taurine or glycine, it is clear that the potential reuptake 
of D4TCA does not give rise to a strong cytosolic accumulation in rat hepatocytes. 
This is supported by the observation that cellular concentrations of conjugated bile 
salts is low after twenty-four hours of incubation, while their concentration in the 
medium is high. Moreover, organelle isolations were performed 3 h after exposing 
hepatocytes to D4CA and at that time point, the amounts of extracellular D4TCA 
and D4GCA were still relatively low.  
All treatments with D4CA were performed with hepatocytes no longer than 24 
hours in culture to avoid yet another limitation, namely the progressive loss of the 
capacity to take up bile salts of cultured hepatocytes (12). We additionally kept rat 
hepatocytes attached to collagen-coated plates/flasks, as those in suspension 
demonstrate reduced bile salt efflux kinetics (12). 
The Nycodenz® gradient of post-nuclear supernatant (Chapters 2 and 3) revealed 
two distinct peroxisomal populations: one migrating as high-density peroxisomes 
at fractions 2-5 and the other migrating together with (light) mitochondria in 
factions 10-11. Similar data have been obtained by others (13, 14). Remarkably, 
high amounts of D4TCA were detected in fractions that contain the low-density 
peroxisomes (see Chapter 2, figure 6). It has been described that peroxisomes in the 
liver exist as a mixed population of organelles at several biogenesis stages (13, 14, 
15), which is manifested by heterogeneous uricase and homogenous catalase 
staining (16) among peroxisomes in the hepatocyte. At present, only the high 
density peroxisomal population has been successfully isolated as a fraction of 
almost 95% purity (17, 18). Early studies suggest that the “low density” 
peroxisomes contain predominantly the newly-synthesized peroxisomal proteins. 
Pulse-chase experiments revealed that Acox first localizes to the low density 
peroxisomes compartment after which it appears in the high-density peroxisomes 




fraction during peroxisomal biogenesis after partial hepatectomy. Consequently, 
these two peroxisomal populations may differ in membrane protein composition 
and metabolic activity. The heterogeneity is transient and it most probably reflects 
the incompetence of mature peroxisomes to incorporate new proteins (20, 21).  
 
The amount of D4TCA detected in the low density peroxisomes seems to correlate 
better with the digitonin latency analyses. The latter suggest that a significant 
amount of cellular D4TCA is present in peroxisome-like organelles surrounded by 
membranes with low cholesterol content. The very small amounts of D4TCA 
cannot account for this. It may be that almost all D4TCA is lost from the high 
density peroxisomes during the isolation procedure (either by transport or 
leakage). However, the alternative possibility is that most of the D4TCA is actually 
trapped in the low-density peroxisomes. This could be a result of a heterogeneous 
distribution of bile salt transporters among the light and heavy fraction during 
peroxisomal biogenesis. In this scenario, the peroxisomal bile salt exporter may not 
be optimally localized/expressed in the light fraction compared to “heavy” 
peroxisomes.  
As indicated before, peroxisomes are fragile organelles in vitro and easily rupture 
in cell fractionation experiments. The level of organelle damage is difficult to 
determine as some proteins leak out easily (e.g. catalase) while others remain well 
associated to peroxisome-enriched fractions (e.g. isocitrate dehydrogenase) (22). 
The phenomenon of peroxisomal leakiness in vitro has not been explained so far. 
Recently, however, the existence of peroxisomal channel formed by Pxmp2 has 
been described (23). This diffusion pore is responsible for the peroxisomal 
membrane permeability to small solutes, but does not seem to allow free passage 
of bulky compounds like bile salts and proteins. On the other hand, the 
peroxisomal membrane contains large (9 nm) pores that allows the translocation of 
large, fully folded, oligomeric peroxisomal matrix proteins (like catalase) (24). 
These pores may become permeable in vitro when losing their cellular environment 
during isolation and lead to the observed leakage of (even complex) compounds.  
Peroxisomal enzymes are made on polysomes in the cytosol and post-
translationally imported into the target organelle. Thus, even if BAAT activity is 
restricted to peroxisomes, some BAAT protein will be present in the cytosol and on 
its way to peroxisomes. A clear cytosolic pool of BAAT was observed when it was 
overexpressed in a fusion with the Green Fluorescent Protein (GFP-BAAT) in 
human fibroblasts (1). However, this fusion protein was efficiently sorted to 
peroxisomes when expressed in hepatocytes (1), suggesting the existence of cell-
type specific factors that enhance peroxisomal sorting of BAAT. 
In summary, we propose that under normal physiological conditions both C27- and 
recycled C24-bile salts are conjugated by BAAT in peroxisomes. Future research 
should establish the physiological relevance of the peroxisomal location of BAAT 
for bile salt homeostasis. The first step may be to try to identify the proteins that 
transport bile salts in and out peroxisomes.  
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In chapter 3, we studied the putative role of the peroxisomal membrane 
transporter Pmp70 in the bile salt re-conjugation process. Pmp70 is the most 
dominant peroxisomal membrane protein in rat liver, still very little is known 
about its function and which substrates it transports. Its ATP-binding site faces the 
cytosol, which suggests that it transports substrates into peroxisomes. Our data 
suggest that this peroxisomal ABC-half transporter is involved in bile acid re-
conjugation and transhepatocyte transport of cholic acid in isolated rat 
hepatocytes. Pmp70 expression was increased by the peroxisome proliferator-
activated receptor-alpha (PPARα) ligand fenofibric acid (FFA) and lead to 
increased conversion of CA to TCA in isolated rat hepatocytes. Simultaneous 
inhibition of Pmp70 expression through RNA interference (Abcd3-siRNA) 
suppressed the conversion of TCA leading to reduced concentrations of TCA in de 
medium. In addition, intracellular levels of CA and TCA decreased in FFA-treated 
rat hepatocytes, which were normalized again when co-treated with PMP70-
specific RNA interference. These data suggest the involvement of PMP70 in 
transcellular bile salt transport and/or conjugation to taurine. 
 
Notably, expression of Bal, Baat, Ntcp and Bsep, e.g. the other proteins in the 
conjugation and transcellular bile acid pathway was not changed in rat 
hepatocytes treated for 24 h with FFA. The differences in cellular and extracellular 
bile acid concentrations could therefore be directly related to the level of Pmp70 in 
FFA and/or Abcd3-siRNA treated rat hepatocytes.  
Newly-synthesized Pmp70 is predominantly targeted to the low-density 
peroxisomes and appears subsequently in „heavy” peroxisomes (13, 14). The 
Pmp70 signal is indeed overrepresented in low-density peroxisomes of FFA-
treated hepatocytes compared to those from control hepatocytes. Baat is also 
present in the low-density peroxisome, but does not seem to be more enriched in 
these fractions after FFA treatment. It will be interesting to determine whether 
FFA-treatment changes the amount of newly conjugated cholic acid in either low-
density and/or high density peroxisomes. If newly sorted PMP70 is immediately 
active, this could result in preferential accumulation of D4TCA in low-density 
peroxisomes. Either way, initial tests should include purification and 
characterization of the low-density organelles to confirm that these structures are 
indeed functional peroxisomes. 
Following our in vitro studies, it is now imperative to obtain support for the 
involvement of PMP70 in bile salt homeostasis in vivo. Pmp70-knockout mice 
would be the ideal model to analyze this. These animals have been described in 
abstracts of scientific meetings; however, no detailed characterization of their 
phenotype is available in peer-reviewed literature so far. Alternatively, siRNA-
based approaches could be applied to specifically suppress Pmp70 expression in 
the liver either by tail vein-injections of siRNA duplexes or short hairpin siRNA 
expressing adenoviruses. The latter approach has pros and cons: acute suppression 
of Pmp70 by siRNA may prevent potential compensatory expression of other 




more likely to occur in Pmp70 knock out mice. However, siRNA-based procedures 
are never 100% effective and it is unknown what the under limit is of Pmp70 before 
a physiological effect becomes apparent.  
In vitro experiments to further establish the involvement of peroxisomes in bile 
acid conjugation may include the addition of unconjugated bile acids to purified 
organelles from a Nycodenz gradient. This experiment would require the use of 
CoA-activated cholic acid,  since plasmamembrane-associated FATP5/Bal/BACS 
is absent from the organellar fractions. Such experiments could also provide 
additional information about the contribution and the bile acid conversion rates by 
low- and high-density peroxisomes.  
Bile salts harboring a fluorescent moiety, e.g. fluorescein or Nϵ-
nitrobenzoxadiazolyl (NBD), have been widely used to analyze transport 
characteristics in hepatocytes and whole liver. In theory, they would be ideal 
compounds to trace the routing of bile salts through peroxisomes of hepatocytes. 
However, most of these fluorescent bile salts contain the fluorescent group 
attached to the side chain, preventing their glycine/taurine conjugation. Moreover, 
it was recently shown that choly-lysyl-fluorescein (CLF)is actually a very poor 
substrate for the typical bile salt transporters NTCP and BSEP and predominantly 
transported by OATP1B3, MRP2 and MRP3 (25). This severely hampers the use 
fluorescent bile salts to study their intracellular transport. We analyzed cellular 
uptake and conjugation of cholic acid containing a NBD group at the 3α, 3β, 7α or 
7β position. Only for 3α-NBD-CA, we found that it was conjugated to glycine or 
taurine, though the conversion was very inefficient compared to deuterium-labeled 
CA. Still, it revealed that the 3α position allows the presence of a fluorescent group 
and is still a substrate for Bal, Baat and putative intracellular transporters. Testing 
different fluorescent groups attached to the 3α position of cholic acid may 
therefore yield fluorescent bile salts that are efficiently handled by genuine bile 
acid modifying enzymes and transporters. Given the recent findings that one of the 
most used fluorescent bile acids, CLF, is actually not a substrate for Ntcp and Bsep, 
further stresses the need for new fluorescently tagged bile acids to trace their 
transport inside cells (25).    
 
The important question is whether defects in putative peroxisomal bile salt 
transporters (both the importer and the exporter) would cause a clinical 
phenotype. Malfunctioning of the peroxisomal bile salt importer could 
hypothetically cause a change in the bile salt profile towards unconjugated bile 
acids. Two different scenarios can be envisioned: 1) the unconjugated bile salts are 
mostly C24-derivatives. This could result from the possibility that independent 
transporters exist in the peroxisomal membrane for C27 (bile salt biosynthesis-
intermediates) and C24 (intestinal deconjugated) – bile salts. 2) The unconjugated 
bile salts are mostly C27-derivatives. In this case, transport of the bile salt 
biosynthesis intermediates into the peroxisomes is hampered and enterohepatic 
cycling of these “immature” bile salts is very inefficient. The latter condition would 
be similar to the bile salt profile of patients with Zellweger Syndrome (ZS), where 
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peroxisome biogenesis is impaired. The bile salt intermediates are partly 
conjugated though in these patients. Baat is most likely residing in the cytosol in 
ZS patients, which may account for the residual conjugation activity. In case of a 
specific blockade of import of C27-bile salt intermediates, we expect that the whole 
bile salt pool would remain unconjugated, because the cytosolic C27 intermediates 
will be physically separated from peroxisomal Baat.  
The impairment of the putative peroxisomal bile salt exporter, on the other hand, 
may lead to the accumulation of bile salts inside this organelle. In such case, 
accumulating bile salts could damage the peroxisome and impair its function and 
biogenesis. In the extreme conditions that all peroxisomes would be involved in 
bile salt conjugation, this may lead to a Zellweger Syndrome-like phenotype, but 
would be strictly limited to hepatocytes. In fact, patients with a liver-specific defect 
in peroxisome biogenesis have been described, where this phenotype was detected 
in most hepatocytes, while fibroblasts from these patients contained normal 
peroxisomes (26, 27). Thus, it may very well be these patients have a defect in 
peroxisomal bile salt export.  
 
The putative activity of cytosolic BAAT is a relevant (and still open) question when 
discussing the hepatocyte capacity to conjugate bile salts in peroxisomal biogenesis 
disorders, such as ZS. ZS is characterized by the lack of functional peroxisomes. 
However, peroxisomal remnants (ghosts) containing PMPs, but lacking most of the 
matrix enzymes, are detected in the majority of ZS patients (28, 29). Though the 
subcellular location of BAAT has never been established in ZS patients, we assume 
that it resides in the cytosol just like catalase.  
ZS patients typically accumulate bile salt biosynthesis intermediates like di- and 
trihydroxycholestanoic acid (D- and THCA). The primary bile acids CA and CDCA 
are also detected, but at strongly reduced levels. Both the bile salt intermediates 
and the primary bile salts are only partly conjugated to glycine or taurine. (30, 31). 
This suggests that BAAT activity is compromised when peroxisomal biogenesis is 
disturbed, however, it is not completely blocked. Similar observations have been 
made in studies with Pex2-/- knock-out mice, an animal model of Zellweger 
Syndrome. These mice accumulate C27 bile salt synthesis intermediates in serum, 
liver and bile, while the C24 bile salt concentrations are strongly reduced. Most of 
these bile salts are unconjugated. Feeding these animal a cholic acid- or 
ursodeoxycholic acid-containing diet reduced the level of C27 bile salt 
intermediates, but unconjugated bile acids remained dominant in the bile acid pool 
(32). In contrast, bile acid-fed wild type mice effectively conjugated the bile acids 
from the diet. Thus, peroxisome deficiency leads to a generalized defect in bile acid 
conjugation. The residual bile salt-conjugating activity is likely the result of Baat 
present in the cytosol, indicating that it retains some enzymatic activity at in this 
subcellular location. Nonetheless, it is clear that the loss of peroxisomal BAAT 
severely affects bile salt conjugation efficiency and therefore supports our data that 





The activity of bile salt transporters present in plasma membranes of enterocytes 
and hepatocytes is modulated by their specific lipid environment, where they 
associate to cholesterol-enriched microdomains, so-called lipid rafts. It seems likely 
that bile acid transporters in organelles share this characteristic and are localized to 
organellar lipid rafts. To determine whether this holds true for the putative 
peroxisomal bile salt transporter PMP70, we studied whether the peroxisomal 
membrane contains lipid rafts. Though lipid rafts have been detected in several 
organellar membranes, this was not particular likely for the peroxisomal 
membrane, which contains relatively low concentrations of cholesterol.  
In chapter 4 (Woudenberg et al. 2010 (33)) we describe the existence of peroxisomal 
lipid rafts and their role in the biogenesis for this organelle. We show that the 
homologous ABC transporters PMP70 and ALDP are differentially associated to 
lipids in the peroxisomal membrane as the former resists solubilization with a 
strong detergent (Triton X-100), whereas the latter only resists the treatment with a 
mild detergent (Lubrol WX). Also Pex14p was found in Triton X-100 resistance 
lipid rafts, whereas an interacting partner, Pex13p does not seem to associate with 
lipid rafts at al. HepG2 cells were depleted from cholesterol, which leads to a 
mislocalisation of catalase to the cytosol. In addition, ALDP lost its typical 
peroxisomal location, most likely accumulating in the ER. In contrast, PMP70 and 
Pex14 retained a largely peroxisome-like location. These processes were largely 
reversible, as catalase sorting to peroxisomes was restored after repletion of 
cholesterol in HepG2 cells. However, ALDP sorting was not effectively restored in 
these cells. These data show that the peroxisomal membrane contains lipid rafts, 
which are essential for peroxisome biogenesis. Highly homologous (PMP70 and 
ALDP) and physically interacting (Pex13p and Pex14p) showed different lipid raft 
association characteristics. The lipid environment of these proteins may strongly 
affect their activity, either in substrate transport (PMP70 and ALDP) or peroxisome 
biogenesis (Pex13p and Pex14p). 
 
It has been suggested that the peroxisomal ABC half transporters, including 
PMP70 and ALDP, may form heterodimers. Formation of such heterodimers could 
greatly broaden the number of substrates transported by the subgroup of ABC 
transporters. The fact that PMP70 and ALDP show clear different lipid raft 
associations seems to argue against the formation of PMP70/ALDP heterodimers 
in HepG2 cells and hepatocytes. This is in line with the analysis of endogenous 
PMP70 and ALDP from mouse liver, which revealed that these proteins are 
predominantly present as homodimers. However, our detergent extraction 
experiments cannot formally exclude the possibility PMP70 and ALDP co-exist in 
one microdomain with high internal lipid heterogeneity that still allows the 
formation of heterodimers. Still, PMP70 and ALDP behave very different in the 
cholesterol depletion-repletion experiments indicating that ALDP/PMP70 
heterodimers are unlikely to be prevalent in HepG2 cells.  
Although PMP70 shares the “lipid raft association-feature with the bile acid 
transporters  in plasmamembranes, the current experimental system (cholesterol 
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depletion-repletion) cannot be used to specifically test whether the presence of 
PMP70 in lipid rafts regulates its transport activity. Depletion of cholesterol in 
whole cells will directly affect the activity of the other bile acid transporters also 
and any effect on bile salt levels in cells or peroxisomes cannot be related to 
PMP70. This will probably require the in vitro reconstitution of PMP70 in 
membrane vesicles and manipulation of the membrane lipids in transport assays. 
 
To further characterize the peroxisomal lipid rafts, we compared the detergent-
extractability and subcellular location of peroxisomal membrane proteins to 
several well-known markers for these lipid microdomains, including Src-1, flotillin 
and caveolin-1. Much to our surprise, we found that caveolin-1 appeared to be 
present in peroxisomal lipid rafts in hepatocytes (chapter 5). Caveolin-1 is one of 
three caveolins, which are structural components of caveolae that are 
characteristically found on small endocytotic pits at the plasmamembrane. 
Previous research on caveolin-1 knock-out mice has shown that it plays a role in 
liver regeneration and lipid metabolism.  
Hepatocytes contain relative low levels of caveolin-1. In the liver, this protein is 
predominantly detected in endothelial cells. We used cell fractionation procedures, 
immunofluorescence and immuno-electron microscopy to localize endogenous 
caveolin-1 in (purified) rat hepatocytes and consistently found that most of the 
protein was found in peroxisomes. On top of this, also green fluorescent protein 
(GFP)-tagged caveolin-1 colocalized to peroxisomal markers when expressed in rat 
hepatocytes. Peroxisomal caveolin-1 retained its characteristic Triton X-100-
inextractable feature as observed when present in the plasmamembrane of other 
cell types. SiRNA-mediated reduction of caveolin-1 in rat hepatocytes as well as 
livers from caveolin-1 knock mice do not reveal a role of this protein in peroxisome 
biogenesis. This seems in line with the observation that fenofibric acid strongly 
repressed the expression of caveolin-1 while this PPARα agonist induced 
peroxisome proliferation. This could even imply that shutting down the expression 
of caveolin-1 is a prerequisite for (the initiation of) peroxisomal proliferation. 
Alternatively, peroxisomal caveolin-1 may be involved in lipid and/or bile salt 
metabolism. Caveolin-1 knock out mice have not yet been studied with respect to 
bile salt homeostasis. It is known, however, that bile salt signaling is important for 
liver regeneration, a process that is disturbed in caveolin-1 knock out mice. It 
seems therefore timely to determine a putative role of caveolin-1 in bile salt 
homeostasis. The work reported in this thesis provides experimental tools to study 
this: caveolin-1 expression can be suppressed in primary rat hepatocytes 
subsequently exposed to D4CA to analyze the conjugation and transcellular 
transport efficiency. These studies can be complemented by analyzing the bile acid 
profile in blood, liver and bile in caveolin-1 -/- mice either on fed a control diet or a 
cholic acid-containing diet.  
 
In conclusion, this thesis shows that the enterohepatic cycle of bile acids does not 




enterocytes, but also across peroxisomal membranes inside hepatocytes. The 70-
kDa peroxisomal membrane protein (PMP70) is likely involved in the import of 
bile acids into peroxisomes to become conjugated to taurine or glycine. Like 
plasmamembrane bile acid transporters, PMP70 is associated to lipid rafts, which 
are likely to control its subcellular sorting and/or transport activity. Peroxisomal 
lipid rafts also contained caveolin-1, a protein involved in lipid and cholesterol 
transport, but in most other cells resides in the plasmamembrane. These results 
warrant follow up studies to identify the peroxisomal bile acid transporters as well 
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The liver is a central organ in regulating body homeostasis. It controls body 
temperature, protein, glucose and fat metabolism as well as the removal of toxic 
(waste) products. It plays an integrative function in the whole organism by 
cooperation with the circular and digestive system. This feature of the liver allows 
for the effective exchange of nutrients between every cell in the body coupled to 
the neutralization and elimination of metabolic waste products. 
A main function of the liver is the production of bile, which is a mixture of water, 
phospholipids, cholesterol and bile salts. Bile salts are synthesized from cholesterol 
in the parenchymal cells of the liver, the hepatocytes. Together with phospholipids, 
bile acids form mixed micelles that are the fat-solubilizing particles that keep 
dietary fats in solution for absorption in the intestine. At the same time they are 
crucial for excretion of cholesterol and toxic waste products via the feces.  
Peroxisomes are single membrane-bound organelles present in cells of all 
eukaryotes. In mammals, they are particularly abundant in the liver. They are 
responsible for a great variety of metabolic processes, including breakdown of 
very-long chain acids, D-amino acids, and polyamines and the biosynthesis of 
plasmalogens and bile salts. Peroxisomes are essential organelles containing a wide 
range of enzymes located inside this organelle to perform the diverse metabolic 
activities. In addition, specific substrate transporters are located in the peroxisomal 
membrane to fuel the metabolic processes and remove their products (ATP, fatty 
acids and bile salts).  
Bile salts biosynthesis involves at least 13 different enzymes located to various 
organelles in liver hepatocytes. The bile salt biosynthesis pathway consists of two 
main routes and starts either in the ER (the “classical pathway” involving CYP7A1) 
or in the mitochondria (the so-called “acidic pathway” involving CYP27A1). Both 
routes yield CoA-activated C-27 bile acid biosynthesis intermediates and converge 
in peroxisomes where the primary C-24 bile salts cholic acid (CA) and 
chenodeoxycholic acid (CDCA) are formed. The final step of bile salt synthesis is 
the conjugation of CA and CDCA to either taurine or glycine. The sole enzyme 
responsible for bile acid conjugation in humans is bile acid-amino acid N-
acytransferase (BAAT), which resides (most probably exclusively) in liver 
peroxisomes. After export from peroxisomes, bile salts are then transported by the 
Bile Salt Export Pump (BSEP) from the hepatocytes to the bile. This way, bile salts 
enter the enterohepatic circulation, where over 95% will be reabsorbed in the 
intestine, specifically at the terminal ileum, and return back to the liver via the 
portal vein for recycling. Bile salts returning from the intestine are imported into 
hepatocytes via the sodium-taurocholate cotransporting polypeptide (NTCP). The 
amount of bile salts that is lost via the feces is compensated for by de novo bile salt 
synthesis in the liver. 
Bile salts in the intestine may undergo modifications by intestinal bacterial flora. 
These modifications include deconjugation of bile salts from taurine or glycine. 
These de-conjugated bile salts need to be re-conjugated by BAAT for effective 
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cycling between liver and ileum. Previous studies described BAAT residence in 
both the cytoplasm and peroxisomes. It seemed logical, as the dual location 
comfortably explains the function of this enzyme in de novo bile salt biosynthesis as 
well as in bile salt reconjugation.  Peroxisomal BAAT was proposed to be involved 
solely in de novo synthesis of bile salts, while its cytoplasmic pool has been 
proposed to play a role in the reconjugation of deconjugated bile acids returning 
from the intestine. However, the dual location of BAAT was primarily based on 
cell fractionation experiments in which BAAT was detected in cytosolic and 
peroxisome-enriched fractions. However, peroxisomes are fragile organelles that 
may easily rupture during such experimental procedures and over 80% of the 
peroxisomal matrix protein content may leak out of these organelles and 
incorrectly designated as (partly) cytosolic. Recent findings based on digitonin 
permeabilization and (immuno) fluorescence identified BAAT as a typical 
peroxisomal protein in both rat and human hepatocytes. The location of BAAT 
inside peroxisomes has consequences for bile salt transport inside hepatocytes and 
requires peroxisomal bile salt transporters that are not identified to date. 
In this thesis, we aimed to answer the question whether C-24 bile salts transit 
through hepatocyte peroxisomes for reconjugation. In chapter 2, we used primary 
rat hepatocytes and exposed them to deuterium-labeled cholic acid (D4CA) that 
represent deconjugated bile acids returning to the liver from the intestine in this 
experimental system. Using this novel assay, we demonstrated a time-dependent 
conversion of D4CA to the taurine and glycine-conjugates (D4TCA and D4GCA). 
Within 24 h, 100 uM D4CA added to the culture medium of 1 million hepatocytes 
was completely converted to D4TCA/D4GCA. A transient cellular accumulation of 
D4TCA/D4GCA was detected peaking at approximately 600-700 uM 3 h after 
adding D4CA to the medium. Digitonin permeabilisation of these hepatocytes 
revealed that the majority of D4TCA remains associated to the cellular fractions 
when treated with 30 ug/mL digitonin, which fully releases all cytosolic proteins. 
Complete D4TCA release was only observed when hepatocytes were treated with 
high (500 ug/ml) concentrations of digitonin, which also release peroxisomal 
catalase. This indicated that D4TCA is retained in a cell compartment of relatively 
low cholesterol membrane content, a typical feature of the peroxisomal membrane. 
To further prove that newly formed conjugates are present in peroxisomes of 
isolated rat hepatocytes, we performed cell fractionation experiments using an 
optimized procedure aimed at minimizing the osmotic damage to this organelle. 
We detected D4TCA in highly purified peroxisomal fractions of these cells. We 
conclude that active transport of deuterated cholic acid into peroxisomes had 
occurring after which it was taurine conjugated. Thus, the enterohepatic cycling of 
unconjugated bile salts includes their shuttling through hepatocyte peroxisomes. 
Our next goal was to try to determine which peroxisomal membrane protein 
(PMP) could be involved in transport of bile salts into this organelle. Extensive 
data is available on transporters responsible for bile salt transport across 
plasmamembranes in hepatocytes and enterocytes. Peroxisomal (and other 




that for the efficient translocation of C-27 bile salts inside peroxisomes ATP is 
required. This suggested an active transport of bile salt biosynthetic intermediates. 
However, no candidate transporter has been identified so far. It has also been 
shown that conjugated bile salts are exported out of peroxisomes in a passive 
transport, not requiring an energy supply. In chapter 3, we studied whether the 
Peroxisomal Membrane Protein of 70-kDa (Pmp70) is involved in the bile salt re-
conjugation process. Although Pmp70 is the most dominant peroxisomal 
membrane protein in rat liver, very limited data is available concerning its function 
and its substrates. The ATP-binding site of Pmp70 faces the cytosol, which 
suggests that this protein transports substrates into peroxisomes. We exposed 
primary rat hepatocytes to fenofibric acid (FFA), a potent agonist of Peroxisome 
Proliferator-Activated Receptor Alpha (PPARα). PPARα stimulation in rodents 
increases peroxisome proliferation. Pmp70 is one of PPARα target genes and its 
expression is elevated in the presence of FFA. Additionally, we inhibited the 
expression of Pmp70 with small interfering RNA (siRNA). We manipulated the 
expression of Pmp70 in primary rat hepatocytes that were subsequently subjected 
to the “CA-conjugation and intracellular transport assay” described in chapter 2, to 
study the glycine/taurine conjugation and transcellular transport of D4CA. We 
show that the induction of Pmp70 expression increases the D4TCA accumulation in 
the medium, while the intracellular levels of D4TCA and D4CA were reduced. In 
the complementary approach, we found that siRNA-mediated inhibition of PMP70 
reversed the FFA-induced Pmp70 overexpression and increased the  intracellular 
levels of D4CA and D4TCA while D4TCA levels in the medium decreased. 
Importantly, other proteins that are involved in bile acid re-conjugation pathway 
(NTCP, FATP5, BAAT and BSEP) were not affected by FFA and/or siRNA 
treatment. These data suggest a role for Pmp70 in the transport of unconjugated 
bile salts into peroxisomes to become conjugated to taurine and efficiently 
exported from hepatocytes. 
The activity of bile salt transporters present in plasma membranes of enterocytes 
and hepatocytes is modulated by their specific lipid environment, where they may 
associate to cholesterol-enriched microdomains, so-called lipid rafts.  
It seems likely that bile acid transporters in organelles share this characteristic and 
are localized to organellar lipid rafts. To determine whether this holds true for the 
putative peroxisomal bile salt transporter PMP70, we studied whether the 
peroxisomal membrane contains lipid rafts. Though lipid rafts have been detected 
in several organellar membranes, this was not particular likely for the peroxisomal 
membrane, which contains relatively low concentrations of cholesterol. In chapter 
4, however, we do describe the existence of peroxisomal lipid rafts and their role in 
the biogenesis for this organelle. We show that the homologous ABC transporters 
PMP70 and Adrenoleukodystrophy protein (ALDP) are differentially associated to 
lipid rafts in the peroxisomal membrane, as the former resists solubilization with a 
strong detergent (Triton X-100), whereas the latter only resists the treatment with a 
mild detergent (Lubrol WX). Also Pex14p was found in Triton X-100-resistance 
lipid rafts, whereas an interacting partner, Pex13p is not associated with lipid rafts 
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at all. HepG2 cells were depleted from cholesterol thereby depleting it from lipid 
rafts, which leads to a mislocalisation of catalase to the cytosol. In addition, ALDP 
lost its typical peroxisomal location, most likely accumulating in the ER. In 
contrast, PMP70 and Pex14 remained predominantly present in peroxisomes. 
These processes were partly reversible, as catalase sorting to peroxisomes was 
restored after repletion of cholesterol in HepG2 cells. In contrast, ALDP sorting 
was not effectively restored in these cells. These data show that the peroxisomal 
membrane contains lipid rafts, which are essential for peroxisome biogenesis. 
Highly homologous (PMP70 and ALDP) and physically interacting (Pex13p and 
Pex14p) showed different lipid raft association characteristics. The lipid 
environment of these proteins may strongly affect their activity.  
To further characterize the peroxisomal lipid rafts, in chapter 5 we compared the 
detergent-extractability and subcellular location of peroxisomal membrane 
proteins to several well-known markers of lipid microdomains, including Src-1, 
flotillin and caveolin-1. Much to our surprise, we found that caveolin-1 appeared 
to be present in peroxisomal lipid rafts in hepatocytes. Caveolin-1 is one of three 
caveolins, which are structural components of caveolae that are characteristically 
found on small endocytic pits at the plasmamembrane. Caveolin-1 expression in 
hepatocytes is relatively low, in particular when compared to endothelial cells. Cell 
fractionation and confocal laser scanning microscopy on purified hepatocytes 
revealed that most of the caveolin-1 in hepatocytes was associated with 
peroxisomes. Also, artificially expressed GFP-tagged caveolin-1 accumulated in 
catalase-positive organelles in hepatocytes. FFA treatment strongly reduced 
caveolin-1 expression in hepatocytes while it stimulated peroxisome proliferation. 
No aberrant peroxisome morphology was detected in liver tissue from caveolin-1 
knockout mice, indicating that it is not an important factor for peroxisome 
biogenesis. Previous research on these mice revealed that they show impaired liver 
regeneration and lipid metabolism.  
In conclusion, this thesis shows that the enterohepatic cycle of bile acids does not 
only require bile acid transport across the plasmamembranes of hepatocytes and 
enterocytes, but also across peroxisomal membranes inside hepatocytes. The 70-
kDa peroxisomal membrane protein (PMP70) is likely involved in the import of 
bile acids into peroxisomes to become conjugated to taurine or glycine. Like 
plasmamembrane bile acid transporters, PMP70 is associated to lipid rafts, which 
likely controls its subcellular sorting and/or transport activity. Peroxisomal lipid 
rafts also contained caveolin-1, a protein involved in lipid and cholesterol 
transport. These results warrant follow up studies to identify the peroxisomal bile 











De lever is een centraal orgaan in het lichaam voor de regulatie van 
lichaamstemperatuur,  eiwit, glucose en vetmetabolisme en het elimineren van 
toxische afval producten. De lever speelt in het lichaam een integrerende rol in de 
samenwerking van het darmstelsel met de systemische circulatie. Hierdoor is de 
lever uitermate geschikt voor het effectief verwerken van nutriënten uit de darmen 
en het in stand houden van systemische bloedspiegelwaardes. Zo balanceert de 
lever toevoer van nutrienten aan alle lichaamscellen en filtratie en eliminatie van 
metabole eindproducten uit het lichaam.  
Een belangrijke functie van de lever is het aanmaken van gal. Gal is een mengsel 
van water, fosfolipiden, cholesterol, galzouten en afvalstoffen. Galzouten worden 
gemaakt van cholesterol in hepatocyten, het meest voorkomende celtype  in de 
lever die het zgn. leverparenchym vormen. Samen met fosfolipiden vormen 
galzouten gemixte micellen die in de darm dieëtvetten emulsificeren voor een 
efficiënte absorptie. Tegelijkertijd is gal cruciaal voor het uitscheiden van 
cholesterol en afvalstoffen uit het lichaam via de feces.   
Peroxisomen zijn celorganellen met een enkelvoudige membraan en komen in alle 
eukaryoten voor. In zoogdieren zijn peroxisomen vooral zeer talrijk verrijkt 
aanwezig in de lever en vooral in hepatocyten aanwezig. Ze zijn betrokken bij 
diverse metabolische processen, zoals het afbreken van (zeer) lange vetzuurketens, 
D-aminozuren en polyamines, maar ook biosynthese van plasmalogens en 
galzouten. Peroxisomen zijn essentiële organellen waarin een breed scala aan 
enzymen aanwezig is voor de diverse metabole functies. Hiervoor zitten in de 
peroxisomale membraan specifieke peroxisomale transporters die de peroxisomale 
enzymen voorzien van substraten en die de producten verwijderen (ATP, vetzuren 
en galzouten).  
Bij de galzoutsynthese zijn tenminste 13 verschillende enzymen betrokken. Deze 
zijn verspreid over diverse organellen, waaronder het endoplasmatisch reticulum 
(ER), mitochondriën en peroxisomen. De galzoutbiosynthese kan via 2 routes 
verlopen, de klassieke en zure route. In de klassieke route is de eerste stap het 
omzetten van cholesterol door Cytochroom P450 (CYP) 7A1 in het  ER. Bij de zure 
route verloopt de omzetting van cholesterol via CYP27A1 in de mitochondriën. In 
beide gevallen worden CoA-geactiveerde C-27 galzout intermediairen gevormd 
die samenkomen in het peroxisoom. Hier worden de primaire C-24 galzuren, 
cholaat (CA) en chenodeoxycholaat (CDCA) gesynthetiseerd. De laatste stap in het 
proces van galzoutsynthese is het conjugeren van CA en CDCA met Glycine of 
Taurine. Bile acid-amino N-acyltransferase  (BAAT) is  het enige enzym dat 
galzuren kan conjugeren.  Het enzym BAAT komt -waarschijnlijk exclusief- in 
leverperoxisomen voor. Na transport uit de peroxisoom worden galzouten via de 
Bile Salt Export Pump (BSEP) uit hepatocyten de gal in getransporteerd voor het 
doorlopen van de enterohepatische kringloop. Meer dan 95% van de galzouten in 
gal zal in de darmen worden geabsorbeerd, met name in het terminaal ilieum, 
waarna ze via de poortader terugkomen in de lever. Circulerende galzouten 
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worden via de Sodium-dependent Taurocholate Co-transporting Peptide (NTCP) 
de hepatocyt in geïmporteerd. De galzouten die verloren gaan via de feces worden 
in de lever met ‘de novo’ synthese gecompenseerd. 
In de darmen kunnen galzouten gemodificeerd worden door de aanwezige 
darmflora. Het verwijderen van de  Glycine of Taurine groep (“deconjugatie”) is 
een veel voorkomende modificatie van galzouten in de darm. Gedeconjugeerde 
galzouten worden opnieuw geconjugeerd in de hepatocyt door BAAT voor 
effectief transport tussen  lever en darm. In vorig onderzoek is beschreven dat 
BAAT zowel in het cytosol als in het peroxisoom aanwezig is. Deze verschillende 
intracellulaire locaties van BAAT zouden specifiek verantwoordelijk kunnen zijn 
voor de conjugatie van ‘de novo’ gesynthetiseerde en gereconjugeerde galzouten. 
Peroxisomaal BAAT zou dan alleen betrokken zijn bij ‘de novo’ galzoutbiosynthese, 
terwijl cytosolisch BAAT een rol zou spelen bij reconjugatie van gedeconjugeerde 
galzouten uit de darmen. De reden waarom men aanneemt dat BAAT zowel in 
peroxisomen als in het cytosol voorkomt, is gebaseerd op 
celfractioneringsexperimenten waain BAAT zowel in het cytosol als in de 
peroxisomale fractie werd aangetoond. Het is echter bekent dat de peroxisomal 
membraan gemakkelijk kapot gaat tijdens dergelijke celfractionerings 
experimenten, waarbij wel meer dan 80% van de peroxisomale enzymen uit deze 
organellen lekken en onterecht als “cytosolisch” worden gekwalificeerd .. Recent is 
met meer geraffineerde methodes, zoals  digitonine permeabilisatie en (immuno) 
fluorescentie microscopie, BAAT voornamelijk, zo niet exclusief, peroxisomaal 
aanwezig in zowel ratten- als humane hepatocyten. De peroxisomale lokalisatie 
van BAAT heeft  consequenties voor het transport van galzouten in hepatocyten. 
Voor reconjugatie moeten galzouten namelijk eerst de peroxisoom in geimporteerd 
worden.  Een peroxisomale galzouttransporter die dit doet is nog niet 
geïdentificeerd.  
In dit proefschrift hebben we geprobeerd om de vraag te beantwoorden of C24 
galzouten voor reconjugatie door peroxisomen van hepatocyten gaan. In 
hoofdstuk 2 zijn primaire ratten hepatocyten blootgesteld aan deuterium-gelabeld 
cholaat (D4CA). Iin dit experiment staat D4CA model voor de gedeconjugeerde 
galzouten die vanuit de darm terugkeren naar de lever. Met deze nieuwe methode 
hebben we een tijdsafhankelijke omzetting van D4CA in taurine-en glycine 
conjugaten (D4TCA en D4GCA) aangetoond. Binnen 24 uur was van de 100 µM 
D4CA die aan kweekmedium met 1 miljoen hepatocyten was toegediend, volledig 
omgezet in D4TCA/D4GCA. Een tijdelijke cellulaire ophoping van D4TCA/D4GCA 
werd waargenomen, met een maximum van ca. 600-700 µM na 3 uur incubatie met  
D4CA. Permeabilisatie van hepatocyten met digitonine (30 µg/mL) liet zien dat het 
grootste deel van D4TCA geassocieerd bleef met cellulaire fracties, terwijl alle 
cytosolische eiwitten wel vrijkwamen. Het volledig vrijkomen van D4TCA uit 
hepatocyten werd bereikt wanneer er een hoge concentratie digitonine (500 
µg/mL) werd gebruikt. Bij deze concentratie kwam ook het peroxisomale matrix 
eiwit Catalase vrij. Deze bevindingen met digitonine permeabilisatie duidde er op 




cholesterol in de membraan, hetgeen karakteristiek is voor  peroxisomen. Om 
verder te bewijzen dat nieuw-gevormde galzoutconjugaten in peroxisomen van 
ratten hepatocyten zitten, hebben we een nieuwe celfractioneringsmethode 
ontwikkeld. Deze methode is zodanig geoptimaliseerd dat osmotische schade aan 
peroxisomen wordt geminimaliseerd.  In deze fractioneringsexperimenten hebben 
we D4TCA in een zeer zuivere peroxisomale fractie kunnen detecteren. Hiermee 
concluderen we dat er transport van deuterium-gelabeld cholaat de peroxisoom in 
heeft plaats gevonden, waarna het met Taurine is geconjugeerd. Dit is het eerste 
experimentele bewijs dat ongeconjugeerde (C-24) galzouten die zich in de 
enterohepatische circulatie bevinden voor reconjugatie door peroxisomen van 
hepatocyten gaan. 
Ons volgend doel was het identificeren van een peroxisomaal membraaneiwit 
(PMP) dat mogelijk betrokken is bij het importeren van galzouten. Er is een 
uitgebreide hoeveelheid data beschikbaar over transporters in hepatocyten en 
enterocyten die galzouten over plasmamembranen transporteren. Voor 
peroxisomen, maar ook andere organellen, zijn dergelijke  galzouttransporters nog 
niet geïdentificeerd.  
In het verleden is aangetoond dat voor efficiente translocatie van C-27 galzouten 
naar de peroxisoom ATP nodig is. Dit wijst op een aktief transport van galzout  
intermediairen in de ‘de novo’ synthese route. Men heeft ook aangetoond dat 
geconjugeerde galzouten d.m.v. passief transport, zonder energie verbruik, de 
peroxisoom uitgaan. 
In hoofdstuk 3 hebben we de mogelijke betrokkenheid van het Peroxisomal 
Membrane Protein – 70 kDa (PMP70) bij reconjugatie van galzouten bestudeerd. 
Hoewel PMP70 het meest dominante peroxisomale eiwit is in rattenlever, is er 
relatief weinig over de functie en substraatspecificiteit van dit eiwit bekend. De 
ATP – bindingsplaats van PMP70 is gericht naar het cytosol. Dit suggereert dat dit 
eiwit betrokken is bij de import van substraten de peroxisoom in.  We hebben 
primaire ratten hepatocyten blootgesteld aan fenofibraatzuur (FFA), een effectieve 
agonist van de transcriptiefactor Peroxisome Proliferator Activated Receptor alpha 
(PPARα). PPARα activatie stimuleert peroxisoom proliferatie in knaagdieren. Ook 
Pmp70 expressie staat onder controle van PPARα en wordt geïnduceerd in 
aanwezigheid van FFA. Daarnaast hebben we de expressie van Pmp70 geremd 
m.b.v. “small interfering RNA’s” (siRNA). We hebben de expressie van Pmp70 in 
ratten hepatocyten gemanipuleerd om vervolgens met de in hoofdstuk 2 
beschreven, “CA-conjugatie en intracellulaire transport proeven”, de 
glycine/taurine conjugatie en transport van D4CA te bestuderen. We laten zien dat 
inductie van Pmp70 expressie een verhoging van D4TCA in het medium geeft, 
terwijl de intracellulaire nivo’s van D4TCA en D4CA verlaagd zijn. Het 
complementaire experiment, waarbij Pmp70 expressie geremd wordt d.m.v. 
siRNA, voorkwam  de FFA-geïnduceerde overexpressie van Pmp70 en verhoogde 
de intracellulaire nivo’s van D4CA en D4TCA, terwijl D4TCA in het medium 
verlaagd was. De behandeling met FFA en siRNA had geen effect op andere 
eiwitten die een effect zouden kunnen hebben op galzout re-conjugatie (NTCP, 
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FATP5, BAAT en BSEP).  Deze data suggereren een rol voor Pmp70 in het 
transport van ongeconjugeerde galzouten de peroxisoom in, om vervolgens met 
Taurine geconjugeerd te worden voor efficiënte excretie uit peroxisomen en 
vervolgens uit hepatocyten.  
De activiteit van galzout transporters in de plasmamembraan van enterocyten en 
hepatocyten wordt gemoduleerd door de specifieke lipide omgeving in de 
membraan. Verschillende galzout transporters zitten in zgn. “lipid rafts”. Dit zijn 
microdomeinen in cellulaire membranen die een relatief hoge concentratie 
cholesterol bevatten.  
Het is waarschijnlijk dat galzouttransporters in membranen van organellen deze 
karakteristiek delen met galzout transporters in plasmamembranen en dus ook 
gelokaliseerd zijn in lipid rafts. Om te bepalen of dit van toepassing is op de 
vermoedelijke peroxisomale galzout transporter PMP70 hebben we eerst gekeken 
of lipide rafts überhaupt aanwezig zijn in de peroxisomale membraan. Hoewel 
lipide rafts gevonden zijn membranen van verschillende organellen , was dit niet 
erg waarschijnlijk voor de peroxisomale membraan , aangezien die een relatief lage 
concentratie cholesterol bevat. Echter, in hoofdstuk 4 beschrijven we het bestaan 
van peroxisomale lipide rafts en hun rol in de biogenese van dit organel. Op basis 
van biochemische extractie experimenten definiëren we op zijn minst 2 
verschillende lipide rafts in de peroxisomale membraan van HepG2 cellen, een 
modelcellijn voor humane hepatocyten. PMP70 is aanwezig in een lipide raft die 
bestand is tegen extractie met een sterk detergent (is een zeepachtige stof), Triton 
X-100. Ook Pex14p, een eiwit dat betrokken is bij eiwitimport in peroxisomen, zit 
in deze Triton X-100 lipide rafts. Opmerkelijk is dat een eiwit wat erg veel op 
PMP70 lijkt en ook in de peroxisomale membraan zit, het Adrenoleukodystrophy 
protein (ALDP) niet in Triton X-100 lipide rafts zit maar juist in lubrol WX (een 
zwakker detergent) lipide rafts.  Pex13p, een ander eiwit betrokken bij eiwitimport 
in peroxisomen, was niet aanwezig in lipide rafts, hetgeen ook verrassend is omdat 
bekend is dat dit een eiwitcomplex vormt met Pex14p. Als de  HepG2 cellen 
werden gedepleteerd van cholesterol om de lipide rafts te onttrekken van de 
membraan, dan  leidde dit tot de mislokalisatie van Catalase naar het cytosol. 
OokALDP verloor zijn typische peroxisomale lokalisatie en accumuleerde 
waarschijnlijk in het ER. Daarentegen bleven PMP70 en Pex14p voornamelijk 
geassocieerd  met peroxisomen. Als vervolgens deze HepG2 cellen opnieuw 
cholesterol toegediend kregen, werd catalase weer efficiënt in peroxisomen 
opgenomen. Er werd echter niet een noemenswaardig herstel van ALDP transport 
naar de peroxisomen waargenomen. Deze resultaten tonen aan dat er lipide rafts in 
de peroxisomale membraan aanwezig zijn, die noodzakelijk zijn voor de vorming 
van dit organel.  Opmerkelijk was dat de sterk homologe PMP70 en ALDP en de 
eiwitcomplex-vormende Pex13p en Pex14p een verschillende lipide raft associatie 
lieten zien. De lipide omgeving van deze eiwitten zou sterk van invloed kunnen 
zijn op hun activiteit. 
Om peroxisomale lipide rafts verder te karakteriseren, hebben we in hoofdstuk 5  




vergeleken met een aantal wel bekende lipide microdomein merkers, nl. Src-1, 
flotillin en Caveolin-1. Tot onze grote verrassing zagen we dat caveolin-1 in 
hepatocyten aanwezig is in peroxisomale lipid rafts. Caveolin-1 is één van de drie 
Caveolines, die een structurele component zijn van Caveolea en normaal 
gesproken op de endocytotische instulpingen van de plasmamembraan zit. 
Caveolin-1 expressie is relatief laag in hepatocyten, vooral als de expressie wordt 
vergeleken met endotheel cellen in de lever. Celfractionering en confocale laser 
scanning microscopie van gezuiverde hepatocyten onthulde dat het merendeel van 
het caveolin-1 in hepatocyten geassocieerd was met peroxisomen. Ook artificiële 
expressie van GFP-gelabeld caveolin-1 in hepatocyten hoopte zich op in organellen 
die  catalase bevatten, de karakteristieke merker voor peroxisomen. FFA stimulatie 
verlaagt Caveolin-1 expressie in hepatocyten, terwijl peroxisoomproliferatie juist 
werd geïnduceerd. In Caveolin-1 knock out muizen werden geen afwijkingen 
gevonden in peroxisoom morfologie. Dit suggereert dat het geen belangrijke factor 
is voor peroxisoombiogenese.  Uit vorig onderzoek met deze muizen is gebleken 
dat er sprake was van een verstoorde leverregeneratie en vetmetabolisme. 
In conclusie, dit proefschrift laat zien dat de enterohepatische circulatie van 
galzouten niet alleen afhankelijk is van galzouttransporters in de plasmamembraan 
van hepatocyten en enterocyten, maar ook van transport door de peroxisomale 
membraan in hepatocyten. Het 70-kDa peroxisomale membraan eiwit (PMP70) is 
waarschijnlijk betrokken bij transport van galzouten in peroxisomen voor 
conjugatie met Taurine of Glycine. Vergelijkbaar met  galzouttransporters in de 
plasmamembraan is PMP70 ook geassocieerd met lipide rafts, die waarschijnlijk de 
subcellulaire lokalisatie en/of transport activiteit controleren. Peroxisomen in 
hepatocyten bevatten Caveolin-1, een eiwit dat betrokken is bij lipiden en 
cholesterol transport, i.t.t.  de meeste andere cellen waar het in de 
plasmambembraan gevonden wordt Deze resultaten geven een goede aanleiding 
voor vervolgonderzoek voor het identificeren van de peroxisomale 
galzouttransporters, maar ook een gedetailleerde analyse van de rol die Caveolin-1 
speelt in galzouthomeostase. 
 
